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Chemical modification of proteins is a rapidly expanding area of interest with tangible 
effects upon society. Numerous therapeutics consisting of chemically functionalised 
proteins see mainstream use in clinical settings, such as proteins enhanced with 
polyethylene glycol or antibodies linked to anti-cancer drugs. Such modifications are no 
mean feats however, requiring powerful chemistry to modify the protein with the desired 
tag in a selective and controlled manner whilst retaining the native protein function. Some 
contemporary strategies achieve this through the introduction of functionality not 
commonly found in nature, with a key area of interest being protein aldehydes. This work 
reveals new methods for the installation of such aldehydes into proteins and their 
suitability as handles for site-specific chemical protein modification. 
 
Amber stop codon suppression has been used to incorporate a wide range of unnatural 
functionality into proteins through the reassignment of the amber stop codon, adding a 
non-canonical amino acid into the protein exclusively at the site of the amber stop codon. 
Two lysine derivatives, one bearing a thiazolidine and the other a 1,2-aminoalcohol 
moiety, were found to be suitable for amber stop codon suppression. The thiazolidine-
containing protein was treated with a palladium complex to decage a reactive glyoxyl 
aldehyde under mild conditions, whilst the same protein glyoxyl aldehyde was also 
exposed through oxidative cleavage of the 1,2-aminoalcohol-containing amino acid. The 
glyoxyl aldehyde was then used as a handle for site-specific chemical modification of 
proteins using oxime ligation, organocatalytic protein aldol ligation and strain-promoted 
alkyne-nitrone cycloaddition. This work enables the installation of the reactive glyoxyl 
aldehyde at a greater range of positions within proteins, no longer restricted to the N-
terminus, and presents exciting new opportunities for aldehyde modification chemistry.  
3 
 
Table of Contents 
 
Abstract ....................................................................................................................... 2 
Table of Contents ....................................................................................................... 3 
List of Figures ............................................................................................................. 7 
List of Accompanying Material ................................................................................ 15 
Acknowledgments .................................................................................................... 16 
Author’s Declaration ................................................................................................ 18 
Chapter 1: Introduction ............................................................................................ 20 
1.1 Chemical protein modification in chemical biology: an overview ........................ 21 
1.1.1 Moving beyond the central dogma .............................................................. 21 
1.1.2 Side-chain post-translational modifications in nature ................................... 23 
1.1.3 Early chemical protein modification: catching up with nature ....................... 24 
1.1.4 Introducing “unnatural” modifications .......................................................... 27 
1.1.5 Contemporary methods for chemical protein modifcation ............................ 30 
1.1.6 The real-life impact of chemical protein modification ................................... 36 
1.1.7 Conclusions ................................................................................................ 37 
1.2 Amber stop codon suppression: a chemical biology tool .................................... 38 
1.2.1 Pyrrolysine, an unusual canonical amino acid ............................................. 38 
1.2.2 A Promiscuous tRNA-RS Pair for Protein Production .................................. 39 
1.2.3 Protecting groups and post-translational mimicry ........................................ 45 
1.2.4 Genetically encoded bioorthogonal chemistry ............................................. 51 
1.2.5 Diverging from Lysine to Other Amino Acid Analogues ............................... 55 
1.2.6 Conclusions ................................................................................................ 62 
1.3 Project Outline ................................................................................................... 63 
Chapter 2: Synthesis of Peptides as Aldehyde Precursors & Reactive Probes ... 65 
2.1 Introduction ....................................................................................................... 66 
2.1.1 Chapter overview ........................................................................................ 66 
2.2 Canonical amino acid dipeptides ....................................................................... 67 
4 
 
2.2.1 Transamination peptide .............................................................................. 67 
2.2.2 Periodate-oxidised peptides ........................................................................ 69 
2.3 Thiazolidine peptide synthesis ........................................................................... 71 
2.4 Reactive peptide probe synthesis ...................................................................... 72 
2.4.1 Aminooxy probes ........................................................................................ 73 
2.4.2 Aryl aldehyde probes .................................................................................. 74 
2.4.3 Strained alkyne probes ............................................................................... 75 
2.5 Conclusions ....................................................................................................... 76 
Chapter 3: Test Protein Design and Production ..................................................... 77 
3.1 Introduction ....................................................................................................... 78 
3.1.1 Wild-type GFP ............................................................................................ 78 
3.1.2 Engineering of GFP .................................................................................... 79 
3.2 Constructs for amber stop codon suppression ................................................... 81 
3.2.1 Test protein design ..................................................................................... 81 
3.2.2 Amber stop codon suppression system ....................................................... 82 
3.3 Determining performance in amber stop codon suppression ............................. 84 
3.3.1 Assaying with the wild-type pylRS ............................................................... 85 
3.3.2 Assaying with the double mutant pylRS ...................................................... 86 
3.3.3 Discussion .................................................................................................. 87 
3.4 Production of ncAA-containing proteins ............................................................. 90 
3.4.1 EGFP(Y39-(thiazolidine)lysine)-His6 ........................................................... 91 
3.4.2 sfGFP(N150-(thiazolidine)lysine)-His6 ......................................................... 93 
3.4.3 sfGFP(N150-(L-threonyl)lysine)-His6 ........................................................... 94 
3.5 Conclusions ....................................................................................................... 96 
Chapter 4: Exploring Aldehyde Decaging ............................................................... 97 
4.1 Introduction ....................................................................................................... 98 
4.2 Thiazolidine decaging ........................................................................................ 98 
4.2.1 Palladium reagent screen ........................................................................... 99 
4.2.2 Optimised procedure ................................................................................. 102 
4.2.3 Aldehyde versus hydrate .......................................................................... 104 
5 
 
4.2.4 Mechanism ............................................................................................... 106 
4.3 Threonine oxidation ......................................................................................... 107 
4.3.1 Condition screen ....................................................................................... 107 
4.3.2 Optimised conditions ................................................................................. 109 
4.4 Beyond the GFP scaffold ................................................................................. 110 
4.4.1 Introducing BiGalK .................................................................................... 110 
4.4.2 Decaging BiGalK ...................................................................................... 112 
4.5 Conclusions ..................................................................................................... 114 
Chapter 5: Modification of the Decaged Aldehyde Handle .................................. 115 
5.1 Introduction ..................................................................................................... 116 
5.2 Oxime ligation ................................................................................................. 116 
5.2.1 Overview ................................................................................................... 116 
5.2.2 Protein modification using oxime ligation .................................................. 117 
5.3 OPAL .............................................................................................................. 119 
5.3.1 Overview ................................................................................................... 119 
5.3.2 Protein modifiation using OPAL ................................................................ 120 
5.4 SPANC ............................................................................................................ 122 
5.4.1 Overview ................................................................................................... 122 
5.4.2 Protein modification using SPANC ............................................................ 123 
5.5 Conclusions ..................................................................................................... 125 
Chapter 6: Conclusions and Future Directions .................................................... 126 
6.1 Summary ......................................................................................................... 127 
6.2 Future work ..................................................................................................... 127 
6.2.1 Optimised amber stop codon suppression ................................................ 127 
6.2.2 Applications of this work: in vitro ............................................................... 128 
6.2.3 Applications of this work: live cell labelling ................................................ 129 
Chapter 7: Experimental ......................................................................................... 130 
7.1 Chemical synthesis ......................................................................................... 131 
7.1.1 General methods ...................................................................................... 131 
7.1.2 Solution-phase synthesis .......................................................................... 133 
6 
 
7.1.3 Solid-phase synthesis ............................................................................... 156 
7.1.4 NMR spectra ............................................................................................. 166 
7.2 Molecular biology and protein expression ........................................................ 186 
7.2.1 Plasmid information .................................................................................. 186 
7.2.2 Site-directed mutagenesis ......................................................................... 186 
7.2.3 tRNA synthetase substrate recognition assay ........................................... 186 
7.2.4 Expression and purification of green fluorescent proteins ......................... 187 
7.2.5 Expression and purification of BiGalK ....................................................... 188 
7.2.6 Protein characterisation ............................................................................ 189 
7.3 Protein modification protocols.......................................................................... 192 
7.3.1 Palladium reagent screen ......................................................................... 192 
7.3.2 Optimised palladium decaging procedure ................................................. 193 
7.3.3 Optimised periodate oxidation procedure .................................................. 194 
7.3.4 Oxime ligation ........................................................................................... 195 
7.3.5 Organocatalytic protein aldol ligation ........................................................ 196 
7.3.6 SPANC ligation ......................................................................................... 197 
Chapter 8: Appendix ............................................................................................... 198 
8.1 Protein sequences ........................................................................................... 198 
Abbreviations .......................................................................................................... 201 





List of Figures 
Figure 1: Crick’s original imagining of the central dogma, an unpublished note from 
1956.2 ......................................................................................................................... 21 
Figure 2: The familiar triangular schematic of the Central Dogma, adapted from Crick’s 
1970 design.3 .............................................................................................................. 22 
Figure 3: Common post-translational modifications of protein side chains.5 ................ 23 
Figure 4: Nucleophilic attack of a peptide α-amino group upon phenylisothiocyanate 
under initially basic conditions forms an adduct which can degrade under subsequent 
acidic conditions, releasing the rest of the peptide, for another cycle of Edman 
degradation, and a phenylhydantoin after rearrangement. The phenylhydantoin bears 
the side-chain from the degraded residue and can be characterised by chromatography 
to identify the residue in question. ............................................................................... 24 
Figure 5: Literature pKA constants of protic protein residues.22 ................................... 26 
Figure 6: Activated PEG derivatives used to acylate or alkylate nucleophilic residues on 
protein surfaces for PEG attachment: primarily lysine residues, but also α-amino groups 
and thiols.25-29 ............................................................................................................. 28 
Figure 7: Biotinylated proteins can be separated from complex mixtures using avidin 
affinity chromatography or selectively detected using Western blotting with avidin-
horseradish peroxidase or avidin-alkaline phosphatase conjugates. ........................... 29 
Figure 8: (from top to bottom) Protein modification of cysteine thiols using maleimides, 
bromomaleimides and dibromomaleimides to form thiosuccinimides (slightly prone to 
retro-Michael addition in the presence of thiols), thiomaleimides (reversibly exchange 
with excess thiol) and maleic/succinic acids (stable in the presence of thiols). A cystine 
disulfide bridge can, once reduced, react with a dithiomaleimide and subsequently ring-
open to form a stable linkage where the cysteine residues are still joined with the addition 
of a tag such as a small-molecule drug. ...................................................................... 32 
Figure 9: Modification of native amino groups at the N-terminus and at selective lysine 
side chains. ................................................................................................................. 33 
Figure 10: Selected methods for the incorporation of aldehydes and dehydroalanine into 
proteins for subsequent chemical modification. ........................................................... 35 
Figure 11: Pyrrolysine 1, unlike post-translational modifications 2-4, is biosynthesised 
prior to translation from L-lysine 5 via 6 and 7. ............................................................ 39 
8 
 
Figure 12: The hydrophobic methylpyrroline ring of 1 occupies a hydrophobic cleft deep 
within PylRS (PDB: 2Q7H). ......................................................................................... 40 
Figure 13: (left) Hydrogen bonding interactions with Tyr384 and Asn346 hold 1 in place; 
(right) various hydrophobic residues line the cavity occupied by the methylpyrroline ring 
(PDB: 2Q7H). ............................................................................................................. 41 
Figure 14: Asymmetric Michael addition of glycine to crotonaldehyde followed by 
hydrolysis and cyclisation forms the crucial methylpyrroline ring (blue) of 1. a: DBU, 
DCM, r.t., 97%. b: HCl, MeOH, Δ, then TMSCl, MeOH, r.t., 43%. ............................... 41 
Figure 15: Two recent synthetic routes to 1: (upper) metal-mediated asymmetric Michael 
addition of a glycine imine to methyl crotonoate prepares the stereocentres and a tandem 
Staudinger/aza-Wittig cyclisation closes the ring; (lower) organocatalytic asymmetric 
Michael addition of ethyl nitroacetate to crotonaldehyde affords the correct 
stereochemistry and subsequent deprotection and cyclisation forms the methylpyrroline 
ring of 1. a: Ca(OiPr)2, 4 Å molecular sieves, THF, -20 °C, 99% e.e., >98% d.e., 92%. b: 
polystyrene-supported PPh3, THF, Δ, quantitative. c: LiOH, MeOH, THF, H2O, 
quantitative. d: Jørgensen catalyst, BzOH, then MeOH, p-TsOH, CH(OMe)3, 90% e.e., 
1:1 mixture of C-2 diasteromers, 96%. e: p-TsOH, MeOH, 32%. ................................. 42 
Figure 16: (left) Pyrrolysine analogues 8 and 9 were found to be suitable substrates for 
M. mazei pylRS, with a crystal structure of 9 bound to pylRS (right; PDB: 2Q7G). ...... 43 
Figure 17: Protected derivatives of lysine recognised by wild-type or mutated pylRS. 44 
Figure 18: An overview of amber stop codon suppression. ......................................... 45 
Figure 19: (left) In the pylRS mutant recognising 2, hydrogen bonds with Asn346 still hold 
the substrate 2 in place but with a different geometry and no interactions between 2 and 
Tyr384; (right) the shrunken binding pocket is capped by three aromatic rings, two 
installed by mutations, all of which appear to orientated in such a way as to interact with 
the carbonyl oxygen of 2 (PDB: 4Q6G). ...................................................................... 46 
Figure 20: Genetic incorporation of 3 can only proceed indirectly via initial incorporation 
of 14 or 15 followed by chemical deprotection. a: 2% (v/v) TFA, 4 h, 37 °C. b: PhSH, 
RuCl(cod)Cp*, 3 h, 37 °C. ........................................................................................... 48 
Figure 21: Protection/deprotection and alkylation strategies required to circumvent the 
inherent difficulties encountered when seeking to incorporate 4 using stop codon 
suppression. a: Cbz-OSu, DIPEA, DMSO. b: TFA, H2O. c: CH2O, DMAB. d: TfOH, DMS, 
TFA. e: TCEP, PBS, pH 7. f: NaBH3CN, dimethylamine, PBS, pH 7. .......................... 49 
Figure 22: Acyl lysine derivatives and precursors suitable for use in amber stop codon 
suppression. ............................................................................................................... 50 
9 
 
Figure 23: Protecting groups on lysine surrogates facilitates lysine activation using 
biocompatible deprotection chemistry. ........................................................................ 51 
Figure 24: Pyrrolysine surrogates used in genetically encoded copper-catalysed and 
strain-promoted azide-alkyne cycloaddition bioconjugations. ...................................... 52 
Figure 25: Lysine surrogates 36-41 developed for SPIEDAC bioconjugations in 
increasing rate order.181, 183, 186, 188 ............................................................................... 54 
Figure 27: Genetically encoded phenylalanine and tyrosine analogues. ..................... 56 
Figure 28: Further genetically encoded phenylalanine and histidine analogues. ......... 57 
Figure 29: Cysteine and genetically encoded analogues. ........................................... 59 
Figure 30: Further cysteine, selenocysteine and aspartate derivatives used in amber stop 
codon suppression. ..................................................................................................... 61 
Figure 31: Retrosynthetic analysis of a protein bioconjugate, where disconnection affords 
1) a protein aldehyde, prepared via amber stop codon suppression and functional group 
interconversion using small molecule pyrrolysine analogues, prepared in in the first half 
of this chapter, and 2) reactive peptide probes, harbouring both a useful label, denoted 
by a star, and functionality to react with the protein aldehyde, with the second half of this 
chapter focussing on the modular solid-phase synthesis used to prepare these probes.
 ................................................................................................................................... 67 
Figure 32: Transamination of amino acids using pyridoxal-5-phosphate. .................... 68 
Figure 33: Synthesis of lysine-glycine dipeptide 96. .................................................... 68 
Figure 34: Sodium periodate oxidation of N-terminal serine and threonine residues. .. 69 
Figure 35: Synthesis of lysine-serine and lysine-threonine (L-configured) dipeptides. . 70 
Figure 36: Synthesis of lysine-serine and lysine-threonine (D-configured) dipeptides. 71 
Figure 37: Synthesis of thiazolidine-lysine dipeptide 86. ............................................. 72 
Figure 38: Structure and schematic of aminooxypeptides 123 and 124. ..................... 73 
Figure 39: Synthesis of OPAL probes 130 and 131. ................................................... 75 
Figure 40: Synthesis of SPANC probes 133 and 134. ................................................. 76 
Figure 41: Inside the GFP β-can (top left, cyan) lies an α-helix (red) where the p-
hydroxybenzylidene imidazolidinone chromophore can be found (bottom left), formed 
through an intramolecular cyclisation and elimination between Ser65 and Gly67 and the 
oxidation of Tyr66 (right). ............................................................................................ 78 
10 
 
Figure 42: Positions of mutated residues: EGFP Y39 (left, PDB 2Y0G) and sfGFP N150 
(right, PDB 2B3P). ...................................................................................................... 82 
Figure 43: Plasmid map of the pEVOL vector harbouring one pyrrolysyl tRNACUA gene 
(dark green) and two copies of the pylRS gene (orange), one under araBAD control 
(white) and one under constitutive control. Map prepared with SnapGene using the 
published description of the pEVOL vector.125 ............................................................. 83 
Figure 44: NCAAs 86, 96, 101, 105, 109 and 105 screened for uptake in amber stop 
codon suppression alongside positive controls 29 (pylRSwt) and 34 (pylRSAF). ........... 85 
Figure 45: SDS-PAGE of cell lysate from the amber stop codon suppression expression 
trial of EGFP with pylRSwt and NCAAs 86, 96, 101, 105, 109 and 110 with negative (-) 
and positive (29) controls. The circled bands in lanes 105, 86 and 29 are attributed to 
full-length EGFP. ........................................................................................................ 85 
Figure 46: Visualisation by white light (left) and fluorescence (right) of cell lysate from 
the exp the amber stop codon suppression expression trial of EGFP with pylRSwt and 
NCAAs 86, 96, 101, 105, 109 and 110 with negative (-) and positive (29) controls. .... 86 
Figure 47: SDS-PAGE of cell lysate from the amber stop codon suppression expression 
trial of EGFP with pylRSAF and NCAAs 86, 96, 101, 105, 109 and 110 with negative (-) 
and positive (34) controls. The circled band in lanes 34 is attributed to full-length EGFP.
 ................................................................................................................................... 87 
Figure 48: Genetic incorporation of 135 followed by Staudinger reduction affords a 
glycine-glycine-lysine motif amenable to transpeptidation with a tagged LPLTGG 
peptide, such as to install ubiquitin on the side chain of a lysine residue with a ubiquitin-
LPLTGG-K linkage similar to native ubiquitin-LRLRGG-K linkages. ............................ 88 
Figure 49: Proposed binding mode between pylRS and 105 (left) and 110 (right), with 
putative hydrogen bonding interactions highlighted in green. ...................................... 90 
Figure 50: (left) 280 nm chromatogram of the purification of 136 by nickel affinity, eluting 
with an imidazole gradient; (right) SDS-PAGE of fractions containing 136: a clear band 
around the expected 28.6 kDa mass. .......................................................................... 91 
Figure 51:  Raw (left) and deconvoluted (right) ESI-FTICR mass spectrum of 136. For 
the neutral species, calc. 28632 Da; found 28633 Da. ................................................ 92 
Figure 52: Trypsin digest of 136, displaying found peptides in blue to map the sequence 
of the protein. The non-canonical amino acid is confirmed in the correct location, 
highlighted in red. ....................................................................................................... 93 
11 
 
Figure 53: (left) 280 nm chromatogram of the purification of 137 by nickel affinity, eluting 
with an imidazole gradient; (right) SDS-PAGE of fractions containing 137: a clear band 
around the expected 28.0 kDa mass. .......................................................................... 93 
Figure 54: Raw (left) and deconvoluted (right) ESI-FTICR mass spectrum of 137. For the 
neutral species, calc. 27957 Da; found 27957 Da. ...................................................... 94 
Figure 55: Trypsin digest of 137, displaying found peptides in blue to map the sequence 
of the protein. The non-canonical amino acid is confirmed in the correct location, 
highlighted in red. ....................................................................................................... 94 
Figure 56: (left) 280 nm chromatogram of the purification of 138 by nickel affinity, eluting 
with an imidazole gradient; (right) SDS-PAGE of fractions containing 138: a clear band 
around the expected 28.0 kDa mass. .......................................................................... 95 
Figure 57: Raw (left) and deconvoluted (right) ESI-FTICR mass spectrum of 138. For the 
neutral species, calc. 27943 Da; found 27942 Da. ...................................................... 95 
Figure 58: Trypsin digest of 138, displaying found peptides in blue to map the sequence 
of the protein. The non-canonical amino acid is confirmed in the correct location, 
highlighted in brown. ................................................................................................... 96 
Figure 59: Proposed mechanism for the silver- and acid-mediated ring opening of a 
thiazolidine to afford a glyoxyl aldehyde and silver-cysteamine complex. ................... 98 
Figure 60: Palladium complexes screened for the decaging of protein thiazolidine 136 to 
afford a protein glyoxyl as aldehyde 139-ald or hydrate 139-hyd. .............................. 99 
Figure 61: From partial to full decaging using 142. Decaging with 100 eq. for 6 h (left) led 
to only ca. 30% decaging of 136 due, at least in part, to protein precipitation, whilst a 
single equivalent for one hour (right) led to complete decaging to form 139-ald (calc. 
28573 Da, found 28573 Da) and 139-hyd (calc. 28591 Da, found 28592 Da), 
predominantly existing as the aldehyde rather than the hydrated diol. ...................... 101 
Figure 62: Decaging of 136, as observed by MS, using 142 prepared in either MeCN 
(blue), DMF (green) or 1,4-dioxane (red). Spectra are normalised relative to the peak for 
139-ald. .................................................................................................................... 103 
Figure 63: Decaging of protein thiazolidine 137 to afford protein glyoxyl 145 (top). ESI-
FTICR-MS data show the consumption of 137 (lower left; calc. 27957 Da, found 27956 
Da) to afford 145-ald (lower right; calc. 27898 Da, found 27900 Da) and 145-hyd (calc. 
27916 Da, found 27918 Da). ..................................................................................... 104 
Figure 64: EGFP residue Y39 forms part of a β-turn (green) with little side-chain 
interaction (left, PDB: 2Y0G). This contrasts with sfGFP residue N39, where the residue 
12 
 
has rotated to position the side chain amide to hydrogen bond with the side chain 
carboxylate of residue D36 (right, PDB: 2B3P). This tighter geometry takes the form of a 
310 helix rather than a β-turn, bringing together two strands of the β-barrel and stabilising 
the protein fold. ......................................................................................................... 105 
Figure 65: Proposed mechanism for the palladium-mediated ring opening of a 
thiazolidine to afford a glyoxyl aldehyde and silver-cysteamine complex. L = coordinating 
solvent ligand, e.g. DMSO. ....................................................................................... 107 
Figure 66: (top) Oxidation of protein 1,2-aminoalcohol 138 to afford protein glyoxyl 145. 
ESI-FTICR-MS data show some consumption of 137 (lower left; calc. 27943 Da, found 
27942 Da) to afford 145-ald (lower right; calc. 27898 Da, found 27897 Da) and 145-hyd 
(calc. 27916 Da, found 27916 Da) to approximately 60% conversion. ...................... 108 
Figure 67: Putative aldol interception of 145 by the acetaldehyde released from periodate 
oxidation, leading to unwanted side product 146, indistinguishable from 138 by intact 
protein mass spectrometry alone. ............................................................................. 109 
Figure 68: Optimised periodate oxidation of 138 affords 139, predominantly as the 
hydrated aldehyde (calc. 27916 Da, found 27918 Da). ............................................. 110 
Figure 69: Preliminary crystal structure of BiGalK, provided by Dr Tessa Keenan 
(unpublished), with residue K417 highlighted. ........................................................... 111 
Figure 70: Raw (left) and deconvoluted (right) ESI-FTICR mass spectrum of 147. For the 
dominant species, a sodiated MeCN adduct, calc. 45936 Da; found 45936 Da. For the 
methionine-cleaved species, calc. 45805 Da; found 45804 Da. ................................ 112 
Figure 71: Decaging of protein thiazolidine 147 to afford protein glyoxyl 148 (top, masses 
shown correspond to the predominant sodiated acetonitrile adduct). ESI-FTICR-MS data 
show ca. 50% decaging at 1.5 eq. 142 at 300 μM (lower left), increasing to 100% 
conversion when 142 is added as 4 eq. at 300 μM (lower right), affording 148-hyd; with 
Met1, calc. 45895 Da, found 45894 Da; without Met1, calc. 45764 Da, found 45765 Da.
 ................................................................................................................................. 113 
Figure 72: The rate of oxime ligation is greatly enhanced by aniline catalysis via the 
protonated aniline Schiff base intermediate. ............................................................. 117 
Figure 73: Oxime ligation of protein aldehyde 139 with aminooxy biotin probe 123 or 
aminooxy dansyl probe 124 (top). In both cases, ESI-FTICR-MS data show the complete 
consumption of 139-ald to afford biotinylated protein 149 (lower left; calc. 29347 Da, 
found 29348 Da) and dansylated protein 150 (lower right, calc. 29355 Da, found 29356 
Da) with the protein-probe linkage schematically depicted as a bold bond. ............... 118 
13 
 
Figure 74: Oxime ligation of protein aldehyde 145 with aminooxy biotin probe 123 or 
aminooxy dansyl probe 124 (top). In both cases, ESI-FTICR-MS data show the complete 
consumption of 145-hyd to afford biotinylated protein 151 (lower left; calc. 28672 Da, 
found 28673 Da) and dansylated protein 152 (lower right, calc. 28680 Da, found 28679 
Da) with the protein-probe linkage schematically depicted as a bold bond. ............... 118 
Figure 75: (left) Coomassie staining (upper) and fluorescence (lower) of unmodified 
negative control 145 and dansylated protein 153 following denaturing SDS-PAGE; (right) 
Coomassie staining (upper) and Western blotting with an anti-biotin substrate (lower) of 
unmodified negative control 139 and biotinylated protein 149 following denaturing SDS-
PAGE. ...................................................................................................................... 119 
Figure 76: Donor aldehydes slowly attack the acceptor aldehyde via the enol tautomer, 
but the use of organocatalyst 154 opens up a much faster pathway through the formation 
of a more nucleophilic enamine. ............................................................................... 120 
Figure 77: OPAL using aminooxy biotin probe 123 with protein aldehydes 139 (upper 
left) and 145 (upper right). In both cases, ESI-FTICR-MS data show the complete 
consumption of the protein aldehyde to afford dansylated proteins protein 155 (lower left; 
calc. 29330 Da, found 29332 Da) and 156 (lower right, calc. 28655 Da, found 28657 Da) 
with the protein-probe linkage schematically depicted as a bold bond. The β-
hydroxyaldehyde is observed only as the aldehyde form without hydration............... 121 
Figure 78: (left) Coomassie staining (upper) and fluorescence (lower) of unmodified 
negative control 139 and dansylated protein 155 following denaturing SDS-PAGE; (left) 
Coomassie staining (upper) and fluorescence (lower) of unmodified negative control 145 
and dansylated protein 156 following denaturing SDS-PAGE. .................................. 121 
Figure 79: Promoted by p-anisidine catalysis, the protein glyoxyl condenses with N-
methylhydroxylamine to form an oxime, becoming a nitrone upon deprotonation. This 
protein nitrone undergoes a [3+2] cycloaddition with a strained alkyne to furnish the 
isoxazoline bioconjugate. .......................................................................................... 122 
Figure 80: SPANC of protein aldehyde 139 with BCN biotin probe 133 or BCN dansyl 
probe 134 (top). In both cases, ESI-FTICR-MS data show the complete consumption of 
139-ald to afford biotinylated protein 157 (lower left; calc. 29497 Da, found 29499 Da) 
and dansylated protein 158 (lower right, calc. 29504 Da, found 29506 Da) with the 
protein-probe linkage schematically depicted as a bold bond.................................... 123 
Figure 81: SPANC of protein aldehyde 145 with BCN biotin probe 133 or BCN dansyl 
probe 134 (top). In both cases, ESI-FTICR-MS data show the complete consumption of 
139-ald to afford biotinylated protein 159 (lower left; calc. 28822 Da, found 28824 Da) 
14 
 
and dansylated protein 160 (lower right, calc. 28829 Da, found 28831 Da) with the 
protein-probe linkage schematically depicted as a bold bond.................................... 124 
Figure 82: (left) Coomassie staining (upper), fluorescence (middle) and Western blotting 
with an anti-biotin substrate (lower) of unmodified negative control 139, biotinylated 
protein 157 and dansylated protein 158 following denaturing SDS-PAGE; (right) 
Coomassie staining (upper), fluorescence (middle) and Western blot with an anti-biotin 
substrate (lower) of unmodified negative control 145, biotinylated protein 159 and 







List of Accompanying Material 
This thesis, as an electronic copy, forms part of a package which also contains the 
following material: 
- Raw NMR data for compounds characterised by NMR described in this thesis 





During the almost four years it has taken to produce this thesis, I have been fortunate to 
have worked amongst a host of talented, conscientious and kind researchers in the B 
block lower laboratory with the Fascione, Parkin and Willems groups and I am truly 
grateful to every single one. Our laboratory has always worked such that we have been 
friends as well as colleagues, supporting each other without a second thought, and I 
know the groups will continue in that spirit. My thanks go to Dr Martin Fascione and Prof. 
Rod Hubbard for their diligent supervision and guidance on this project, ensuring that 
this thesis did indeed reach fruition, and to Prof. Ian Fairlamb for his warmly welcomed 
wise words at many points along the way. 
As the final member of the Fascione Four to produce a thesis, I must pay thanks to the 
three other members of this quartet, having spent almost four years together and without 
you all I really would not have got this far. It will be a big change working without you all. 
Dr Emily Flack, HRH Queen of Biochemistry, you have been a kindred spirit throughout 
our time together in so many ways, whether in the lab throwing around “robust” DNA gels 
amid an atmosphere of destain or making positive life choices in the sanctuary that was 
Willow, and I could not have asked for someone better to go through this PhD with. Dr 
Harriet Chidwick, you have been a beacon of kindness, always giving out the best hugs 
and advice, whilst being an inspirational part of the Team Hamily Pse pioneers with the 
ability to conjure up litres of LB from nowhere in a flash. Dr Richard Spears, I have been 
proud to follow in many of your footsteps on protein modification whilst providing you with 
regular briefings on politics, gaming, and various aspects of the zeitgeist, and it has been 
a pleasure to work together on our shared interests. 
As part of the “grown-ups’ office”, I am also highly thankful to Dr Tessa Keenan, who has 
provided me with so many fresh perspectives on how to be a better researcher in 
countless ways, and Dr Clare Mahon, who has been a joy to work alongside and witness 
her kicking the right backsides. The lovely Dr Darshita Budhadev, whilst you did forsake 
our office, nevertheless I cannot thank you enough for your kindness and encouragement 
(thankfully not as a Useless Boy) and for your immense lab knowledge, as well as our 
many chats on the walk home from swimming or the lab. Mark Dowsett, as you are pretty 
much already in the “grown-ups’ office”, it has been a pleasure to work and teach 
alongside you so much over the past three years, and we have made a great team 
together. Of course I must thank Julia Walton for everything has done in keeping the lab 
not just functioning but succeeding, for teaching me so much of the protein prep work 
with far more patience than I was due, and for being the hero who can always swoop 
down and make things right again. Beyond the “grown-ups’ office”, I have been lucky to 
17 
 
have shared the lab with many wonderful PhD students: Nick, Jenny, Tasha, Lewis, Tom, 
Katie, Sol, Alexandra, Chris, Sophie, Hope, and Lindsey, to whom I wish the best of 
success. My thanks also go to the teaching labs staff, a place in which I ended up far too 
frequently, for making that an enjoyable and memorable experience, and Dr Ed 
Bergström for all his support and brainpower with uncooperative mass spectrometers. 
I am also grateful to many people outside of the lab and their efforts in helping me to 
retain some elements of sanity. Tom, Matt and Scott, you three have been alongside me 
for this time in its entirety, witnessing many highs and even more lows, and your 
friendship has meant a lot to me through those difficult moments. There are many 
additional queers, politicos, and queer politicos to whom I am also thankful for the 
multitude of distractions provided. As probably the worst Green possible, it has been a 
pleasure to have worked with so many of York’s Liberal Democrats over the past few 
years, including the Remain campaign and finally being able to enjoy some positive 
election results together for once. I am particularly grateful to Erin Yarrow, fellow Old 
Person and dear muse, and someone who has challenged my thinking with her sharp, 
highly astute yet always good-natured discussions. I am also thankful to so many past 
and present people at the Students’ Union, from my time chairing UoY Greens through 
to my time as a Trustee, who have given me many significant opportunities and helped 
me shape the university I hold dear. My friends from high school- Ste, Kate, George, 
Matt, Adam, Sophie, Dave, Jake, Alex, Jonathan, Phil, and others- have provided much-
needed breaths of fresh air, be that at the Woodlands every Christmas Eve or whenever 
we get the time to meet up, and coming back to you all is always a particular joy. 
Over most of the past seven years I have been fortunate enough to live with Tasha 
Trainor, to the extent of becoming an extended member of the Trainor family. We have 
seen each other at our weirdest- the regular speakers wars or fighting over the privilege 
of vacuuming the stairs in order to put off exam prep- and been there for each other 
during many difficult times. Finishing this PhD unfortunately means moving out as well 
and I will miss your companionship: I doubt I will find as wonderful a housemate as you.  
Finally, I am deeply grateful to my family for their love and support through out this PhD, 
my studies and far beyond. My mother Ceri and my father Nigel have been on my side 
unwaveringly, never doubting my abilities and always being there as my biggest 
supporters. I am where I am in no small part due to you both, and my gratitude extends 
well beyond this acknowledgments section. That love and support has also come from 
Oma Jo, fortunately still with us and demonstrating a Teutonic fortitude that I hope to 
have acquired, as well as Opa Basil, Grandma Pat, step-grandfather Ron and aunt 
Andrea. Whilst they did not get to see this point of completion, they had every confidence 




I, Robin Louis Brabham, declare that this thesis is a presentation of original work and 
that I am the sole author. This work has not been previously presented for an award at 
this, or any other, University. All sources are acknowledged as References. The work 
submitted for this thesis is my own, with the exception of work that has formed part of 
jointly authored publications. The contributions made by the other authors towards this 
work are explicitly stated below. I can confirm that appropriate credit has been given 
within this thesis where reference has been made to work carried out by others and, 
above all, I am resoundingly grateful to those colleagues and friends listed below whose 
contributions have had a positive impact upon the direction of this thesis. 
- Chapter 1: section 1.2 contains content from the publication “Pyrrolysine Amber 
Stop Codon Suppression: Development and Applications”, ChemBioChem. The 
manuscript was prepared by R. L. Brabham and M. A. Fascione. 
- Chapter 2: the concepts of the respective glycine and serine peptides 96 and 101 
were initially explored to a preliminary extent by BSc student A. Hüsken, 
supervised by M. A. Fascione with assistance from R. L. Brabham; aminooxy 
peptides 123 & 124 were synthesised and purified by M. A. Fascione; 
phenacetaldehyde precursor 125 was synthesised by D. Budhadev; peptides 128 
& 129 were oxidised to form OPAL probes 130 & 131 by R. J. Spears. 
- Chapter 3: the plasmids pBAD-EGFP(Y39TAG)-His6, pEVOL-pylT-pylRSwt and 
pEVOL-pylT-pylRSAF were received from E. Lemke abiding by an MTA; the 
plasmid pBAD-sfGFP(N150TAG)-His6 was received from R. Mehl via Addgene. 
- Chapter 4: section 4.2 contains content from the publication “Palladium-
unleashed proteins: gentle aldehyde decgaing for site-selective protein 
modification”, Chemical Communications. The manuscript was prepared by R. L. 
Brabham, R. J. Spears, J. Walton, S. Tyagi, E. A. Lemke and M. A. Fascione. 
Section 4.2 also forms part of patent PCT/GB2017/052896, with inventors M. A. 
Fascione, R. J. Spears, D. Budhadev and T. Keenan, filed through Secerna LLP. 
In section 4.2, R. J. Spears trialled the use of one equivalent of palladium reagent 
142 for decaging, which was independently reproduced and further optimised by 
R. L. Brabham. In section 4.3, the stock of sfGFP(N150Threonyl-lysine)-His6 
used to trial oxidation in the absence of potassium chloride was prepared by T. 
Keenan. In section 4.4, the plasmid pET22b-BiGalK-His6 plasmid was provided 
by T. Keenan. 
19 
 
- Chapter 5: J. Walton provided support with Western blots; R. Spears performed 
biotinylation using OPAL upon various GFPs in vitro and on cell lysate material 
using respective protein stocks or cell pellets of 136 or 137, prepared by R. L. 
Brabham. 
- Chapter 7: all small-molecule HRMS data were recorded by K. Heaton; all 
analytical HPLC traces of peptide probes were recorded by A. Dixon or S. Hicks; 
trypsin digests were performed by A. Dowle.  
20 
 
Chapter 1: Introduction 




1.1 Chemical protein modification in chemical biology: an overview 
1.1.1 Moving beyond the central dogma 
A paradigm shift in the understanding and philosophy of life itself came in 1957 when 
Francis Crick proposed the Central Dogma as a framework linking genetic information 
with its supposed function in the form of protein synthesis, stating “the main function of 
the genetic material is to control (not necessarily direct) the synthesis of proteins”. An 
early graphical representation (Figure 1) depicted these processes with arrows, implying 
that a protein was the ultimate vessel for information from which no information could be 
back-transferred, crucially defining information as “the sequence of amino acid residues, 
or other sequences related to it”.2 The boldness of this grand conjecture was not lost 
upon Crick, sternly advocating for this proposition despite the recognised lack of 
supportive experimental data. 
 
Figure 1: Crick’s original imagining of the central dogma, an unpublished note from 1956.2 
The lack of supportive experimental data led to a slight redesign of the central dogma. 
Information could in fact be transferred from RNA to DNA through the use of reverse 
transcriptase, although this process was far less common than other forms of information 
transfer. Crick made a minor reconfiguration of the topology of the central dogma graph, 
producing the elegantly simple triangular network (Figure 2).3 Of the nine possible 
arrows, three are omitted due to originating from proteins, three dashed as special cases, 




Figure 2: The familiar triangular schematic of the Central Dogma, adapted from Crick’s 1970 design.3 
Like many pieces of art, the subjectivity of the central dogma opens up a range of 
interpretations and misinterpretations. The common “DNA goes to RNA that then goes 
to proteins” statement fails to grasp the information transfer aspect of the central dogma, 
particularly the irreversibility implications. Indeed, the definition of information is arguably 
the most significant self-imposed limitation of the central dogma. Essentially restricted to 
primary sequence, this definition does not include the conformation of the resultant 
protein, the quantity expressed of the resultant protein, and the variation over time in 
these and other factors (with the exception of primary sequence). The fields of 
epigenetics and prions have together created problematic scenarios which challenge this 
central dogma and its underlying definition, where a protein product may be considered 
to change not only expression levels or conformation but also, to a debatable extent, 
primary sequence.4 
A further consequence of this limiting definition is the omission of a vast network of 
downstream processes occurring beyond nucleic acid replication, transcription and 
translation. A translated protein is by no means the final product, with folding and 
subsequent conformational changes determining protein function, but this definition 
omits any structural organisation beyond the primary sequence. An additional limitation 
is that the information as a primary sequence contained within nucleic acids is not 
necessarily representative of the information as the primary sequence forming the 
framework of a protein. If a protein is a language, then whilst nucleic acids may be 
considered to contain only the basic English alphabet, nature has introduced diacritical 
marks such as circumflexes, çédilles, ligatures and tildes into proteins, conferring new 
meaning through altered functionality. Just as the tilde introduces a profound change of 
meaning between the words años and anos, so too can modifications of the primary 
sequence of a protein, sometimes more profound than the basic letters alone. 
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1.1.2 Side-chain post-translational modifications in nature 
DNA in most organisms uses just four distinct bases organised as a triplet code, with the 
64 possible triplet combinations encoding 20 standard amino acids and three 
terminations. As higher life forms with more complex functions and demands have 
evolved, nature has been compelled to keep up by developing alternative pathways to 
add functionality to the limited canon of 20 amino acids. Side-chain post-translational 
modifications (PTMs) most commonly involve nucleophilic moieties (Figure 3), where 
hydroxyl groups are typically modified with phosphate or glycans and amino groups often 
form isopeptide bonds such as acetylations and acylations with ubiquitin.5 The redox 
activity of cysteine also sees use through the formation of disulphide bonds between 
cysteine residues or with S-nitrosylation.6 
 
Figure 3: Common post-translational modifications of protein side chains.5 
The crucial aspect of PTMs is the ability to transfer additional information, often 
reversibly, beyond that contained within the primary sequence, i.e. information not 
considered by the central dogma. Phosphorylation is a key example, acting as a switch 
to alter the protein conformation that can lead to activation or inactivation of protein 
function, permitting or blocking the transfer of a signal.7 Ubiquitination is additional 
information itself, often acting as a signal that the labelled protein is to be degraded.8 
Glycosylation bestows some of the most intricate detail found on proteins, a secondary 
language beyond that of the primary sequence, such that an organism making use of 
glycosylation patterns may discriminate between its own matter and that of foreign and 
potentially harmful bodies to produce a selective defensive response.9 Similarly, an 
invasive organism such as the trypanosome, well versed in nature’s argot of 
glycosylation, can dupe a host into recognising the trypanosome as a native species and 
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not producing a defensive response.10 Information itself can be considered to be an 
abstract selection pressure,11 and the incorporation of post-translational modifications is 
one way devised by nature to continue to produce viable organisms fit for purpose in 
their complex, fluxional and hazardous environment, despite the apparent metabolic 
expense of devising such additional and elaborate pathways. 
1.1.3 Early chemical protein modification: catching up with nature 
Decoding the information in proteins has usually mandated destructive processes, from 
early Kjeldahl digestion to the paradigm-shifting Edman degradation.12 Whilst proper use 
of Edman degradation could provide the primary sequence of a protein in many cases, 
little further could be gleaned: no information on secondary or higher structure, no 
information on function, and no information on the importance of various residues. In 
isolation, the results are a monotonous soliloquy, devoid of intonation and meaning. 
Whilst overall a destructive process, the initial step of Edman degradation is in fact a 
largely chemoselective and regioselective covalent protein modification (Figure 4). By 
controlling pH, only α-amino groups are sufficiently nucleophilic to attack the 
isothiocyanate reagent, with protonated lysine and arginine amino groups rendered 
largely inert. This represented an important early step in the use of chemical protein 
modification to understand the true significance of proteins and demonstrated that 
proteins can transfer information to a body not represented in the central dogma. 
 
Figure 4: Nucleophilic attack of a peptide α-amino group upon phenylisothiocyanate under initially basic 
conditions forms an adduct which can degrade under subsequent acidic conditions, releasing the rest of the 
peptide, for another cycle of Edman degradation, and a phenylhydantoin after rearrangement. The 
phenylhydantoin bears the side-chain from the degraded residue and can be characterised by 
chromatography to identify the residue in question. 
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Whilst the sequence of amino acids is certainly important information, knowing the role 
of each residue provides more valuable insight into the function and context of a protein. 
Following on from reactions at the α-amino terminus, several reagents were found to 
selectively react with particular residues. If the chemical perturbation of a particular 
residue significantly altered protein function, then somehow this residue must be involved 
in protein function. Just as with post-translational modifications, nucleophilic residues 
proved to be suitable quarries for such chemical methods, offering good reactivity distinct 
from other residues to reduce off-target modification and provide more convincing 
results. The ε-amino group of lysine residues can be alkylated by reductive amination,13 
mimicking post-translational methylation,14 or acylated with succinic anhydride15 or acetic 
anhydride, used to imply the presence of a lysine residue in the binding site of an 
antibody.16 Cysteine thiols are alkylated by iodoacetate or iodoacetamide in a reaction 
still enjoying ubiquitous usage in contemporary protein analysis.17 The information 
conveyed in this way is still limited in utility, however. Unambiguously pinpointing which 
particular reactive residue participates in protein function may not be possible where 
multiple residues occur in a region of interest as the modifying reagent will likely modify 
all such residues. Furthermore, the modifying reagent may also denature the protein, 
such as where the modified residue may not be an active participant but may be crucial 
to maintaining the protein fold required for activity, presenting an additional confounding 
variable in this analysis. Arguably the most logically robust application of this method is 
to rule out the participation of one amino acid, e.g. cysteine, such that if modification with 
iodoacetamide does not significantly affect protein function, then the protein has not been 
denatured and the modified cysteine residues do not participate in protein activity. 
Interrogating proteins using these early modification strategies required a highly 
judicious selection of modification methods and the fortune of working on a well-behaved 
protein substrate.15-17 
An important advance in protein modification came through the consideration of residue 
selectivity. The differences in pKA values of various amino groups had already been 
exploited through Edman degradation; use of an analogous yet non-destructive reagent 
at a suitable pH could also lead to selective modification of residues, such as where 
nucleophilic residues are rendered largely inert due to protonation at low pH (Figure 5). 
The α-amino residue again proved to be a useful starting point for this venture, with 
alkylation using fluorodinitrobenzene used to determine the pKA of the α-amino residue 
of human haemoglobin as 6.7 and finding a classic sigmoidal relationship between the 
rate and the pH.18 The same reaction with bovine pancreatic RNAse A demonstrated 
some reactivity at the α-amino group with an estimated pKA of 7.8, but the predominant 
product was instead modified at lysine-41, with the rate constant for the latter 
26 
 
modification an order of magnitude greater than that of the α-amino group rate 
constant.19 Unusual lack of reactivity and high pKA values of α-amino groups was also 
observed in porcine elastase, with a pKA of 9.7, adding a note of caution to the reliance 
upon reactivity of α-amino groups.20 This strategy was subsequently refined using 
radiolabelled fluorodinitrobenzene in the form of a pH-dependence assay for particular 
reactive residues, such as the single histidine residue in hen egg-white lysozyme and 
the α-amino group of a Streptomyces trypsin.21  
 
Figure 5: Literature pKA constants of protic protein residues.22 
Beyond the immediate kinetic and thermodynamic parameters obtained, this collective 
work highlighted a number of practical and philosophical considerations in the chemical 
protein modification field. Firstly, the variations in the proteome are manifested in the 
success (or lack thereof) of a modification strategy. A modification performed on one 
protein with one particular reagent may not perturb functionality, whilst the same process 
may render a different protein inert; one particular residue may be targeted in one 
protein, whilst a different amino acid is modified in another. Secondly, a consequence of 
the previous point, a protein modification strategy is likely to require some level of 
optimisation of conditions for each individual protein to achieve the desired outcome. It 
is not inconceivable, however, that a general modification strategy could be designed 
that minimises dependence upon variation amongst protein substrates and hence 
requires minimal tailoring. Thirdly, a protein is more than the sum of its parts: residue 
environment factors into residue reactivity, alongside which functional groups are 
present. At the time of this work, protein structure visualisation through methods such as 
crystallography and NMR was still not commonplace, meaning the information in the 
secondary, tertiary and quaternary structures of proteins could seldom be 
unambiguously considered. The modulation of residue pKA values or the surprising lack 
of reactivity from some residues demonstrated the need to consider the 
microenvironment of reactive residues, their positioning on the surface of the protein and 
distance from interfering bulk protein regions. A synthetic chemist’s perception of a 
particular amino acid may be wildly different from the role in which nature has deployed 
the residue in a protein. Finally, site selectivity is a crucial aspect of chemical protein 
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modification. Punctuating a sentence with a circumflex, when deployed correctly, can 
confer new, useful meaning; peppering the sentence with circumflexes will at best be of 
no use or hindrance, whilst at worst can completely diminish and obscure all of the 
information and meaning. Modification at one particular lysine residue may be innocuous, 
whilst modification at another, as observed with bovine pancreatic RNAse A, can leave 
the protein useless, whilst the generation of complex mixtures prevents unambiguous 
inference of the mixture composition. An ideal method would allow exclusive modification 
at the residue or residues desired with total control over reactivity- as nature has, of 
course, been doing. 
1.1.4 Introducing “unnatural” modifications 
The value of protein modification is not restricted to merely understanding the existing 
information bound inside a protein. Just as nature evolved PTMs to expand and augment 
the protein language beyond the initial canon of amino acids, so too can chemical protein 
modification be used to introduce new meaning or even an entirely new context. A major 
development was the conjugation of polyethylene glycol (PEG) polymers to proteins, with 
PEGylation attributed to improving protein solubility across a range of solvents, such as 
for industrial use of biocatalysis,23 and increasing the stability and half-life of a 
therapeutic protein in vivo.24 Initial PEGylation methods exploited the predictable 
nucleophilic character of lysine side chains with activated electrophilic derivatives of 
PEG, forming stable amine, amide or carbamate protein-PEG linkages (Figure 6).25-27 
The use of PEG activated with cyanuric chloride led to somewhat predictable off-target 
modification of nucleophilic active site cysteine thiols to inactivate enzyme functionality, 
but N-hydroxysuccinimidyl-PEG modification was found to offer minimal perturbation of 
functionality, presumably due to the milder activation method leading to fewer off-target 
modification of such thiol groups.28 Cognisant of the shotgun-like nature of these 
methods, one approach made use of protecting group chemistry to add a further level of 
control over site selectivity. More nucleophilic α- and ε-amino groups were first protected 
with a water-soluble alkyoxycarbonyl protecting group, ensuring that mixed anhydride 
PEGylation only acylated two amino groups in the insulin protein used, with a final 
saponification treatment cleaving the remaining protecting groups.29 Without such an 
approach, and when more complex proteins are used, PEGylation typically afforded a 
heterogenous mixture of proteins of varying molecular weights, with optimisation of 
conditions (usually varying the excess equivalents of the activated PEG reagent) 
required to target a particular average proportion of lysine residues targeted. 
Nevertheless, in this instance the end often justified the means, with even crudely 





Figure 6: Activated PEG derivatives used to acylate or alkylate nucleophilic residues on protein surfaces for 
PEG attachment: primarily lysine residues, but also α-amino groups and thiols.25-29 
An inspiration from nature came in the form of the use of the biotin-avidin pair, exhibiting 
one of the strongest binding constants known (KD ≈ 10-15 mol dm-3).32 The initial discovery 
of this pair came through the onset of biotin deficiency in rats fed predominantly on raw 
albumen.33 This was attributed to the high avidin content of this diet, with biotin, the so-
called vitamin H,34 being sequestered by the protein avidin and Streptomyces analogue 
streptavidin.35 Biotin primarily acts as a cofactor in carbon transfer during metabolism, 
attached to and cleaved from the ε-amino group of a lysine residue of carboxylase 
proteins as a PTM where the ureido group captures carbonate to be attached as a 
carboxylate group to substrates such as pyruvate.36 Avidin and analogues are suggested 
to have evolved as a defense mechanism: the decreased availability of biotin reduces 
the viability of bacterial pathogens in such environments by inhibiting metabolism, a 
conjecture supported by the localisation of avidin in avian eggs and seldom elsewhere 
in the same organisms.37 More recently a further role of biotin was discovered as a PTM 
of lysine residues on histone proteins;38 the precise nature and mechanism of this PTM 
is not yet fully understood, although various postulates consider biotinylation as a 
process involved in the regulation of gene expression or as a signal for DNA damage 
rather than a process involving an interaction with avidin or analogues.39 Nevertheless, 
the power of the biotin-avidin pair was swiftly exploited as a biotechnological tool, 
intuitively used to demonstrate that pyruvate carboxylase was biotinylated through its 
retention on an avidin-Sepharose column.40 It was quickly realised that the utility of biotin 
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lay in its role as the quarry of avidin, acting as a superb affinity tag for biomolecule 
substrates through avidin affinity chromatography or Western blotting (Figure 7). 
 
Figure 7: Biotinylated proteins can be separated from complex mixtures using avidin affinity chromatography 
or selectively detected using Western blotting with avidin-horseradish peroxidase or avidin-alkaline 
phosphatase conjugates. 
Methods for the installation of biotin were quickly developed, following those used for 
chemical protein PEGylation. The free carboxylate group served as a helpful handle to 
prepare biotin activated with para-nitrophenyl, bromoacetyl and diazo groups for 
reactions with lysine, cysteine, and tyrosine/histidine residues respectively, with the 
same considerations and drawbacks as the analogous methods used for PEGylation.41 
An early limitation of the biotin-avidin pair was the occasional finding that the complexes 
of biotinylated proteins with avidin were less stable than anticipated, attributed to protein 
steric bulk impeding the biotin from accessing the binding site on avidin.42 To ameliorate 
this issue, a spacer group was installed between the biotin and protein of interest. Whilst 
six-carbon alkyl linkers offered some improvement,43 the best results were observed 
when short PEG spacers were used, owing to the enhanced aqueous solubility and 
reduced immugenicity conferred by conjugation to this polymer.44 Optimisation of the 
affinity purification protocol has led to the use of monomeric avidin, rather than wild-type 
tetrameric avidin, which displays the same specificity for biotin but with a far lower 
binding constant (KD ≈ 10-7 mol dm-3) so that biotin-tagged proteins can be eluted under 
milder conditions compared to the harsh denaturing treatment required when using 
tetrameric avidin.45 A frequent usage has been deploying biotin-tagged antibodies or 
hormones to bind with unknown antigens and receptors, with avidin affinity purification 
allowing isolation and elucidation of the binding partner.46, 47 Through the repackaging of 
this evolutionary curiosity, biotinylation has become a staple of chemical protein 
modification, owing to the ease and reliability of avidin affinity as a method of detecting 
conjugated biotin and to the powerful biological probing abilities of the biotin tag.  
Perhaps the most visually striking chemical protein modification is the introduction of 
fluorescence. In nature, fluorescence is commonly confined to small molecules rather 
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than proteins, bar a comparatively tiny family of fluorescent proteins. This paucity of 
protein fluorophores can be attributed to two shortcomings: the often-hydrophobic nature 
of fluorophores, hence poorly suited for aqueous milieu, and the common quenching or 
photocatalysed degradation of fluorophore excited states, to the extent that biosynthesis 
of the fluorophore is too inefficient a strategy compared to others in nature’s possession. 
Development of synthetic protein fluorophores has also been sculpted by these two 
challenges and the two main fluorescent dyes used are dansyl and fluorescein 
derivatives,48 where the problem of hydrophobicity is mitigated by polar substituents 
attached to the fused ring systems. The initial utility of this modification is the ease of 
verification, where SDS-PAGE shows a fluorescent protein band to qualitatively confirm 
successful bioconjugation. More intricate applications make use of donor-acceptor dye 
pairs through Förster resonance energy transfer (FRET), where the distance-dependent 
quenching of fluorescence of the donor dye by an acceptor dye can be used to estimate 
the distance between fluorophores.49 In one such strategy, a surface-exposed tyrosine 
residue of liposome-bound gramicidin C peptides was labelled with either a donor dansyl 
dye or an acceptor diazo dye, with FRET-mediated quenching of dansyl fluorescence 
demonstrating that gramidicin C peptides are organised as dimers within membrane 
channels, separated by 33 Å.50 This work highlights how chemical protein modification 
need not be particularly elaborate or sophisticated, but can still offer great insight when 
given a suitable biological application.  
1.1.5 Contemporary methods for chemical protein modifcation 
Chemical protein modification has been a fortunate beneficiary of the advances seen in 
analytical biochemistry. The structures obtained from protein crystallography are almost 
indispensible when designing a modification strategy for a protein of interest; molecular 
biology techniques allow access to target proteins produced reliably in house, rather than 
crudely extracting a protein of interest from a biological mixture; and mass spectrometry 
offers rapid access to high-resolution protein mass data which can quantify the extent of 
modification and characterise the bioconjugate through top-down or bottom-up 
proteomics. The sophistication of modern chemical protein modification is, at least in 
part, attributable to the power of these analytical tools which have enabled chemical 
biologists to ask more probing questions and to receive more unequivocal answers. This 
has, in turn, guided the current strategies in chemical protein modification. Site selectivity 
and specificity have become key characteristics of modification methods, with two main 
directions used to achieve this: tuning the chemistry to modify the native protein, or 
introducing a reactive, unnatural handle into the protein to open up a greater range of 
chemical methods.  
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Where native proteins are to be used for chemical protein modification, the same 
constraints seen for decades in this field pervade and strategies generally centre on the 
two most reliably reactive functional groups of α- or ε-amines and cysteinyl thiols. The 
latter functional group has received particular attention, where the rarity of this residue 
amongst proteins in nature goes some way towards solving the site selectivity problem 
and with the sulfur atom still offering a wealth of chemical reactivity. Sulfa-Michael 
addition reactions have received particular attention for this purpose, where the softness 
of the thiol compared to amino or hydroxyl nucleophiles affords a useful level of 
chemoselectivity. Maleimide-type chemistry (Figure 8) stands out as the favoured 
method for cysteine modifications: initially developed to quantify free thiol groups in 
proteins,51 followed by as a cross-linking reagent,52 maleimides were soon exploited as 
a superb handle for bioconjugations owing to the mild conjugation conditions, 
chemoselectivity, lack of side reactions, and the versatility and stability of the ensuing 
linkage. Wide-ranging applications of maleimide chemistry speak to the reliability and 
success of this work: fluorescent protein labelling,53 designing biologically active protein-
polymer conjugates,54 immobilising proteins on quantum dots as part of a sensitive 
fluoroimmunoassay,55 and preparing therapeutic antibody-drug conjugates.56  
A known, minor limitation of maleimide chemistry is the tendency for a retro-Michael 
addition to occur, cleaving the bioconjugate in an uncontrolled and potentially 
undesirable manner.57 This has been circumvented through either purposefully 
hydrolysing the thiosuccinimide ring,58 which will subsequently not undergo retro-Michael 
addition,59 or by tuning the maleimide reagent such that cleavage can be induced in a 
controlled manner. To this end, bromomaleimides have been developed, where the 
thiomaleimide formed following cysteine alkylation with bromomaleimide can be cleaved 
completely by treatment with a large excess of competing thiol.60 Alternatively, the 
thiomaleimide can undergo a further sulfa-Michael addition with stoichiometric quantities 
of a second thiol, forming a dithiosuccinimide which is as resistant to thiol-mediated 
degradation as the thiosuccinimide formed when regular maleimides are used. The 
lability of dithiomaleimides was exploited using dibromomaleimides: a protein thiol can 
be alkylated and then linked via the maleimide core to a thiol tag, all of which can be 
cleaved by treatment with excess thiol or hydrolysed to stabilise the linkage.61 Similarly, 
a dibromomaleimide or a dithiomaleimide tagging reagent can be inserted into disulfide 
bridges to retain native structural integrity whilst modifying with a useful tag, such as 
labelling an antibody with a drug payload at the interchain disulfide bridges.62, 63 The 
development of maleimide chemistry has offered a high level of control particularly well 
suited to therapeutic applications, where payload delivery may necessitate reversible or 




































































































































































































































































































































































































Several strategies for modification of native N-termini via the α-amino group have 
emerged, most commonly relying on the same pKA difference to establish site selectivity. 
The use of low pH favours modifications exclusively at the α-amino group, such as 
acylations using N-hydroxysuccinimide (NHS) esters and reductive amination, although 
such acidic conditions may not be suitable for all proteins and are often outside the 
optimal pH range for a given chemical modification strategy, leading to reduced 
bioconjugation yields.64 Fortunately, the side chain functionality of the N-terminal residue 
can be drafted in to assist with such reactivity. Seryl and threonyl 1,2-aminoalcohols can 
form oxazolidines with aldehydes (Figure 9),64 whilst cysteinyl 1,2-aminothiols can 
similarly trap aldehydes to form thiazolidines,65 react with cyanobenzothiazolines,66 or 
partake in the powerful native chemical ligation reaction.67 The limitations of N-terminal 
strategies do hinder these strategies, however: the N-terminal residue may be buried 
within the protein or rendered unavailable for chemistry due to participation in active site 
function,68 the modification can only be applied once to the protein, and the restriction of 
the modification to the N-terminus may not be desirable for the purpose of the 
bioconjugation, e.g. too close to the active site. 
 
Figure 9: Modification of native amino groups at the N-terminus and at selective lysine side chains. 
Modification of lysine amino groups is still held back by the distribution of multiple 
reactive ε-amino groups across the protein surface. In one instance, extensive kinetic 
optimisation of acylation using NHS esters afforded labelling at a single residue, but the 
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use of low equivalents (0.5) of labelling reagent lead to incomplete labelling and 
mandated affinity purification using an installed biotin tag.69 A more sophisticated 
evolution of this strategy used computational modelling of the pKA constants and 
microenvironments of ε-amino groups along with the design of various electrophilic aza-
Michael acceptors to devise a labelling strategy modifying only a single lysine residue to 
completion (Figure 10).70 From initial crystal structures to complex molecular dynamics 
calculations, the use of computational modelling to inform labelling of native proteins is 
likely to continue its expansion over the coming years, countering the diversity of the 
proteome with methods tailored both in silico and in vitro to every protein modification 
scenario imaginable. 
Constrained by the limitations of early chemical modification methods for native 
substrates, attention turned upon the alteration of native residues to install non-native 
chemical functionality as a handle for new chemistries. This was initially discovered 
through harsh chemical methods used to understand protein structure, where proteins 
containing N-terminal serine or threonine residues exhibited a greater level of reactivity 
towards periodic acid71 or periodate than expected, with the detection of formaldehyde 
byproduct used to confirm the presence of an N-terminal serine or threonine residue.72 
The residue left behind was identified as a glyoxylamide (Figure 10) owing in part to its 
reduction by borohydride,73 the utility of which was then exploited through the 
transamination of this reactive aldehyde in the presence of Cu2+ and an amine donor to 
form a native glycine residue: a “chemical mutation”.74 Intuitively the reverse reaction 
was also discovered, transaminating a native N-terminal glycine residue using Cu2+ and 
glyoxylic acid as an amine acceptor and subsequently exploiting the reactivity of the 
protein glyoxyl aldehyde with anilines to form Schiff base bioconjugates.75 This reaction 
has now been optimised to work under milder conditions without any metals through the 
biomimetic use of pyridoxal-5-phosphate (PLP), a staple of biosynthetic transaminations, 
although the reaction remains an equilibrium which can hamper conversions.76 A rich 
vocabulary of aldehyde chemistry has hence been translated for use on protein aldehyde 
substrates,77 as the presence of a single aldehyde in a protein means that 
bioconjugations are inherently site-specific if the chemistry is chemospecific for 
aldehydes. Oxime/hydrazone ligations have surpassed Schiff base formation as the 
premier strategy for conjugating to protein aldehydes, where the hydroxylamine or 
hydrazine reagent is not only more nucleophilic, leading to greater rates of reaction, but 
the resulting bioconjugate, especially the oxime linkage, is also less electrophilic and 




Figure 10: Selected methods for the incorporation of aldehydes and dehydroalanine into proteins for 
subsequent chemical modification. 
A further demonstration of “chemical mutation” was observed through reactions at a 
nucleophilic active site serine residue: following activation with an acyl halide, the leaving 
group could either be substituted by a thioacetate nucleophile and hydrolysed to yield a 
native cysteine residue,81 or eliminated with a base to form the residue dehydroalanine.82 
Whilst initially a novelty perturbing enzymatic performance, the authors noted the 
opportunities opened up by dehydroalanine as a means through which additional 
functionality could be installed in proteins.83 Of course nature had already exploited this 
tool, such as generating dehydroalanine in lantibiotics through the enzymatic 
dehydration of specific serine or threonine residues and forming cyclic peptides through 
intramolecular sulfa-Michael additions with cysteine thiols.84 Not wishing to be outdone 
by nature, intense research on the generation and reactivity of dehydroalanine ensued. 
Multiple methods have been devised for the installation of dehydroalanine, with perhaps 
the most useful method being the elimination of cysteine thiols (Figure 10), often 
activating the thiol as a sulfonium ion leaving group via bis-alkylation.85 A notable 
consideration is the scrambling of chirality at the dehydroalanine residue, where the lack 
of chiral induction in subsequent chemical modification methods leads to a roughly 1:1 
mixture of epimers.86 In addition to afore-mentioned hetero-Michael additions, 
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dehydroalanine residues can undergo radical additions to form stable carbon-carbon 
bonds with a range of small molecule tags, including synthetically challenging post-
translational modification mimics.87  
A final boost to chemical protein modification has come directly from nature itself. As 
molecular biology techniques progressed, many useful enzymes suddenly became 
available in laboratories with very little effort required for production and some of nature’s 
own protein modification strategies were uncovered. The active sites across a range of 
sulfatases contained the unusual aldehyde residue formylglycine, where the hydrated 
aldehyde diol played a mechanistic role in sulfate ester hydrolysis.88 This residue was 
found to arise in a highly conserved CXPXR recognition sequence in which the cysteine 
residue is converted to formylglycine by formylglycine-generating enzyme (FGE). The 
biotechnological applications of this quirk were quickly realised: the installation of a short 
CXPXR sequence within a protein led to the exposure of a reactive aldehyde following 
treatment with FGE (Figure 10),89 opening up aldehyde chemistry beyond the N terminus 
and even enjoying use for preparing antibody-drug conjugates.90 A booming area of 
investigation is the use of amber stop codon suppression, in which an amber stop codon 
is reassigned as a proteinogenic amino acid with the assistance of an amber stop codon 
tRNA and the corresponding tRNA synthetase. Through the use of a 
Methanocaldococcus janaschii tRNA-synthetase pair, many tyrosine/phenylalanine 
analogues, including one bearing a reactive aldehyde,91 have been incorporated into 
proteins and subsequently functionalised, with the single amino acid mutation 
representing a small structural perturbation with a big potential for chemical protein 
modification.92 
1.1.6 The real-life impact of chemical protein modification 
It is far too easy to continuously ponder and philosophise over chemical protein 
modification, and indeed most of science, when the repercussions of this technology on 
daily life are absolutely worth consideration. For chemical protein modification, or indeed 
any area of research, to be truly useful, the positive findings espoused in myriads of 
publications must be translated into beneficial tools for society. This has been the case 
with chemically PEGylated proteins, such as Pegasys. As a PEGylated derivative of 
interferon-2α, Pegasys was first approved in Switzerland in 2001 for the treatment of 
chronic hepatitis B and C infections,93 with PEGylation responsible for the superior 
antiviral activity and longer half-life compared to standard interferon-2α. The PEGylation 
process uses a  standard acylation method between a free interferon-2α amino group 
and a 40 kDa PEG NHS ester, with conditions optimised for monoacylation at the side 
chains of Lys-31, Lys-121, Lys-131 or Lys-134.94 Pegasys is now listed on the World 
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Health Organisation List of Essential Medicines as a clear testament to its efficacy and 
thus to its impact on public health. 
Perhaps the most celebrated example of chemical protein modification is the antibody-
drug conjugate (ADC) trastuzumab emtansine, marketed as Kadcyla. Trastuzumab, 
marketed as Herceptin, is an antibody therapeutic which targets HER2 receptors, 
overexpressed on certain types of breast cancer, blocking this signalling pathway 
attributed to cell proliferation.95 Combined with chemotherapy, trastuzumab just as the 
antibody was found to increase median survival time by 25%, approximately five months 
of extra time alive.96 Kadcyla combines the targeting and HER2 binding of the 
trastuzumab antibody with the small molecule drug DM1 via a stable covalent linkage. 
To achieve this, first a bifunctional linker is attached via the NHS-activated carboxylate 
end to amino groups on trastuzumab, followed by sulfa-Michael addition of the DM1 thiol 
to the maleimide portion of the linker.97 Every trastuzumab antibody is loaded with 
approximately 3.5 molecules of DM1 on average, as the lack of control in the NHS 
acylation step leads to some heterogeneity.98 Nevertheless Kadcyla is approved for use 
against challenging cases of advanced HER2-positive breast cancer, with a significant 
phase III trial finding a 20% increase in median survival rates in patients receiving 
Kadcyla treatment,99 and surely represents the boldest move yet for chemical protein 
modification out of the lab and into society. 
1.1.7 Conclusions 
The rise of chemical protein modification has been an evolution against evolution itself. 
This powerful technique has aided with the unravelling of nature’s protein language, 
offered entirely new words for the protein vocabulary, and has been translated into forms 
that widely benefit humankind in the unwinnable fight against nature’s planned 
obsolescence mechanisms, just as nature developed post-translational modifications to 
protract this struggle. Formerly an analytical tool primarily used to translate the protein 
language into human knowledge, powerful mass spectrometry and other methods now 
serve the needs of chemical protein modification, unlocking its full potential as a means 
to introduce new meaning into the protein language. The current directions of the field 
can be summarised by two main objectives: developing the most diverse array of 
methods, so that the toolbox contains a tool for every one of nature’s diverse proteins, 
and developing further applications of this technology which further improve daily life, 
which primarily leads in a therapeutic direction. Given the rapidity with which this field 
moves, certainly over the past decade, there is no doubt that many inspired and 
imaginative strategies will be devised to meet these objectives.  
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1.2 Amber stop codon suppression: a chemical biology tool 
1.2.1 Pyrrolysine, an unusual canonical amino acid 
Arising from peculiarities observed in the proteome and genome of an otherwise 
innocuous methanogenic microorganism, an entirely new canonical amino acid was 
added to the genetic code. The archaeal species Methanosarcina barkeri, capable of 
utilising a range of alkylamines for methanogenesis,100 was found to utilise three 
methyltransferase enzymes at the start of three analogous converging catabolic 
pathways in which mono-, di- and trimethylamine substrates were demethylated and 
reduced to ammonia and methane. Unusually the genes encoding the three 
methyltransferase enzymes were found to contain in-frame amber stop codons, TAG, 
which did not appear to terminate translation and were posited to genetically encode a 
lysine derivative based upon trypsin digests of the methyltransferases.101 Around the 
gene cluster encoding the methyltransferases were two further oddities: the gene pylT, 
encoding a tRNA with a CUA anticodon, which would be complimentary to a UAG mRNA 
codon, and the gene pylS, encoding an aminoacyl-tRNA synthetase, pylRS, which was 
found to aminoacylate tRNACUA.102 Mass spectrometry and crystallisation of a TAG-
containing methyltransferase permitted elucidation of the recondite residue, assigned as 
pyrrolysine 1 (Pyl; single letter code O) in which the methylpyrroline ring, appended to a 
lysine backbone, was proposed as playing a crucial role as an electrophilic catalytic 
residue, trapping methylamines and activating the methyl group towards capture by the 
cobalt(I) centre of a corrinoid metalloenzyme.103 Addition of the methylpyrroline ring was 
postulated to not be a PTM in the same vein as other acylated/alkylated lysines 2-4, but 
instead the product of a biosynthetic pathway.104 This was later demonstrated to be 
correct, as 1 was found to be biosynthesised from two units of lysine 5 via 6 and 7105 by 




Figure 11: Pyrrolysine 1, unlike post-translational modifications 2-4, is biosynthesised prior to translation 
from L-lysine 5 via 6 and 7. 
With this reasoning established, the pathway to pyrrolysine-containing proteins can be 
posited. During translation, tRNACUA is produced and charged with pyrrolysine by pylRS, 
affording pyrrolysyl-tRNACUA which can be utilised in the ribosome to add pyrrolysine to 
the growing polypeptide chain at UAG codons. Thus, for amber stop codon suppression 
of a UAG-containing gene, three components are necessary: the amino acid pyrrolysine, 
the tRNACUA, and the pyrrolysyl tRNA synthetase, which nature has gifted M. barkeri and 
Methanosarcina mazei (inter alia) in the form of the pylBCDST genes. The orthogonality 
of the pyrrolysyl tRNA-RS pair to canonical amino acids is a further blessing, affording 
reliable pyrrolysine incorporation: only pyrrolysine, and no other canonical amino acids 
such as lysine, are suitable substrates for pylRS, whilst no canonical tRNA synthetases 
can charge any tRNA with pyrrolysine.111 Given the criticality of pyrrolysine to the survival 
of M. barkeri in such inhospitable anaerobic environments, it is no wonder that nature 
has evolved such a disciplined mechanism for the utilisation of this privileged amino acid.  
1.2.2 A Promiscuous tRNA-RS Pair for Protein Production 
As mentioned, the pyrrolysyl tRNA-RS pair is orthogonal to canonical amino acids other 
than pyrrolysine. This orthogonality can be rationalised through nature’s careful 
engineering of the structure and active site of the pylRS protein. A crystal structure of 
the wild type M. mazei in complex with Pyl-AMP, an intermediate in the formation of the 
aminoacyl-tRNA complex, exposed the presence of an unusually hydrophobic and 
caverous pocket (Figure 12).112 This additional binding space accommodates the 
pyrroline ring of pyrrolysine, otherwise too bulky to be accommodated in the active site 
of canonical RNA synthetases. The overall structure of this RS and its propensity to exist 
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as a homodimer, with a homotetrameric complex considered possible, led to its 
classification as a class IIc RS with its closest relative being an ancestral form of 
phenylalanyl RS, putatively existing as a homotetramer.112 
 
Figure 12: The hydrophobic methylpyrroline ring of 1 occupies a hydrophobic cleft deep within PylRS (PDB: 
2Q7H). 
Closer examination of the hydrophobic binding pocket affords a more complete 
rationalisation of the specificity of the pyrrolysyl RS. Tyr384 and Asn346 are arguably 
the most crucial residues, given both their function and their highly conserved nature:112 
Tyr384 acts as a kingpin, hydrogen-bonding to both the α-amino and α'-imine groups of 
pyrrolysine through the phenolic hydroxyl group,113 whilst Asn346 hydrogen bonds 
directly with the amide carbonyl and through a water molecule with the α-amino group 
(Figure 13, left). Beyond these two gatekeeper residues, the outline of the deep 
hydrophobic pocket can be seen defined by the non-polar side chains of residues 
Ala302, Leu305, Tyr306, Leu309, Cys348 and Trp417 (Figure 13, right), accommodating 
the hydrophobic region of the methylpyrroline ring. The arrangement of this binding 
pocket clearly permits comfortable binding of pyrrolysine whilst deterring all other 
canonical amino acids. Obtaining a crystal structure of pylRS certainly offered a greater 
level of insight into the workings of this enzyme. However, this process directly yet 
perhaps unintentionally led to further discoveries which are arguably of far greater 
magnitude and consequence. 
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Attempts to obtain holo structures of pylRS were impaired by limited access to 
pyrrolysine itself. The methylpyrroline ring acts as a highly uncooperative moiety of the 
ligand in this sense, hydrolysing and ring-opening in a range of conditions and, for the 
same reason and the presence of two chiral centres, presenting a menacing synthetic 
challenge.  The first reported synthesis of pyrrolysine constructed the methylpyrroline 
ring through a complex-directed asymmetric Michael addition between a nickel-
coordinated glycine ligand and crotonaldehyde, followed by hydrolysis and cyclisation 
(Figure 14).114 This latter step, achieving 43% yield, hampers the utility of this synthesis, 
affording only 9% final product over eight steps. 
 
Figure 14: Asymmetric Michael addition of glycine to crotonaldehyde followed by hydrolysis and cyclisation 
forms the crucial methylpyrroline ring (blue) of 1. a: DBU, DCM, r.t., 97%. b: HCl, MeOH, Δ, then TMSCl, 









Figure 13: (left) Hydrogen bonding interactions with Tyr384 and Asn346 hold 1 in place; (right) various 




Figure 15: Two recent synthetic routes to 1: (upper) metal-mediated asymmetric Michael addition of a glycine 
imine to methyl crotonoate prepares the stereocentres and a tandem Staudinger/aza-Wittig cyclisation 
closes the ring; (lower) organocatalytic asymmetric Michael addition of ethyl nitroacetate to crotonaldehyde 
affords the correct stereochemistry and subsequent deprotection and cyclisation forms the methylpyrroline 
ring of 1. a: Ca(OiPr)2, 4 Å molecular sieves, THF, -20 °C, 99% e.e., >98% d.e., 92%. b: polystyrene-
supported PPh3, THF, Δ, quantitative. c: LiOH, MeOH, THF, H2O, quantitative. d: Jørgensen catalyst, BzOH, 
then MeOH, p-TsOH, CH(OMe)3, 90% e.e., 1:1 mixture of C-2 diasteromers, 96%. e: p-TsOH, MeOH, 32%. 
To date, few strategies have improved upon these results. One strategy makes use of 
another metal-mediated asymmetric Michael addition to prepare both chiral centres with 
the correct configuration, with the final step of imine cyclisation via a tandem 
Staudinger/aza-Wittig reaction and subsequent deprotection affording pyrrolysine in 20% 
yield over 13 steps (Figure 15).115 The shortest strategy, six steps, affords pyrrolysine in 
19% yield: starting again with an asymmetric Michael addition, this time directed by a 
Jørgensen organocatalyst,116 albeit affording a 1:1 mixture of diastereomers at C-2. 
Fortunately the “incorrect” diasteromer was found to isomerise to the correct 
diastereomer under strongly basic conditions, leading to the conclusion of the strategy 
with tandem deprotection and imine formation.117 Nature’s neat four-step biosynthesis 
easily outpaces these strategies, although pyrrolysine synthesised in this way would 
suffer from the same impractical degradation predicament impeding crystal preparation.  
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Evidently sufficient quantities of pyrrolysine were scraped out to lead to successful 
crystallisation of pylRS with Pyl-AMP. However a fortuitous discovery demonstrated that 
analogues 8 and 9 were suitable substrates for pylRS,118 and an alternative holo 
structure of pylRS with ATP and 9 ligands was obtained (Figure 16).112 Both pyrrolysine 
analogues also demonstrated suitability for proteinogenic amber stop codon 
suppression, allowing the production of active β-galactosidase despite the presence of 
an otherwise destructive Trp220-TAG mutation in the lacZ gene.118 By this time, amber 
stop codon suppression had already been used to prepare useful protein constructs 
using leucyl119 and tyrosyl tRNACUA-RS pairs from Eschericia coli120 and M. janaschii,121 
all of which exhibited a broad tolerance to various non-canonical amino acids (NCAAs). 
Hence the greater utility of pylRS was theorised: as monogamous for pyrrolysine as 
pylRS may be amongst canonical amino acids, perhaps pylRS exhibits a more open 
relationship with non-canonical pyrrolysine analogues and can introduce a range of non-
canonical lysine analogues into the genetic code, complementing existing non-canonical 
tyrosine and leucine analogues.  
 
Figure 16: (left) Pyrrolysine analogues 8 and 9 were found to be suitable substrates for M. mazei pylRS, with 
a crystal structure of 9 bound to pylRS (right; PDB: 2Q7G). 
The limits of the promiscuity of pylRS were further tested by lysine derivatives 10-13 
(Figure 17). Both 10 and 11 were found to be suitable substrates for wild-type M. mazei 
pylRS122 but 12 and 13 were not.123 Through the use of enzyme engineering, key active 
site residues were randomised and, through multiple selection rounds, pylRS mutants 
were identified which could recognise 12 and 13 as substrates. The three mutations 
L309A, C348V and Y384F permitted turnover of 12,123 whilst with only two mutations, a 
Y306A Y384F pylRS variant (pylRSAF) recognised both 12 and 13, with the ortho 
substituent seemingly well-tolerated owing to the greater space in the enlargened binding 
pocket.122 Furthermore, incorporation of 13 into a protein, in this case GST, allowed 
chemical modification using Bertozzi-Staudinger ligation,124 affording a fluorescently 
labelled GST bioconjugate. It was also discovered that the single Y384 mutation 
enhanced turnover of 1, 10 and 11, albeit at the expense of introducing some undesirable 
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turnover of canonical amino acids. A higher rate in the generation of aminoacyl-tRNA 
was ascribed to a secondary role of the Y384 residue: as a physical gatekeeper, in 
addition to a figurative gatekeeper. Removal of the Y384 hydroxyl group putatively opens 
up access for the tRNACUA terminal base to be acylated by the carboxylate phosphoester, 
lowering the activation energy for this pathway, although this kinetic boost is 
accompanied by the unwanted thermodynamic boost in non-specific amino acid binding. 
Nevertheless, this work demonstrated two crucial findings: not only the possibilities and 
limitations of enzyme engineering in broadening the range of pyrrolysine analogues used 
with pylRS, but also the utility of the expanded range of pyrrolysine analogues for protein 
modification and beyond. 
 
Figure 17: Protected derivatives of lysine recognised by wild-type or mutated pylRS. 
For a tRNA-RS pair to be useful for protein modification, the protein production process 
must first be established (Figure 18). Owing to the absence of tRNACUA and pylRS genes, 
host organisms must be transfected not only with the gene of interest but also with the 
suppressor pair genes. Multiple vectors have been designed which combine various 
genes on the same vector,125 utilise evolved  tRNACUA species for superior stop codon 
suppression,126 permit  suppression of multiple stop codons127 using multiple NCAAs,128 
and can be successfully used in eukaryotic host organisms.129-131 During protein 
production, growth medium must also be supplanted with the NCAA(s) of choice, which 
can be through chemical synthesis or host biosynthesis.132 Yields of the protein of 
interest are generally lower when amber stop codon suppression is used, in part due to 
premature termination of translation at the reassigned stop codon. Efforts to circumvent 
this problem have involved the generation of a viable host species of E. coli with all native 
amber stop codons mutated to opal or ochre133 and through the gene knock-out of 





Figure 18: An overview of amber stop codon suppression. 
1.2.3 Protecting groups and post-translational mimicry 
One of the immediate priorities in the development of the pyrrolysyl tRNA-RS pair was 
the ability to genetically incorporate acetylated lysine 2, as this residue is highly abundant 
in the proteome as a PTM. One set of high-value targets of this nature are histone 
proteins, in which the acylation and alkylation of various lysine residues has implications 
for various disease states and processes. An early method of preparing histone H4 with 
K16 acetylation required the use of native chemical ligation, stitching together a 22-mer 
synthetic peptide containing 2 with the remaining 80-mer peptide produced using 
recombinant methods.135 As innovative and powerful a use of semisynthetic chemistry 
this may have been, it remains a laborious, challenging process and offers no guarantee 
that the final protein adopts the native fold and retains full function. 
Amber stop codon suppression offered a superior solution, producing full-length 
recombinant proteins far more efficiently, yet was limited by the poor turnover of 2 by 
pylRS. Rational engineering of both M. barkeri and M. mazei pylRS proteins led to 
successful recognition of 2, with analogous mutations possible due to the substantial 
level of homology between the two variants.136 The four key mutations of L305I, Y306F, 
L309A and C348F applied to the M. mazei pylRS closed off the deepest portion of the 
binding pocket, allowing the comparatively small 2 to comfortably occupy the now-
shrunken space (Figure 19).123 The binding mode adopted is vastly different from that of 
1 in the wild-type M. mazei pylRS: N346 mostly interacts with the α-amino and 
carboxylate groups whilst Y384 plays little role, appearing highly disordered. The carbon 
chain of 2 has straightened out: the α' centre lies deeper within the binding pocket, 
potentially to place the carbonyl oxygen atom in reach of aromatic residues for n→π* 
interactions, although this binding mode is overall suboptimal both upon inspection and 
by the measured amber stop codon suppression efficiency.137 Nevertheless, with 
success demonstrated by the production of 2-containing myoglobin, this methodology 
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was then applied to histone H3 in order to understand the effect of K56 acetylation, as 
the acetylation at this site in the middle of the protein rendered many synthetic methods 
unsuitable. Homogeneous samples of H3 containing native or acetylated lysine residues 
at position 56 were both prepared, the latter using amber stop codon suppression and 2, 
permitting a thorough investigation into the function of H3 K56 acetylation in processes 
such as DNA breathing,138 alongside the preparation of a variety of other monoacetylated 
H2A, H2B and H3 histones.  
 
Figure 19: (left) In the pylRS mutant recognising 2, hydrogen bonds with Asn346 still hold the substrate 2 in 
place but with a different geometry and no interactions between 2 and Tyr384; (right) the shrunken binding 
pocket is capped by three aromatic rings, two installed by mutations, all of which appear to orientated in 
such a way as to interact with the carbonyl oxygen of 2 (PDB: 4Q6G). 
Given that acylation of histones frequently occurs at multiple lysine residues, the next 
logical development was the ability to incorporate more than one 2 residue into a protein. 
Through optimisation of the amber stop suppression protocol, homogenous samples of 
histone H3 acylated at up to four specific lysine residues could be produced in quantities 
sufficient for mononucleosome preparation and assaying.139 Further development of a 
highly optimised cassette facilitated the production of histone H3 with as many as six 
acetylated lysine residues in mammalian cells, elucidating the effect of histone acylation 
in gene expression.140  
However, acylation is not the only commonplace post-translational modification for 












monomethylated lysine 3 through the use of rationally guided directed evolution 
strategies failed to reproduce the success observed with 2:141 the methyl group is simply 
too small to sufficiently occupy the hydrophobic pocket, whilst discrimination between 
lysine and 3 also becomes challenging.  
An astute strategy proposed a combination of traditional deprotection chemistry with 
amber stop codon suppression to solve this problem. Incorporation of 10 was known,123 
as was its lability under even mildly acidic conditions, so perhaps a methylated derivative 
14 could still be deprotected but affording a methylated lysine residue rather than native 
lysine. Indeed 14 was found to remain a suitable substrate for the wild-type M. barkeri 
pylRS, with the extra methyl group seemingly causing little perturbation of substrate 
recognition with the result of full-length histone H3 containing 14 at position K9. 
Deprotection under conditions reported as mild, 2% TFA (Figure 20), completely cleaved 
the Boc group within four hours to afford the desired protein, H3K9Me1,141 with 
methylation demonstrated not only by MS but also by the binding of heterochromatin 
protein 1, a protein specific for the full-length monomethylated histone. This work was 
subsequently expanded to produce histone H3 containing four 3 residues through the 
same general strategy, albeit making use of even more forcing conditions (50-60% 
TFA).142  
An alternative strategy made use of a different protecting group: the Alloc-containing 15, 
given that 11 was also a known substrate for pylRS and given the tolerance exhibited for 
the additional methyl group in amber stop codon suppression (Figure 20).122 The primary 
advantage of this strategy is the less harsh manner in which the Alloc group can be 
removed, requiring a ruthenium complex in place of strong acid, rendering this strategy 
somewhat more biocompatible.143 The introduction of 3 into proteins remains in essence 
a post-translational modification; now the modification is not an enzymatic methylation, 






Figure 20: Genetic incorporation of 3 can only proceed indirectly via initial incorporation of 14 or 15 followed 
by chemical deprotection. a: 2% (v/v) TFA, 4 h, 37 °C. b: PhSH, RuCl(cod)Cp*, 3 h, 37 °C. 
An even greater challenge is the addition of dimethylated lysine 4 to the genetic code. 
Discrimination between this amino acid and native lysine remains an issue, worsened by 
the inability to add a further protecting group to the ε-amino group due to the limited 
valency of nitrogen and the instability of suitable quaternary ammonium salts. The first 
strategy to produce proteins containing 4 more resembled a classical synthetic 
procedure, relying heavily on protecting group manipulation, than a recombinant method. 
Once again 10 was reliably incorporated into the protein, followed by chemical protection 
of all 12 other lysine residues in histone H3. Upon deprotection of the Boc group in 60% 
TFA, the single exposed lysine can undergo reductive methylation twice to form the 
desired dimethylated lysine residue, followed by global deprotection (Figure 21).144 
Whilst certainly an impressive effort, the multiple harsh chemical protection and 
deprotection steps limit the effectiveness and scope of a methodology which ought to be 
broadly applicable and efficient. Later work sought to remedy these deficiencies by 
designing a simpler and less harsh route for the installation of 4. This time only a single 
deprotection step was required: reductive decomposition of 16, using an analogue of the 
protecting group seen with 13, exposed an enamine on the residue side-chain. Upon 
spontaneous hydrolysis, the resulting aldehyde underwent reductive amination to form 
the desired dimethylated lysine residue (Figure 21).145 With the exception of the lengthy 
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synthesis required to obtain 13, this new methodology offered a far simpler route to 
proteins containing 4 merely through reversing the location of the required aldehyde and 
amine. 
 
Figure 21: Protection/deprotection and alkylation strategies required to circumvent the inherent difficulties 
encountered when seeking to incorporate 4 using stop codon suppression. a: Cbz-OSu, DIPEA, DMSO. b: 
TFA, H2O. c: CH2O, DMAB. d: TfOH, DMS, TFA. e: TCEP, PBS, pH 7. f: NaBH3CN, dimethylamine, PBS, 
pH 7. 
Other various lysine acylations have been observed in the proteome and attempts to 
mimic these post-translational modifications using amber stop codon suppression have 
been met with some success. Short fatty acyl lysines 17, 18 and 19 (Figure 22) were 
recognised by engineered M. barkeri pylRS mutants146, 147 and even wild type M. mazei 
pylRS,148, 149 with yields eventually sufficient to allow the assembly and isolation of 
homogeneous histone H4 octamer samples. Two further lysine post-translational 
modifications, both found in endogenous histones, were also introduced into 
recombinant histones using NCAAs 20150 and 21,151 with an engineered pylRS variant 
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recognising not only the latter derivative but also analogues 22 and 23, likely due to the 
inability of pylRS to discriminate between such comparatively small differences at the 
isobutyl group.  
 
Figure 22: Acyl lysine derivatives and precursors suitable for use in amber stop codon suppression. 
The medium-length fatty acyl lysine 24 proved to be amenable to amber stop codon 
suppression as well. The standard directed evolution of M. mazei pylRS facilitated 
access to recombinant heptanoylated glucagon-like peptide 1, with the heptanoylation 
reportedly improving binding to human serum albumin and increasing the half-life of this 
therapeutic protein.152 Long-chain fatty acyl lysine derivatives eventually established the 
limits of amber stop codon suppression in this direction due to solubility problems: whilst 
25 was soluble at the required concentrations in aqueous media for directed evolution of 
M. mazei pylRS and subsequent incorporation into histones, the longer-chain 26 was 
simply too hydrophobic and insoluble to be of any utility.153 Whilst more labour-intensive, 
a more biomimetic strategy sought to use a genetically encoded reactive lysine derivative 
27 which could undergo post-translational chemical modification, with the latter step 
allowing a greater range of possible acylations due to the lack of enzyme specificity 
limitations. Through the use of a traceless Staudinger ligation between the azide and a 
phosphinothioester bearing the desired acyl group, acetylation and novel succinylation 
of test proteins and histone H3 was observed.154 A limitation of this method is the 
competition between Staudinger reduction and Staudinger ligation, producing an 
approximately 1:1 mixture of acylated:non-acylated protein. 
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The dovetailing of genetic incorporation of traditional synthetic chemistry protecting 
groups with bioorthogonal deprotection procedures has not only benefitted the study of 
histone proteins. An evolution in protecting strategies was adapted to the protein 
modification paradigm: as lysine derivatives 12123 and 28131 were an established part of 
the expanded genetic code, more mild deprotection of such lysine residues using 
palladium/H2 and long-wave UV irradiation respectively was feasible in place of highly 
acidic conditions (Figure 23). Almost concomitantly, two different groups jumped upon 
this idea: whilst on-protein hydrogenation of the N-methyl derivative of 12 failed due to 
protein aggregation and poor yield,155 both groups were able to photodecage the N-
methyl derivative of 28 successfully. Later use of palladium, this time as a complex rather 
than elemental, fully showcased its excellent potential as a reagent in bioorthogonal 
deprotection with 11 and 29.156 The latter protecting group was shown to be easier to 
cleave in aqueous conditions than the former using two readily available, biologically 
compatible palladium complexes, culminating in the metal-mediated activation of a 
bacterial toxin through this palladium decaging of a key lysine residue. 
 
Figure 23: Protecting groups on lysine surrogates facilitates lysine activation using biocompatible 
deprotection chemistry. 
1.2.4 Genetically encoded bioorthogonal chemistry 
Click chemistry has quickly become the first thought at every mention of the phrase 
“bioorthogonal chemistry”: versatility, biocompatibility, coupling partner stability and 
comparatively rapid kinetics have all contributed to this well-earned reputation. An early 
use of click chemistry for protein modification saw a viral coat protein non-selectively 
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modified with an azido-acyl linker followed by ligation with an alkynyl fluorescein and an 
alkynyl dansyl-BSA bioconjugate.157 Whilst the utility of the copper-catalysed azide-
alkyne cycloaddition (CuAAC) had indeed been demonstrated, this work also revealed a 
limitation of this chemistry: the uncontrollable off-target labelling, as installation methods 
for both coupling partners were severely lacking in site specificity. Amber stop codon 
suppression has proven to be a near-perfect solution to this problem and its synergistic 
relationship with CuAAC, together offering unparalleled site specificity of coupling 
partner incorporation and therefore reactivity, has facilitated an unfettered infatuation 
with CuAAC amongst the chemical biology research community. Interest quickly honed 
in on suitable lysine derivatives such as alkynes 29-31 and azides 32 and 33 (Figure 24), 
generating newly CuAAC-modified bioconjugates such as proteins bearing fluorescent, 
affinity or spectroscopy tags;158-161 dually labelled proteins for FRET studies both in 
vitro162 and in vivo;163 SUMOylated proteins;164 and the site-specific furnishing of active 
hepatitis D virus surface proteins with purification tags whilst retaining infectivity of the 
viral particle.165 
 
Figure 24: Pyrrolysine surrogates used in genetically encoded copper-catalysed and strain-promoted azide-
alkyne cycloaddition bioconjugations. 
Even as the field of bioorthogonal chemistry advanced, amber stop codon suppression 
maintained pace. CuAAC was superseded by the strain-promoted azide-alkyne 
cycloaddition (SPAAC), foregoing an often cytotoxic CuI catalyst in place of a more 
reactive alkyne166 and hence marketed as “copper-free click chemistry” with the selling 
point of greater compatibility with in vivo applications.167, 168 The shift from small linear 
alkynes to large, hydrophobic cyclooctynes was in fact well tolerated, with the pylRSAF 
mutant readily accepting both cyclooctyne 34169 and the more reactive bicyclononyne 
(BCN) 35.170 The lack of cytotoxic copper reagent required for SPAAC ligation, in 
conjunction with the other properties of azide-alkyne cycloaddition, led to a range of 
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applications of this site-specific protein bioconjugation strategy in challenging in vivo and 
therapeutic settings requiring strict homogeneity and minimal contamination: production 
of ADCs using mammalian171 or insect expression systems,172 where prokaryotic 
expression systems often fail; stapling together of antibody fragments to modulate 
biological activity;173 PEGylation of adeno-associated viruses174 and interferon,175 
increasing the stability and half-life respectively of the two therapeutics; and protein 
labelling with a 64Cu-chelator to produce a positron-emitting antibody for localised 
positron emission tomography diagnostics.176 
One of the shortcomings of SPAAC is the relatively slow kinetic profile of this ligation, 
significantly outpaced by CuAAC.177 Whilst some tailoring of the cyclooctynes with 
electron-withdrawing substituents, such as difluorocyclooctyne compounds,178 or with 
additional ring strain, such as dibenzocyclooctyne compounds,179 significantly reduced 
this rate gap, the large structural perturbations required precluded the usage of such 
cyclooctyne derivatives in amber stop codon suppression, too bulky or polar to fit in even 
the most cavernous of hydrophobic binding pockets present among pylRS mutants. 
Another cycloaddition emerged to improve upon SPANC: strain-promoted inverse 
electron demand Diels-Alder cycloaddition (SPIEDAC), offering even faster kinetics than 
SPAAC or CuAAC180 under metal-free conditions compatible with in vivo and therapeutic 
applications.181, 182 Instead of an azide, a tetrazine acts as the diene to undergo a 
cycloaddition with a strained dienophile: not just BCNs, but also cyclopropenes, 
cyclobutenes, norbornenes and trans-cyclooctenes (TCOs). Just as with cyclooctynes, 
these three strained cycloalkenes were also highly amenable to use in amber stop codon 
suppression. Lysine derivatives 36-41 (Figure 25), as well as 35, were rapidly developed 
to exploit SPIEDAC, exactly as predecessors SPANC and CuAAC had been, with TCOs 
such as 40 and 41 exhibiting the highest rates of SPIEDAC of all the dienophiles 
studied.183 Some protein glycosylation has taken advantage of this genetically encoded 
SPIEDAC tool,184 but the primary application of 36-40 has been fluorescent protein 
labelling, both in vitro185-187 and on the surfaces of live prokaryotic188, 189 and mammalian 
cells,190 where the SPIEDAC properties of mildness, rapidity and fluorogenicity are highly 
germane. Notably 41 decomposes upon undergoing SPIEDAC to liberate the free amine 
group of the lysine backbone,191 permitting lysine decaging in live cells observable over 




Figure 25: Lysine surrogates 36-41 developed for SPIEDAC bioconjugations in increasing rate order.181, 183, 
186, 188 
The ability to incorporate reactive azides, alkenes and alkynes into proteins using genetic 
code expansion has opened up a wide range of site-specific chemical bioconjugation 
strategies, where such incorporation had been the main bottleneck in the use of these 
strategies. Beyond click and Diels-Alder chemistry, a range of other bioorthogonal 
chemical modification strategies have been developed to take advantage of such 
reactivity enabled by amber stop codon suppression (Figure 26). 
 
Figure 26: Bioorthogonal chemistry using genetically encoded functionality.154, 193-196 
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1.2.5 Diverging from Lysine to Other Amino Acid Analogues 
Evidently a great range of lysine derivatives can be genetically encoded using the 
pylT/pylRS pair. Quickly it was realised that if pylRS mutants can recognise a diverse 
mélange of lysine derivatives, perhaps derivatives of other canonical amino acids, those 
with similar long alkyl or aryl groups, would also be suitable substrates. Through the 
mutation of six active site residues- L305, Y306, L309, N346, C348 and W417- a library 
of PylRS mutants were screened against canonical amino acid L-phenylalanine 42 and 
non-canonical derivative 43 (Figure 27). Only the mutations N346A and C348L were 
required to recognise 42 as a substrate, whilst uptake of 43 and analogue 44 required 
mutations to five out of the six key active site residues.197 The utility of this discovery was 
quickly seized upon by using the aryl halide 44 as an on-protein handle for a Suzuki-
Miyaura coupling with a dansylated boronic acid for fluorescent labelling. 44 had already 
enjoyed use both as a heavy atom source for protein crystal structure determination198 
and as a handle for Mizoroki-Heck, Sonogashira and Suzuki-Miyaura  palladium-
mediated cross-coupling bioconjugations both in vitro199 and in vivo,200 incorporated into 
proteins through genetic code expansion using a tyrosyl tRNACUA from 
Methanocaldococcus janaschii198 or a phenylalanyl tRNACUA from E. coli.201 At this point 
the M. janaschii tyrosyl tRNACUA was renowned for its diverse established library of 
tyrosyl analogues used in genetic code expansion, including other reactive handles such 
as azides, alkynes and ketones.202 Knowledge of this promiscuity whet the appetites of 
many keen to exploit the pyrrolysyl tRNACUA system in a similar fashion. 
Indeed a flurry of publications ensued. The pylRS mutant N346A C348A (pylRSAA) was 
found to recognise unsaturated tyrosyl ethers 45-48 well and methyl ether 49 slightly;203 
further mutations were required for greater recognition of 49.204 Beyond para-substituted 
phenylalanyl/tyrosyl analogues, the pylRSAA mutant was found to encode an array of 
meta-substituted phenylalanine derivatives 50-60, including the reactive handles of 
ketones, halides, azides and alkynes.205 With these findings came the caveat that poorly 
recognised substrates such as 50 were outcompeted by canonical 42, demonstrating 
that the promiscuity of the pylRSAA mutant was offset by a diminished level of 
orthogonality, analogous to mutations applied to Y384 (vide supra).  
Aldehyde 61 was also found to be a substrate for pylRSAA, facilitating protein modification 
via oxime ligation.91 This finding breathed fresh life into well-established protein carbonyl 
chemical modification, which had been hampered by the limitations on the positioning of 
the required reactive aldehydes. Previous methods to install protein aldehydes required 
an enzymatic tag, such as use of FGE or an exposed N-terminal serine, threonine or 
glycine residue; through 62, site-specific protein aldehyde modification could now move 
beyond such sequence limitations with far greater freedom with an electronically distinct 
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aldehyde substrate.77 Whilst pyrrolysine 1 and its demethylated analogue did find some 
use as protein aldehydes for modification,206 the use of 61 was far more practical due to 
its stability and straightforward synthesis compared to the need to utilise the pyrrolysyl 
biosynthetic pathway in order to incorporate 1.132  
 
Figure 27: Genetically encoded phenylalanine and tyrosine analogues. 
Further probing of the pylRSAA mutant revealed that in addition to further meta-
substituted hydrophobic phenylalanine derivatives 62-65,207 ortho-substituted 
compounds 66-71 were also recognised by pylRSAA (Figure 28).208 Given that 
hydrophobic ether substituents seemed broadly compatible with this mutant, SPAAC and 
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SPIEDAC substrates 72-74 were investigated as substrates for pylRSAA but 
disappointingly no stop codon suppression was detected. Two further mutations were 
required: the same Y306A and Y384F mutations required, producing quadruple mutant 
pylRSAAAF which proved to recognise 72-74 well and opened up an alternative route to 
genetically encode click chemistry.209 The same mutant was also able to recognise 
fluorinated compounds 75-77, with the fluorination pattern of 75 able to perturb and 
hence elucidate a key cation-pi interaction between a histone reader protein containing 
75 and a histone containing a cationic trimethylysine residue.210 
 
Figure 28: Further genetically encoded phenylalanine and histidine analogues. 
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Given that phenylalanyl and tyrosyl analogues were suitable for genetic incorporation, 
the next logical step turned towards analogues of another small, aromatic canonical 
amino acid: histidine 78. Shrinking the pocket size and knocking out key hydrogen 
bonding interactions through respective Y306F and C348F key mutations led to 
recognition of histidine analogues 79-81.211 The pocket remained sufficiently 
hydrophobic to recognise only these hydrophobic histidine derivatives, whilst histidine 78 
proved to be too polar to nestle inside thus retaining the orthogonality of this pylRS 
mutant to canonical amino acids. The size of the aromatic ring substituent had a clear 
effect on binding and hence TAG-containing protein yields: from the thiophene 
substituent of 79 to the N-methylimidazole ring of 80 yields double, whilst the additional 
bromine atom on 81 affords protein in three times the yield compared to 79. Arguably 
the most useful analogue incorporated here is 80, as N-methylation of histidine is a 
known post-translational modification. Substitution of 80 in place of 78 perturbs hydrogen 
bonding, prevents tautomerisation and can impede free rotation of the ring; archaeal M. 
barkeri methyl-coenzyme R reductase containing 80 is postulated to do so on account 
of this latter property, leading to greater binding of coenzyme B.212  Subsequent use of 
80 in amber stop codon suppression made use of these differing properties to alter the 
performance of a biotechnological enzyme. Ascorbate peroxidase containing 80 in place 
of a catalytic histidine residue was found to have a far greater turnover and mildly higher 
catalytic efficiency in the oxidation of guaiacol than the wild type enzyme, ascribed to 
disruption of active site hydrogen bonding and hyperconjugation stabilising radical 
intermediates.213 This work neatly demonstrated the suitability of amber stop codon 
suppression in biotechnological applications where more chemical functionality is 
required than the basic canon of amino acids can provide. 
Perhaps the most attractive canonical amino acid to a chemical biologist is cysteine 82 
(Figure 29). A wealth of uses exists for this particular residue through the depth of known 
sulfur chemistry, sometimes to the extent of unwanted participation in side reactions. The 
ability to tame this wild beast is paramount to capitalising on its functionality, so genetic 
code expansion seemed a natural technique for this purpose. Other tRNA/RS pairs had 
been shown to successfully genetically encode cysteine derivatives,119, 214 setting a high 
bar for success. Lysine-cysteine dipeptides 83R and 83S were the first breakthroughs, 
enabling incorporation of a 1,2-aminothiol at a location beyond the N terminus.215 This 
moiety is highly useful due to its reactivity in native chemical ligation (NCL), with both 
isomers of 83 used to ubiquitinate proteins via NCL as ubiquitin is typically conjugated 
to lysine residues via an amide bond. In combination with a C-terminal thioester, this 
strategy was also used for protein cyclisation.216 NCL was further exploited using 84 
which, upon spontaneous cleavage of the nitrobenzyloxycarbonyl group after translation, 
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exposed the reactive 1,2-aminothiol for protein ubiquitination.217 The leftover thiol was 
then removed by desulfurisation, pleasingly generating a native protein-ubiquitin linkage 
matching that found in nature. 
 
Figure 29: Cysteine and genetically encoded analogues. 
Whilst the 1,2-aminothiol motif is indeed useful in protein modification on account of its 
reactivity, this property often becomes a hindrance. N-terminal cysteine residues, 
harbouring the 1,2-aminothiol motif, often trap electrophilic aldehydes and ketones such 
as metabolite pyruvate to form thiazolidine adducts,218 with this undesired process 
affording a heterogeneous mixture of proteins with reduced reactivity. 4-substituted 
thiazolidine 85 was used to control this process, ensuring homogeneity in the protection 
of the 1,2-aminothiol group in this residue. The thiazolidine was then opened through the 
use of a stronger nucleophile, methoxyamine, to trap the electrophilic formaldehyde and 
liberate the 1,2-aminothiol.219 This reactive residue was then used as a handle for 
cyanobenzothiazoline condensation ligation and, somewhat ironically, for thiazolidine 
ligation, where a further aldehyde bearing a useful substituent condensed again with the 
1,2-aminothiol,  reforming the stable thiazolidine linkage with the addition of added 
functionality.220 The thiazolidine had demonstrated its utility as a protecting group for 
nucleophilic 1,2-aminothiols by electrophilic aldehydes; reversal of this arrangement 
would allow for the genetic incorporation of an aldehyde rather than a 1,2-aminothiol. 2-
substituted thiazolidine 86 was designed with this exact strategy in mind, where 
treatment with a suitable electrophile exposed a highly reactive glyoxylamide group 
capable of undergoing oxime ligation.221 The limitations of this methodology lay in the 
harsh deprotection conditions: incubation with silver acetate in 10% (v/v) acetic acid 
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certainly opened the thiazolidine, but these conditions are likely to denature the vast 
majority of protein samples. 
A notable attribute of 83R/S and 85 is the ease with which these compounds can be 
genetically encoded. Using the wild type pylRS from M. barkeri, all three compounds are 
successfully incorporated into proteins, albeit to a lesser extent than positive control 10. 
This is perhaps somewhat obvious: the thiazolidine ring of 85 closely resembles the 
pyrroline ring of 1, whilst the methylene thiol side chain of 83R/S is seemingly sufficiently 
hydrophobic to fit in the binding pocket. However the wild type pylRS from M. mazei only 
recognises 83S and neither of the other two close analogues.219 The reasons behind this 
rather important difference in substrate recognition between the two variants, both 
commonly used and seen as almost interchangeable in this field, are largely unknown 
and here lies something of a gap in the literature. Both pylRS variants possess a 
conserved C-terminal catalytic domain with sequence differences only apparent in the 
N-terminal domain. Many crystal structures of the M. mazei pylRS variant have been 
obtained, often omitting the N-terminal domain yet still providing a helpful level of insight. 
Sadly, no crystal structures of the M. barkeri pylRS variant have been obtained to date, 
rendering as mere conjecture any attempted rationalisation of the differences in 
substrate recognition between the two variants. 
Successful incorporation of cysteine so far relied upon the presence of a lysine backbone 
for recognition by pylRS. This seems logical given the small size of cysteine compared 
to lysine and the size of the hydrophobic pocket in the active site of pylRS. Genetic 
incorporation of cysteine derivatives without a lysine backbone would likely need some 
additional bulk in order to fit the cavernous binding site. The solution was again found in 
the use of protecting groups. Compound 87, bearing the photolabile o-nitrobenzyl 
protecting group previously seen in 28, offered the ability to genetically encode a native 
cysteine residue exposed by photolysis (Figure 30).222 However biological use of the o-
nitrobenzyl protecting group is limited by the deprotection conditions required, as only 
shortwave UV irradiation affords complete deprotection at the expense of damaging the 
protein or other biological structures. An alternative protecting group was deployed and 
88 was shown to be more suitable, with photolysis requiring only minutes of irradiation 
with less harmful longwave UV. This photodecaging procedure was shown to be 
amenable to both in vitro and in vivo settings, restoring activity to catalytic cysteine 




Figure 30: Further cysteine, selenocysteine and aspartate derivatives used in amber stop codon 
suppression. 
One of the rarest canonical amino acids is cysteine analogue selenocysteine 89. Given 
the successful incorporation of cysteine derivatives using amber stop codon 
suppression, selenocysteine derivatives would be a logical next step. Two similar 
strategies emerged concomitantly, both making use of protecting groups so that the 
NCAA is sufficiently bulky to be recognised by a pylRS mutant which retains 
orthogonality to smaller canonical amino acids. The first method made use of the allyl 
protecting group, seen previously with 11, given the mild conditions required for 
deprotection.224 Engineering of a pylRS mutant from M. barkeri led to the incorporation 
of 90 in native selenoproteins, with activity fully restored following overnight incubation 
with a palladium complex.225 A second effort utilised photocaged derivative 91, similarly 
affording active selenoproteins following longwave UV irradiation over a few minutes.226 
A further cysteine analogue is 92, bearing an amino group in place of the thiol and useful 
as a tool to probe the mechanistic roles played by active site cysteine or serine residues. 
A quadruple mutant M. barkeri pylRS was suitable for incorporating 93 in place of a 
catalytic cysteine residue in a protease, exposing 92 following mild photolysis. This led 
to trapping of a covalent intermediate, where a stable amide product was formed in place 
of the regular transient thioester intermediate. Further exploitation led to the capture and 
crystallisation of analogous covalent intermediates in the biosynthesis of cyclic peptides, 
providing exceptional insight into the mechanistic pathways underpinning this process.227 
A final example demonstrated that even derivatives of aspartate 94 could be genetically 
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encoded. Compound 95, bearing the cyclopentyloxycarbonyl group to aid recognition by 
pylRS, was incorporated into proteins as a handle for NCL, where the ability to generate 
protein thioesters had previously been restricted to the C terminus.228 Complementary to 
the use of 84, following NCL and desulfurisation the modification would resemble that of 
a native asparagine modification, showing clear further utility in the mimicry of such 
PTMS. Unfortunately, the thioester was found to possess some off-target reactivity, 
being trapped by reactive thiols such as glutathione or being hydrolysed to revert to 
canonical 94, meaning that attempts to perform NCL on proteins containing 95 afforded 
heterogenous protein samples bearing varying modifications at the location of the amber 
stop codon.   
 
1.2.6 Conclusions 
The field of chemical biology has been truly enriched by the emergence and success of 
the pyrrolysyl tRNA/RS pair. Protein modification has been a major beneficiary, with the 
expanded amino acid alphabet providing a range of new reactive handles for site-specific 
bioorthogonal chemistry, translating reactions into the protein domain both in vitro and in 
vivo. This has enabled the generation of scores of bioconjugates bearing remarkable 
new functionality such as fluorescence, post-translational modifications, and cytotoxicity 
through linked drugs. Over 100 NCAAs stand in the repertoire of this system, permitting 
interrogation of biological systems impervious to previous human intervention to expand 
the understanding and development of modern therapeutics. Excitingly, new pyrrolysyl 
tRNA synthetases have been discovered in other methanogenic species of archaea,229 
offering further understanding into the promiscuous tRNA synthetase and opportunities 
to enhance the utility of this system.230 The development of the pylT/RS pair has armed 
chemical biologists with an expansive array of tools which will continue to reward astute, 
creative utilisation.   
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1.3 Project Outline 
The project was an investigation into the development of new strategies for chemical 
modification of proteins. The success of the field depends on the presence of a well-
stocked toolbox of chemical methods for linking small molecules to proteins, with every 
tool possessing its own niches and drawbacks, and it is to this collection that this work 
sought to add. 
This project focussed on the introduction of non-canonical reactivity into proteins through 
the installation of aldehydes. The glyoxyl aldehyde formed at the N terminal seryl, 
threonyl or glycyl residue of a protein has seen a range of uses in chemical protein 
modification, owing to the site specificity and general reliability of the chemistry 
developed for this purpose. 77, 231 However, this functionality is currently restricted to the 
N-terminus of the protein which may be unavailable for a variety of reasons, such as 
acylation, active site involvement, or burial within the protein. Furthermore, only one 
aldehyde is available for this purpose, a problem in the design of antibody-drug 
conjugates when often multiple drugs are attached to the same antibody scaffold.56 
Amber stop codon suppression has quickly found its feet as a versatile method for the 
introduction of non-canonical functionality into proteins.92 Use of the pyrrolysyl tRNA-RS 
pair has proven to be a highly suitable platform for this purpose, as the previous section 
indicates. With sufficient optimisation, multiple NCAAs can be genetically encoded into 
a protein.147 As each NCAA represents only a single addition or substitution within the 
primary sequence, the structural perturbation is minimal and thus the positioning of each 
NCAA is highly flexible. The pyrrolysyl tRNA-RS appeared to be the perfect partner for 
the glyoxyl aldehyde to enable site-specific aldehyde modification beyond the protein N 
terminus. 
The first objective was to design a glyoxyl aldehyde derivative suitable for genetic 
incorporation using the pyrrolysyl tRNA-RS pair. Due to the reactivity of the glyoxyl 
aldehyde, a “caged” analogue was considered in order to survive the aqueous milieu 
during protein biosynthesis. This analogue must be a suitable substrate for a pyrrolysyl 
tRNA synthetase, or genetic incorporation would not succeed. Hence the aldehyde 
derivative would likely need to contain a lysine backbone in order to sufficiently mimic 
pyrrolsyine, with the caged aldehyde moiety similarly not too distinct from the native 
tRNA synthetase substrate. 
The second objective was to develop a suitable method for decaging the aldehyde on 
the protein, essentially combining traditional deprotection group chemistry and functional 
group conversions with the demands of biological chemistry. Ultimately the protein must 
“survive” the decaging process, retaining fold and function, but the decaging process 
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also ought to be rapid and lead to maximum conversion to produce a homogenous 
construct. Furthermore, the decaging chemistry must also work in aqueous milieu at a 
suitable pH for the protein without any side reactions with the native functionality of the 
protein. 
The third and final objective was to demonstrate the functionality of the decaged glyoxyl 
aldehyde as a handle for chemical protein modification beyond the N terminus. The 
exposed aldehyde must be able to perform the repertoire of modification chemistry 
already showcased at the N terminus if it is to be of any use. To achieve this would be a 
symbiotic process: demonstrating the utility of the internal glyoxyl aldehyde and adding 
a new perspective to the established aldehyde modification methods, liberated from N-




Chapter 2: Synthesis of Peptides as Aldehyde 





The promiscuity of the pylT-S pair has been shown to extend to lysine dipeptides such 
as 83R and 83S, with the utility of these canonical amino acid dipeptides demonstrated 
through the use of the additional cysteine residue as a handle for native chemical 
ligation.215 This reaction requires the presence of an α-amino group, which is retained 
through the “pseudo-N-terminal” or “internal” (i.e. not at a terminal location)  positioning 
of the cysteine residues on the lysine backbone. In this way, it was posited that native 
chemical ligation could now be used for protein functionalisation at a broad range of 
positions rather than just the N-terminus; theoretically, the genetically encoded cysteine 
derivative need only be at an accessible surface position for successful modification. In 
further developments to this system, the corresponding thiazolidine derivatives 85220 and 
86221 were found to be similarly acceptable substrates for various wild-type pylT-S pairs 
and acted as “caged” cysteine handles for bioorthogonal modification, circumventing 
problematic trapping of the 1,2-aminothiol group by electrophilic carbonyl compounds 
such as pyruvate, omnipresent in the aqueous milieu of biological systems.219 The limits 
of the pylT-S promiscuity, however, have arguably not yet been fully reached or pushed; 
attractive opportunities to incorporate further lysine dipeptides with “caged” reactivity for 
bioorthogonal purposes lie unexplored. Furthermore, various small molecules are 
required in order to perform the subsequent chemical modification of the exposed 
aldehyde and demonstrate its utility. In this chapter, the underpinning rationale and 
synthesis of such target compounds will be outlined. 
2.1.1 Chapter overview 
This chapter is composed of two main areas. Firstly, this chapter discusses the small 
molecules prepared using solution-phase synthesis: analogues of pyrrolysine as 
candidates for non-canonical amino acid mutagenesis with potential to be transformed 
into reactive aldehyde species. Secondly, this chapter discusses the larger peptide 
probes synthesised using solid-phase methods, combining reactivity towards a protein 
aldehyde with a useful label. This can be considered as the starting points of working 
forwards following a retrosynthesis of a protein bioconjugate (Figure 31): disconnecting 
between the protein and label leads to a reactive peptide probe and a protein aldehyde. 
The protein aldehyde can be obtained through a functional group interconversion from 




Figure 31: Retrosynthetic analysis of a protein bioconjugate, where disconnection affords 1) a protein 
aldehyde, prepared via amber stop codon suppression and functional group interconversion using small 
molecule pyrrolysine analogues, prepared in in the first half of this chapter, and 2) reactive peptide probes, 
harbouring both a useful label, denoted by a star, and functionality to react with the protein aldehyde, with 
the second half of this chapter focussing on the modular solid-phase synthesis used to prepare these probes. 
 
2.2 Canonical amino acid dipeptides 
Cysteine is not, however, the only canonical amino acid which would be of use when 
appended to the ε-amino group of a lysine residue. The pseudo-N-terminal location of 
an amino acid in such a location would present the α-amino group for reactivity; a useful 
property, given that the α-amino group of certain canonical amino acids is 
mechanistically vital for the transformation of these residues into reactive aldehyde 
species to be used in chemical modification strategies. 
2.2.1 Transamination peptide  
N-terminal glycine residues are well-known to undergo transamination in a biomimetic 
fashion using PLP.76 Mechanistically, this reaction makes use of PLP as an amine sink 
to acquire the α-amino group from the residue in question, forming pyridoxamine-5-
phosphate and the corresponding carbonyl (Figure 32). For all canonical amino acids 
with a β-carbon atom, a ketone is formed in this process, whilst glycine stands alone in 
forming a more reactive aldehyde: a glyoxyl aldehyde, with sufficient electrophilic 
character arising from the 1,2-dicarbonyl system to reliably undergo many carbonyl 
reactions with excellent conversions on reasonably short timescales.77 Through both the 
well-established nature of glycine transamination232 and the reactivity of the product, this 
procedure has led to the design and use of numerous bioconjugation methodologies; 
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myoglobin, being both readily available and harbouring an N-terminal glycine residue, 
has been superb fodder for these purposes.233, 234 
 
Figure 32: Transamination of amino acids using pyridoxal-5-phosphate. 
It is the availability of the α-amino group which predisposes an N-terminal glycine residue 
to be transaminated. In this way, a pseudo-N-terminal glycine residue would retain this 
important moiety without the restriction of being located exclusively at the N terminus of 
a protein. Dipeptide 96 (Figure 33) putatively combines this aldehyde precursor with a 
lysine backbone, smuggling “caged” aldehyde reactivity into a protein sequence through 
the use of amber stop codon suppression. 
 
Figure 33: Synthesis of lysine-glycine dipeptide 96. 
The synthesis of 96 was achieved through an activation-coupling-deprotection strategy 
over three steps, following the route initially designed for and used by Annika Hüsken.235 
Protected glycine 97 was activated as the NHS ester 98 ahead of coupling to partially 
protected lysine 99 to afford dipeptide 100. Deprotection and lyophilisation afforded 96 
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in a final yield of 36% over three steps. This strategy was preferred to an in situ activation 
route due to the additional C-protection which would be required on the lysine partner, 
with this reagent being in short supply. The NHS activation step offers the least pleasing 
yield, with optimisation likely being required for further iterations. Nevertheless, through 
a straightforward synthetic route, 96 was obtained in sufficient quantity and of the 
required purity for later biological studies. 
2.2.2 Periodate-oxidised peptides 
Transamination of N-terminal glycine residues is not, however, the exclusive route to 
protein glyoxylamides. N-terminal serine and threonine residues can also be transformed 
into the reactive glyoxylamide through a simple oxidation using sodium metaperiodate.78 
This procedure requires vicinal nucleophiles, such as 1,2-diols and 1,2-aminoalcohols, 
which initially attack the electrophilic iodine(VII) centre. The resulting cyclic periodate 
ester decomposes to afford an iodine(V) salt and two aldehydes, of which one will be a 
glyoxyl species when serine and threonine are used (Figure 34). Whilst this reaction is 
generally fast (requiring only a few minutes to reach completion), periodate will also 
undergo various competing, slower side reactions with protein systems, such as 
oxidation of electron-rich aryl or sulfur(II)-containing residues,236 necessitating careful 
control of reaction time, stoichiometry, and quenching. 
 
Figure 34: Sodium periodate oxidation of N-terminal serine and threonine residues. 
Similar to transamination of N-terminal glycine residues, periodate oxidation requires a 
free α-amino group, in addition to a vicinal hydroxyl group; consequently, in native 
systems, only serine and threonine residues at a protein N-terminus undergo this 
oxidative cleavage reaction. As an alternative strategy to generate a protein 
glyoxylamide species, a putative route in which the periodate-mediated cleavage of a 
genetically encoded lysine dipeptide harbouring a 1,2-aminoalcohol motif, arising from a 
serine or threonine residue, was proposed. 
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In order to maximise the chances of discovering a suitable substrate for amber stop 
codon suppression, four dipeptides were synthesised, differing in the absence/presence 
of a β-methyl group (serine/threonine respectively) and the α-configuration (S/R, 
“natural” vs. “unnatural” respectively). For threonine derivatives, the β-configuration was 
unaltered and allothreonine derivatives not used on account of difficulties in obtaining 
the relevant starting materials. The modulation of α-configuration and β-methyl groups 
was considered to offer insight into the amber stop codon suppression process, with 
these changes subtly altering amino acid polarity, steric bulk, and positioning within the 
pylS active site. 
An analogous activation-coupling-deprotection strategy was used to synthesise all four 
dipeptides.235 First, the two “naturally” configured (2S) serine and threonine peptides 
were synthesised, with activation as the NHS esters followed by coupling to form 
protected dipeptides. Deprotection required the use of nucleophilic scavengers, namely 
water and triethylsilane, in order to intercept reversible O-alkylation commonly 
encountered during acidic deprotection of t-butyl ether groups.237 Over all three steps, 
comparable cumulative yields of 39% and 32% of 101 via 102-104 and 105 via 106-108 
were achieved (Figure 35), again in sufficient quantity and of sufficient purity for further 
work. 
 
Figure 35: Synthesis of lysine-serine and lysine-threonine (L-configured) dipeptides. 
The two “unnaturally” configured (2R) serine and threonine peptides 109 and 110 
respectively were then synthesised in largely the same manner via 111-115 and 114-
116 (Figure 36). An increase in the excess quantities of NHS and DCC raised the yields 
of NHS esters, followed by standard dipeptide coupling to form protected dipeptides. 
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Following deprotection and lyophilisation, dipeptides were obtained in improved 
cumulative yields of 50% and 56% respectively. 
 
Figure 36: Synthesis of lysine-serine and lysine-threonine (D-configured) dipeptides. 
2.3 Thiazolidine peptide synthesis 
Whilst N-terminal glycine, serine and threonine residues can be considered to be 
canonical “caged” glyoxyls, a non-canonical precursor to a glyoxyl group may also prove 
to be useful. As mentioned, 1,2-aminothiols on cysteine derivatives have been protected 
with aldehyde-based protecting groups, with release of the cysteine derivative effected 
by a strong nucleophile such as methoxyamine.219 The reverse scenario can be 
considered: release of the aldehyde effected by an electrophile. Furthermore, a 
thiazolidine carboxylate bears high structural similarity to a pyrroline carboxylate, the 
additional group attached to the lysine backbone of pyrrolysine. Indeed, 2- and 4-
carboxythiazolidine derivatives have both been shown to be suitable substrates for 
amber stop codon suppression.220, 221 Hence the third strategy for exposure of protein 
glyoxyl aldehydes presents itself: genetic incorporation of 2-carboxythiazolidine 86 
followed by treatment with an appropriate, biocompatible electrophile. 
A racemic synthesis of 86 has been reported;221 whilst useful for the preparation of the 
thiazolidine group, the procedure made use of an in situ activation coupling strategy, 
unattractive for reasons already presented, and hence another two-step activation-
coupling procedure was deployed (Figure 37). The condensation of cystamine 117 with 
glyoxylic acid 118 proceeded well as reported, although the absence of chiral induction 
affords 119 as a racemate. Boc protection was modified from the original procedure, 
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using reduced quantities of Boc anhydride to aid purification, and was almost quantitative 
in yield, with 119 obtained in 80% yield over two steps. Formation of NHS ester 120, 
coupling to form protected dipeptide 121, and standard TFA deprotection afforded 86 in 
66% yield over three steps. This synthetic route was highly amenable to upscaling, with 
large quantities (20 mmol) of 86 synthesised in anticipation of the extensive work 
required in developing a suitable decaging method. 
 
Figure 37: Synthesis of thiazolidine-lysine dipeptide 86. 
2.4 Reactive peptide probe synthesis 
One of the virtues of a protein glyoxyl aldehyde is its reliable canon of reactivity. To this 
end, various small reactive probes are required in order to chemically modify the exposed 
protein aldehyde. Such probes must combine an aldehyde-reactive functional group with 
a group of utility, with fluorescent and affinity groups being prime examples, whilst 
maintaining biocompatibility such as solubility in aqueous solution. 
Solid-phase peptide synthesis provided an elegant solution for the synthesis of these 
peptides, combining modularity with straightforward synthesis and minimal purification. 
Each peptide can be considered to follow the same “flag-like” template, from N-terminus 
to C-terminus: i) reactive functional group, for modification of the protein aldehyde, the 
“attachment point” of the flag; ii) a PEG-type spacer, increasing aqueous solubility and 
minimising steric bulk around the reactive functional group, effectively the “mast”; iii) 
either a fluorescent (dansyl) or affinity (biotin) tag, for further demonstration of successful 
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modification, the “flag” itself; iv) a resin attachment residue, for simplicity a glycine, the 
“cap”.  
2.4.1 Aminooxy probes 
A well-established bioorthogonal aldehyde modification strategy is oxime ligation, the 
condensation of an aldehyde with a highly nucleophilic aminooxy reagent.79 This strategy 
typically requires some form of catalysis to be effective, which has generally taken the 
form of Brønsted-Lowry acid catalysis at pH 4-5 via a protonated carbonyl reactive 
intermediate.238 Further developments have shown that nucleophilic catalysts such as 
aniline can be used to drive the reaction to completion at neutral pH,239 forming a highly 
electrophilic iminium ion greatly susceptible to nucleophilic attack by the aminooxy 
reagent. The glyoxyl aldehyde has enjoyed much usage in this way, as the electrophilic 
character of this aldehyde to some extent balances out the sluggish conversions often 
observed with this reaction and has been used to generate a diverse portfolio of 
bioconjugates.240-242 
 
Figure 38: Structure and schematic of aminooxypeptides 123 and 124. 
Hence reactive aminooxy peptides 123 and 124 were synthesised by Dr Martin Fascione 
using Fmoc SPPS methodology (Figure 38). Whilst most residues were coupled by in 
situ activation using HCTU, the N-terminal aminooxyacetic acid unit was preactivated as 
the NHS ester. This is due to the ability of N-Boc-aminooxyacetic acid to be sufficiently 
nucleophilic, despite N protection, to intercept HCTU-activated carboxylates, whilst 
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preactivation circumvents this unwarranted side-reaction.243 Both peptides were 
obtained in ca. 15% yield, with no purification required. 
2.4.2 Aryl aldehyde probes 
Work undertaken in the Fascione group has led to the development of the 
Organocatalytic Protein Aldol Ligation (OPAL): a cross-aldol reaction in which an 
enolisable aldehyde, typically in excess, reacts with a non-enolisable protein aldehyde 
in the presence of an organocatalytic proline derivative, forming a new carbon-carbon 
bond between aldehyde partners.244 This reaction has been shown to be rapid and 
biocompatible, with full conversion typically taking one hour at neutral pH. Protein glyoxyl 
aldehydes are an ideal substrate for this reaction on account of the reliable reactivity and 
the inability to enolise. Furthermore, this reaction affords a product containing a further 
aldehyde, a β-hydroxyaldehyde, which is resistant to further OPAL modification but can 
be modified by oxime ligation. Hence OPAL is a second excellent ligation strategy to take 
advantage of an exposed protein aldehyde located at a non-terminal position. 
The most reactive enolisable aldehydes have been shown to be arylacetaldehyde 
derivatives, whilst reactions with alkyl aldehydes tend to display much lower rate 
constants (two orders of magnitude smaller). This is likely due to the aryl group providing 
a thermodynamic boost to enamine formation, the putative rate-determining step in this 
reaction: the α-protons are more acidic (pKA of phenylacetaldehyde vs. propanal are 15 
vs. 17 respectively) and the p-orbitals of the amine and enamine π bond are conjugated 
to the aryl group to form an extended conjugated system. These two factors contribute 
to a greater concentration of enamine existing in solution, increasing the rate of the 
reaction. With this in mind, the reactive functional group to be installed on the appropriate 
OPAL probes needed to be carefully considered. Compound 125 was synthesised by Dr 
Darshita Budhadev for this purpose: a tyrosinol derivative containing an isopropylidene 
hemiaminal, which exposes a 1,2-aminoalcohol upon TFA deprotection/cleavage ready 
for periodate-mediated oxidation to form the phenylacetaldehyde-containing probe. 125 
was attached to 126-resin and 127-resin (Figure 39), prepared using the same Fmoc 
SPPS protocol, whilst still on the resin, to afford probe precursors 128 and 129 in 84% 
and 50% yields respectively after cleavage, deprotection and isolation. Oxidation and 
purification were performed by Dr Richard Spears to afford probes 130 and 131 in 




Figure 39: Synthesis of OPAL probes 130 and 131. 
2.4.3 Strained alkyne probes 
A third bioconjugation strategy making use of the glyoxyl aldehyde is the strain-promoted 
alkyne-nitrone cycloaddition (SPANC).245 In this reaction, a nitrone, formed in situ from 
a protein glyoxyl aldehyde and an N-substituted hydroxylamine reagent under p-
anisidine nucleophilic catalysis, undergoes a [3+2] cycloaddition with a strained alkyne, 
typically a cyclooctyne or a BCN.246 Arguably this procedure is a biocompatible 
translation of the so-called A3 reaction,247 in which an aldehyde and amine form an imine 
which can be attacked by a metallated alkyne, albeit using the alkyne as a dipolarophile 
rather than as a nucleophile and using ring strain instead of metals to activate the alkyne. 
Two new carbon-carbon bonds are generated under mild conditions to form a stable 
isoxazoline heterocycle linking the three components. SPANC is a further demonstration 
of the power of the glyoxyl aldehyde, capable of undergoing a three-component reaction 
with potential for multiple points of functionalisation.  
Following the previous probe design, the SPANC probes required a strained alkyne on 
the N-terminus. A BCN was chosen for this purpose, on account of the greater reactivity 
of a BCN compared to a regular cyclooctyne. However, attempts to cap the N-terminus 
of precursor probes 126-resin and 127-resin on the solid phase using activated BCN 
132 were largely unsuccessful, with no capping detected by LC-MS and with a significant 
quantity of 132 wasted due to the excess used for the solid phase. To circumvent this 
problem, the precursor probes were cleaved from the resin and the N-terminal capping 
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was performed in solution on 126-OH and 127-OH (Figure 40). Pleasingly, full 
conversion was observed by LC-MS within one hour. Subsequent purification by size-
exclusion chromatography afforded 133 and 134 in 68% and 55% yields respectively. 
 
Figure 40: Synthesis of SPANC probes 133 and 134. 
2.5 Conclusions 
Three strategies for the incorporation and unmasking of glyoxyl aldehyde groups in 
protein systems have been devised. Six lysine-based dipeptides required for these 
strategies have been synthesised in yields ranging from 32% to 66%, in the quantity and 
of the purity required for further biological studies. 
Furthermore, three ligation strategies have been outlined to demonstrate the utility of the 
exposed glyoxyl aldehyde. Probes for oxime ligation and OPAL were synthesised using 
SPPS, whilst probes for SPANC were prepared using a combination of solid- and 
solution-phase synthesis, ahead of bioconjugation usage.  
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In order to identify genetically encoded caged aldehydes and develop strategies for the 
genetic incorporation of caged aldehydes into proteins, a suitable protein scaffold is 
required. Ideally such a test protein would be readily produced and purified, observable 
by mass spectrometry and tolerant of a judiciously placed TAG mutation, whilst 
remaining a representative example of the wider proteome. Green fluorescent protein 
(GFP) is an excellent candidate for this role. 
3.1.1 Wild-type GFP 
The prototypical GFP hails from Aequorea victoria, a bioluminescent species of jellyfish, 
in this instance playing the role of a light transducer. In a species of A. victoria, the protein 
aequorin, a luciferin-luciferase pair, is activated and releases a flash of blue light in the 
absence of GFP and green light in the presence of GFP.248 Why exactly this jellyfish 
evolved to produce this transducer protein, adding a second colour to the visual palette, 
is not known;249 one hypothesis is that the ability to modulate the wavelength of 
bioluminescence reflects the two sea depths at which the organism lives and the 
wavelength most visible at that depth.250 
 
Figure 41: Inside the GFP β-can (top left, cyan) lies an α-helix (red) where the p-hydroxybenzylidene 
imidazolidinone chromophore can be found (bottom left), formed through an intramolecular cyclisation and 
elimination between Ser65 and Gly67 and the oxidation of Tyr66 (right). 
The structure of GFP is highly optimised towards the function of fluorescence: a so-called 
“β-can”, formed of a β-barrel capped by α helices threading through the centre, in the 
middle of which the chromophore is encapsulated (Figure 41).251 Diligent toil by 




GFP, elucidated the structure of this chromophore as a p-hydroxybenzylidene 
imidazolidinone derivative,253 later proposed to be formed by a spontaneous dehydrative 
cyclisation of residues Ser65, Tyr66 and Gly67 followed by oxidation by dioxygen.254 The 
β-can acts as a stiff protective scaffold, enhancing the fluorescent properties of the 
chromophore: excluding dioxygen, a potential quenching or photobleaching agent;255 
reducing pathways for undesirable excited state quenching by vibrational relaxation, 
instead of fluorescence emission, by maintaining conformational rigidity and minimising 
collisions with solvent, presumably also reducing the Stokes’ shift; and providing some 
shielding from fluctuations in pH, with fluorescence observed between the large range of 
pH 4 and pH 12.256 With an absorption maximum at 476 nm, almost matching the 
emission maximum of aequorin,257 and a high fluorescence quantum yield φf = 0.79 at 
an emission maximum of 504 nm,258 clearly nature has painstakingly evolved GFP to 
complement and accentuate aequorin, affording the result of an elegant yet surreal 
example of bioluminescent resonant energy transfer noted even by Roman scholar Pliny 
the Elder almost 2000 years ago. 
3.1.2 Engineering of GFP 
The biotechnological potential of GFP was soon exploited, making the move from its 
original marine environment to its new home in the lab. Just as any living organism would 
be expected to adapt in order to better fit its updated ecological niche, so too was GFP 
forced to evolve to meet the demands of researchers through designed mutations and 
an entire evolutionary line of GFPs has been constructed.  
One of the earliest mutants, and perhaps the most prominent, is enhanced GFP (EGFP), 
bearing two key mutations of F64L and S65T.259 The S65T mutation has a profound 
impact upon the absorption profile of EGFP: a single absorption peak at 488 nm, emitting 
at 507 nm, with a molar absorption coefficient of 5.3 × 104 dm3 mol-1 cm-1.258 A similar 
peak occurs in the absorption spectrum of wild-type GFP (wtGFP), centred at 476 nm 
but with a much smaller absorption coefficient of 9.5 × 103 dm3 mol-1 cm-1, the peak 
responsible for energy transfer from aequorin. However, an additional peak occurs at 
395 nm with a molar absorption coefficient of 2.5 × 104 dm3 mol-1 cm-1, with both peaks 
emitting at 507 nm. The same GFP chromophore structure possesses two different 
absorption maxima and this has been attributed to the protonation state of the phenolic 
oxygen atom. The protonated species is responsible for the 395 nm absorption and the 
deprotonated species absorbs at 475 nm;260 emission at 507 nm arises from fluorescent 
deexcitation of the excited state of the deprotonated chromophore, which can be 
accessed from the protonated chromophore excited state by a rapid proton exchange 
pathway. Whilst the wtGFP chromophore is mostly protonated at a pH below 12,261 the 
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S65T mutation rearranges hydrogen bonding so that the chromophore exists exclusively 
in the deprotonated state, losing the absorption peak at 395 nm but greatly enhancing 
the molar absorption coefficient of the 475 nm absorption maximum.262 On first glance, 
the S65T mutation appears to overcome one of nature’s shortcomings in GFP design, 
producing a simpler absorption spectrum leading to greater fluorescence and hence a 
more efficient energy transfer from aequorin. However, the S65T mutation also leads to 
greater acid sensitivity of EGFP, increasing the protein pKA by two units.263 In nature’s 
judgement, GFP design has been a balance between efficient energy transfer with 
aequorin and survival of GFP across cellular environments at varying pH; in the lab 
environment, where the aqueous milieu is generally pH-controlled, the latter factor loses 
relevance and chromophore efficiency becomes the main selection pressure.  
The S65T mutation is synergistic with the F64L mutation in two ways: red-shifting the 
absorption maximum by 10 nm through stabilisation of the anionic excited state and 
improving folding efficiency at 37 °C, which had proven highly problematic with wtGFP.258 
The lab environment once again proves to come with its own selection pressures, where 
the production of protein at 37 °C becomes a highly desirable trait that had never been 
needed in the cold, cnidarian former habitat for wtGFP. From this same selection 
pressure arose a trio of different mutations: the “cycle3” mutations of F99S, M153T and 
V163A that, when installed in a wtGFP scaffold, led to a 40-fold increase in protein 
fluorescence.264 This was attributed to a greater proportion of correctly folded GFP when 
the cycle3 mutations were present, as wtGFP exhibited a tendency to languish within 
inclusion bodies without the correct fold and chromophore when overexpressed in 
prokaryotic host systems. The side-chains of residues 99 and 153 are solvent-exposed, 
whilst the side chain of residue 163 is angled towards a hydrophilic internal pocket 
composed of Gln183, Tyr151, Lys162 and Asn164.265 By increasing the hydrophilicity of 
the surface-exposed residues 99 and 153 and decreasing the hydrophobicity of the side-
chain of residue 163 in a hydrophilic pocket, the cycle3 mutations were found to inhibit 
protein aggregation and hence inclusion body formation.266 An unneeded variation in 
nature where GFP concentration is typically low, but a very practical solution to improve 
the yield of recombinant GFP. 
Spurred by the success of the cycle3 and EGFP mutations, further optimisation of the 
GFP primary structure produced superfolder GFP (sfGFP) bearing six new key mutations 
of S30R, Y39N, N105T, Y145F, I171V and A206V in addition to the EGFP and cycle3 
mutations.267 sfGFP was found to exhibit some of the fastest folding kinetics of any GFP 
mutant, high tolerance of denaturing urea and superior in-cell fluorescence, owing to the 
stability of the fold and the reduced propensity for misfolded, aggregated, non-
fluorescent sfGFP variants to form. Of the six mutations, S30R and Y39N contribute the 
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most to the enhanced sfGFP properties, with the former mutation forming a stabilising 
network of electrostatic interactions across the protein surface and the latter contorting 
a β-turn into a more favourable 310 helix. Notably, the six mutations do not confer any 
additional pH stability or perturbation of spectroscopic properties. The pKA of both EGFP 
and sfGFP is 5.9 and the absorbance/emission profiles overlap,268 implying that the six 
new mutations in sfGFP are purely structural and do not alter the photochemistry of the 
chromophore. Owing to the enhancements arising from the respective mutations, EGFP 
and sfGFP have both seen extensive usage in chemical protein modification as practical 
test proteins for exploring new chemistries, easily produced in sufficient quantities via 
recombinant methods.76, 196, 228 To this end, GFPs can serve as both a sensitive reporter 
protein in an amber stop codon suppression assay and also a useful test bed for new 
chemical protein modification strategies. 
3.2 Constructs for amber stop codon suppression 
3.2.1 Test protein design 
Two GFPs were selected as test systems for amber stop codon suppression: EGFP and 
sfGFP. Two pBAD expression vectors harbouring the genes encoding the respective 
GFPs with C-terminal His6 tags were received: EGFP(Y39TAG) from the Lemke group 
and sfGFP(N150TAG) from the Mehl group, where TAG represents a mutation of the 
native residue to the amber stop codon. Both constructs have been used in previous 
successful examples of amber stop codon suppression in prokaryotic systems.169, 269 
For both proteins, the amber stop codon has been located in a position occupied by a 
surface-exposed residue in the wild-type protein, with a side chain extending towards 
the solvent rather than towards the centre of the protein (Figure 42). This rational design 
ensures that substitution with the NCAA offers minimal perturbation of the protein fold, 
as the side chain is not responsible for any key interactions with other residues which 
hold the structure together in the native fold. Furthermore, the side chain of the non-
canonical residue will be available for reactions due to its placement on the surface of 




Figure 42: Positions of mutated residues: EGFP Y39 (left, PDB 2Y0G) and sfGFP N150 (right, PDB 2B3P). 
The plasmid containing the gene for sfGFP(N150TAG) was used as received. The 
EGFP(Y39TAG) gene contains an additional N-terminal FLAG tag, however, and whilst 
this tag is generally functionally benign, the initial aspartate residue of the DYKDDDDK tag 
reduces the extent of N-terminal methionine cleavage.270 In the absence of treatment 
with a more effective aminopeptidase, when observed by mass spectrometry a mixture 
of EGFP with and without the N-terminal methionine residue would be detected. No 
usage of the FLAG tag was desired thus this unnecessary additional complexity which 
would be seen in the protein mass spectrum arising from this tag could not be justified. 
Hence the N-terminal aspartate residue was mutated to become a serine residue. With 
a serine residue following the N-terminal methionine residue, complete cleavage of the 
N-terminal methionine residue would be expected,271 with gene expression affording 
homogenous (by MS) EGFP. The choice of serine also permits oxidation with sodium 
periodate to afford an N-terminal protein glyoxyl, setting up the option of dual aldehyde 
decaging in tandem with a potential pyrrolysine surrogate incorporated at the position of 
the amber stop codon. Using site-directed mutagenesis and appropriate forward and 
reverse primers, the initial aspartate residue was mutated from the triplet GAT to the 
triplet TCT, a mutation involving the fewest possible base mismatches whilst still 
encoding a commonly utilised serine codon in E. coli, the desired host system for protein 
production. Sequencing confirmed successful installation of only the desired mutation in 
plasmid DNA isolated from five of eight colonies isolated, affording the desired construct 
ready for protein production. 
3.2.2 Amber stop codon suppression system 
The other two requisite components of amber stop suppression in this instance are the 
pyrrolysyl tRNACUA and the corresponding pylRS. A pEVOL vector containing the 
pyrrolylyl tRNACUA gene and two copies of the pylRS (M. mazei) gene, one constitutive 
and one under araBAD control, was received from the Lemke group (Figure 43). The 
pEVOL vector was designed specifically to maximise protein yields in amber stop codon 
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suppression.125 The use of araBAD control over one copy of the pylRS gene allows 
controlled overexpression of the pylRS gene, improving the efficiency of amber stop 
codon suppression with minimal disruption to host growth through unintentional 
suppression of native amber stop codons.272 Basal control over the other copy of the 
pylRS gene and the tRNACUA gene also ensures that the concentrations are not high 
enough to be cytotoxic  whilst also allows the production of a consistent yet moderate 
quantity of aminoacyl-tRNACUA, ensuring that translation of the protein of interest can 
begin immediately upon induction.   
 
Figure 43: Plasmid map of the pEVOL vector harbouring one pyrrolysyl tRNACUA gene (dark green) and two 
copies of the pylRS gene (orange), one under araBAD control (white) and one under constitutive control. 
Map prepared with SnapGene using the published description of the pEVOL vector.125 
Two variants of this plasmid were received, differing in the sequence of the pylRS: one 
in which both copies correspond to that of the wild type (pylRSwt), and one in which both 
copies correspond to the double mutant Y306A Y384F (pylRSAF), known to tolerate 
bulkier, more hydrophobic moieties in the enlarged binding pocket.122 Access to two 
pylRS variants will increase the likelihood of discovering a pyrrolysine analogue which 
can be successfully incorporated using amber stop codon suppression and allow for a 
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comparison and some level of insight into substrate recognition. Both derivatives of this 
plasmid have also seen successful use in amber stop codon suppression.169 
3.3 Determining performance in amber stop codon suppression 
With two pylRS mutants and six synthesised lysine derivatives to hand, a protein 
production-based assay was designed to ascertain whether each NCAA could indeed be 
genetically encoded by each pylRS variant. EGFP(Y39TAG)-His6 was selected as the 
reporter protein on account of the highly optimised expression system available for use 
in amber stop codon suppression. Furthermore, the presence of EGFP can be 
determined not only through stained SDS-PAGE but also using the fluorescent properties 
of EGFP, visible in the cell pellet or cell lysate.125 Together these properties ensure that 
the limit of detection of this assay is sufficiently low such that any successful amber stop 
codon suppression can be observed unequivocally, albeit in a qualitative rather than 
quantitative manner. 
The assay takes the form of a miniaturised expression trial following a reported 
procedure for the expression of EGFP containing NCAAs.169 In brief, Top10 E. coli cells 
transformed by vectors containing genes for EGFP(Y39TAG)-His6, pylT, and either 
pylRSwt or pyRSAF were grown from a starter culture containing appropriate antibiotics 
and subsequently used to inoculate a separate preparative culture. The two preparative 
cultures were incubated until OD600 of 0.2 – 0.3 was reached, at which point the cultures 
were split into aliquots and a solution of NCAA (freshly prepared in aqueous 0.1 M NaOH) 
added to the culture aliquots to a final concentration of 2 mM. All aliquots were incubated 
for a further 30 minutes, induced at the same time and incubated overnight. Culture 
aliquots were subsequently centrifuged and cell pellets lysed chemically. Each 
centrifuged cell lysate aliquot was then analysed by Coomassie-stained SDS-PAGE. For 
negative control aliquots, a blank solution of aqueous 0.1 M NaOH was added. As a 
positive control for aliquots containing the pylRSwt variant, 29 was used; for aliquots 
containing the pylRSwt mutant, 34 was used (Figure 44). Synthesised NCAAs 86, 96, 




Figure 44: NCAAs 86, 96, 101, 105, 109 and 105 screened for uptake in amber stop codon suppression 
alongside positive controls 29 (pylRSwt) and 34 (pylRSAF). 
3.3.1 Assaying with the wild-type pylRS 
In the first assay, all six synthesised lysine analogues were studied alongside positive 
and negative controls in the presence of wild-type pylRS, affording eight samples to be 
analysed by SDS-PAGE. 86 is a known substrate of wild type M. barkeri pylRS;221 given 
the generally overlapping set of substrates between analogous M. barkeri and M. mazei 
pylRS variants, 86 is expected to be a substrate for wild-type M. mazei pylRS. 
 
Figure 45: SDS-PAGE of cell lysate from the amber stop codon suppression expression trial of EGFP with 
pylRSwt and NCAAs 86, 96, 101, 105, 109 and 110 with negative (-) and positive (29) controls. The circled 
bands in lanes 105, 86 and 29 are attributed to full-length EGFP. 
Analysis of the gel confirms presence of full-length EGFP in the positive control lane 
using 29, with a clear, thick band corresponding to EGFP overexpression at ca. 28 kDa, 
the mass expected (Figure 45). No band at this position is observed in the negative 
control lane, confirming the orthogonality of the pylRS used to canonical amino acids. As 
expected, a band corresponding to EGFP can be seen in the 86 lane, albeit much thinner 
implying poorer recognition of 86 by pylRSwt compared to 29. The only other EGFP band 







visible is found in the 105 lane, with this band also being far less pronounced than the 
corresponding band in the positive control lane, whilst lanes for 96, 101, 109 and 110 
contained no bands for full-length EGFP. 
To confirm these data, portions of the cell lysate were monitored by fluorescence. The 
results of the SDS-PAGE are reflected in the fluorescence observed here too: strong 
fluorescence in the positive control aliquot, mild fluorescence in the aliquots containing 
86 and 105, and only background visible for all other samples including the negative 
control (Figure 46). From this assay, amino acids 86 and 105 have been shown to 
recognised by wild type M. mazei pylRS to an appreciable extent, whilst all other NCAAs 
assayed showed no detectable extent of amber stop codon suppression. 
 
Figure 46: Visualisation by white light (left) and fluorescence (right) of cell lysate from the exp the amber 
stop codon suppression expression trial of EGFP with pylRSwt and NCAAs 86, 96, 101, 105, 109 and 110 
with negative (-) and positive (29) controls.  
3.3.2 Assaying with the double mutant pylRS 
The same assay was performed using the doubly mutated pylRSAF with the same set of 
amino acids, bar the altered positive control of 34, and analysed by SDS-PAGE (Figure 
47). 
 











Figure 47: SDS-PAGE of cell lysate from the amber stop codon suppression expression trial of EGFP with 
pylRSAF and NCAAs 86, 96, 101, 105, 109 and 110 with negative (-) and positive (34) controls. The circled 
band in lanes 34 is attributed to full-length EGFP. 
This time only a single band corresponding to EGFP overexpression was observed in 
the positive control lanes, with all other lanes free of this band and resembling the 
negative control.  
3.3.3 Discussion 
Placing these results in the context of the active site understanding of pylRSwt adds some 
justification. The small size of 96, only one NH3 unit larger than acetylated derivative 2, 
presumably leads to poor occupancy of the large binding pocket. 2 could only be 
recognised by a pylRS variant following mutations to close off most of the binding 
pocket,123 with the extra amino group of 96 projecting into a particularly hydrophobic 
portion of the binding pocket. Within the pylRSAF binding pocket, the additional space 
opened up by the mutations is too deep to be accessed by 96, suggesting even poorer 
binding in this synthetase mutant. 
Recent work has found that 135, an analogue of 96 following a similar objective of 
genetically encoding a pseudo-N-terminal glycine motif, was recognised by a pylRS 
derivative from M. barkeri (Figure 48).273 Directed evolution led to just three mutations: 
L309A, N346Q and C346S (numbered according to the homologous M. mazei active site 
sequence), although no crystal structure displaying the exact binding mode was 
reported. Following protein production and Staudinger reduction, the pseudo-N-terminal 
glycine-glycine motif was used with sortase-mediated ligation to append ubiquitin to a 
protein of interest via a near-native linkage. This work suggests that the lack of 
recognition of 96 by pylRSwt is not unsurprising, given the mutations required for 
recognition of 135. The presence of the extra bulk provided by the azido group further 
supports the argument that the side chain of 96 is simply too small for adequate 
recognition by pylRS. Whilst the reduction of 135 to afford the N-terminal glycine residue 
is an innocuous step, it is still an additional task, implying that the azido group is a 
necessity to improve recognition by pylRS compared to a smaller amino group. This work 







demonstrates both the possibility and utility of genetic encoding of pseudo-N-terminal 
glycine residues, albeit via different routes from those outlined within this thesis. 
 
Figure 48: Genetic incorporation of 135 followed by Staudinger reduction affords a glycine-glycine-lysine 
motif amenable to transpeptidation with a tagged LPLTGG peptide, such as to install ubiquitin on the side 
chain of a lysine residue with a ubiquitin-LPLTGG-K linkage similar to native ubiquitin-LRLRGG-K linkages. 
For the larger serine and threonine derivatives, the mode of binding is less simple to 
predict reliably due to the additional chiral centres, larger bulk and more hydrogen-
bonding atoms. The likely explanation for a threonine derivative being a superior pylRS 
substrate to a serine derivative is that the extra methyl group can better occupy the 
hydrophobic space within the pocket. Even so, 105 is a far poorer substrate for pylRSwt 
than positive control 29, as seen from the relative size of the EGFP bands seen on the 
gel. The rationale behind the use of a Ser-Lys derivative arose from the genetic 
incorporation of Cys-Lys derivatives 83R and 83S, where the M. mazei pylRSwt was 
found to recognise both diastereomers.215 Exchanging a sulfur atom for an oxygen atom 
seemed to be a sufficiently small structural perturbation such that some recognition by 
pylRSwt would be retained; clearly this is not the case. The seryl oxygen atom in 101 or 
109 is smaller and more polar than the sulfur atom in either diastereomer of 83, 
suggesting poor occupancy of the large hydrophobic binding pocket. 86 combines the 
large, soft sulfur heteroatom of 83 with a somewhat hydrophobic saturated heterocycle 




Further work demonstrated a marked sensitivity of the M. mazei towards the α'-
configuration of 83, with 83S using “unnatural” D-cysteine a superior substrate to 83R, 
just as the α' chiral centre in pyrrolysine is from “unnatural” D-methylornithine.219 As 
neither Ser-Lys diastereomer 101 or 109 could be recognised by pylRSwt, this implies 
that the loss of binding arising from the heteroatom change is not sufficiently 
compensated by the supposed boost offered by the “unnatural” configuration. The 
addition of a methyl group does clearly improve recognition, as can be seen comparing 
the assay results for 101 and 105, although this is not the case between 109 and 110.  
105 appears to hit a sweet spot of the correct configuration and sufficient hydrophobicity 
from the methyl group. It is not clear which threonyl chiral centre in 110 is incorrectly 
configured. Comparisons with allo-Thr-Lys peptides would give some indication of the 
incorrectly configured centre or centres, as would a crystal structure of pylRSwt bound to 
105. The reasons why configuration at the α’ centre, and perhaps the β' centre as well, 
affect substrate recognition are not entirely clear. Assuming a similar mode of binding to 
pyrrolysine 1, where the α' amino group is locked in place through hydrogen bonding to 
Y384, “unnatural” Thr-Lys 110 should be the best fit, with the α'-amino and β'-methyl 
groups of 110 matching the conformation adopted by 1 in the binding pocket. This 
conformation does, however, place the β' hydroxyl group pointing into a particularly 
hydrophobic region of the pocket composed of L309, C346 and W417. An alternative 
binding mode uses the β' hydroxyl group to hydrogen bond with Y384. For “natural” Thr-
Lys 105 this would angle the β' methyl group at the side chains of W417 whilst the α' 
amino group lines up for hydrogen bonding with the side chain carbonyl oxygen atom of 
N346 (Figure 49), but for the “unnatural” 110 the α' amino group would be positioned in 
a way where no such hydrogen bonds could be established, implying that a “natural” α' 
configuration is key in this new binding mode. This binding mode, and arguably other 
conceivable modes too, still leads to poor occupancy of the rear of the pocket, likely a 




Figure 49: Proposed binding mode between pylRS and 105 (left) and 110 (right), with putative hydrogen 
bonding interactions highlighted in green. 
Of course, these postulated binding modes are all based upon the assumption that the 
active site of pylRS is mostly rigid. In reality, this is likely not the case: whilst the 
interactions are retained, the precise geometry of the binding pocket will slightly distort 
in a different manner for each recognised substrate. Without a crystal structure to provide 
more definitive evidence of precise binding modes, establishing the precise reasons why 
105 is recognised by pylRSwt is not possible. Furthermore, this process exposes the flaws 
in designing NCAAs for amber stop codon suppression using a rigid ab initio rationale, 
unquestioning of the assumptions made about the flexibility of the active site of the tRNA 
synthetase. The organic chemist’s assumptive 2D perspective is not fit for purpose in a 
complex 3D biological world. 
Rationalising the results with pylRSAF is more straightforward. As mentioned, the Y306A 
mutation opens the rear of the hydrophobic pocket and the Y384F mutation knocks out 
the gatekeeper residue. Whilst the Y384F mutation alone appears to increase 
promiscuity of pylRS, to the point that it is no longer completely orthogonal to canonical 
amino acids, with the Y306A mutation this pylRS mutant becomes highly selective for 
lysine derivatives bearing large, hydrophobic side chains such as 34, the positive control. 
All of the studied lysine derivatives are far smaller and more polar than 34, resulting in a 
poor fit in the hydrophobic binding pocket and negligible recognition by pylRSAF. 
3.4 Production of ncAA-containing proteins 
With two novel NCAAs suitable for amber stop codon suppression, protein production 
was scaled up to obtain sufficient quantities for modification purposes. The 
EGFP(Y39TAG)-His6 was selected as the first construct to be produced containing 86 as 














method for decaging 86 has been developed. A second construct, sfGFP(N150TAG)-
His6, was also used to provide a second test subject. For the test decaging of 105, the 
construct sfGFP(N150TAG)-His6 was selected so that oxidation using sodium periodate 
would occur exclusively at the non-canonical residue without occurring additionally at the 
N terminus, which would impair attempts to quantify the extent of oxidation. 
3.4.1 EGFP(Y39-(thiazolidine)lysine)-His6 
A scaled-up version of the protein production protocol used in expression trials was 
utilised for the preparation of EGFP(Y39-86)-His6, 136. A single culture was grown with 
the addition of 86, induced and left to grow overnight. The harvested cell pellet was lysed 
by sonication and the lysate purified by Ni affinity chromatography. Fractions containing 
pure full-length protein, as determined by Coomassie-stained SDS-PAGE and the UV 
chromatographic trace (Figure 50), were pooled, desalted and concentrated. Whilst the 
fluorescence of fractions provides some indication of the presence and concentration of 
EGFP, this is of no use during SDS-PAGE. Boiling of the samples, required to 
homogenise the sample in a completely unfolded state and associate with SDS, ensures 
that any EGFP is no longer fluorescent, so any EGFP bands in SDS-PAGE can only be 
reliably detected with staining, e.g. Coomassie, rather than fluorescence. When the 
samples are not boiled, fluorescence is mostly retained, implying retention of the protein 
fold, but the resulting bands in SDS-PAGE do not correspond to the correct masses 
when visualised by fluorescence or by staining and the band is often more diffuse, likely 
due to the variance in folding states present in the sample. Approximately 40 mg protein 
was obtained per litre of culture. This protocol is facile, scalable and high-yielding, 
affording sufficient quantities of 136 for modification trials. 
  
Figure 50: (left) 280 nm chromatogram of the purification of 136 by nickel affinity, eluting with an imidazole 
gradient; (right) SDS-PAGE of fractions containing 136: a clear band around the expected 28.6 kDa mass. 
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ESI-FTICR-MS analysis also confirmed the purity and homogeneity of the sample, with 
the single peak in the deconvoluted mass spectrum displaying a mass consistent with 
the calculated mass of intact 136 (Figure 51).  The mass of the intact protein should 
correspond to the mass of the amino acid sequence, factoring in the NCAA, as well as 
the mass difference associated with the post-translational modification required to form 
the chromophore, a loss of 20 Da. The protein mass is calculated as the molecular weight 
when considering the elemental composition of all residues and post-translational 
modifications, assuming no degradation. The protein is predominantly detected as 
[136+nH]n+, although sodium adducts such as [136+(n-1)H+Na]n+, 22 Da higher m/z, and 
phosphate (Pi) adducts such as [136+nH+H3PO4]n+, 98 Da higher m/z, were also 
observed, likely due to incomplete removal of buffer salts. The deconvoluted spectrum 
depicts the protein as a neutral species, the mass of which is obtained from the peaks in 
the charge ladder of the raw spectrum assumed to be [M+nH]n+ species, as the m/z and 
charge of such adducts are known. The base peak corresponds to the molecular weight 
of the protein species. The mass found of the neutral species was correct to within 2 Da, 
confirming the identity of 136. A trypsin digest of 136, performed by Dr Adam Dowle, 
confirmed that NCAA 86 had been installed only at position 39 (Figure 52) and confirmed 
the expected primary sequence of 136. 
 
Figure 51:  Raw (left) and deconvoluted (right) ESI-FTICR mass spectrum of 136. For the neutral species, 











Figure 52: Trypsin digest of 136, displaying found peptides in blue to map the sequence of the protein. The 
non-canonical amino acid is confirmed in the correct location, highlighted in red. 
3.4.2 sfGFP(N150-(thiazolidine)lysine)-His6 
Due to the similarities between the constructs and the proteins, the same protocol was 
used for the preparation of sfGFP(N150-86)-His6 137, obtained in a comparable yield of 
ca. 50 mg per litre of culture. Purification by nickel affinity afforded pure 137 as 
determined by SDS-PAGE (Figure 53). 
 
Figure 53: (left) 280 nm chromatogram of the purification of 137 by nickel affinity, eluting with an imidazole 
gradient; (right) SDS-PAGE of fractions containing 137: a clear band around the expected 28.0 kDa mass. 
Characterisation by ESI-FTICR-MS further confirmed the purity of 137 (Figure 54). 
Again, a phosphate adduct was observed, as well as an acetonitrile adduct arising from 
the use of 50:50:1 H2O:MeCN:FA, but the principle species corresponds to neutral 137 
within ± 2 Da. Trypsin digest again confirmed that NCAA 86 was installed exclusively at 
residue 150 whilst the rest of the protein corresponded to the expected native sequence 
(Figure 55). 






Figure 54: Raw (left) and deconvoluted (right) ESI-FTICR mass spectrum of 137. For the neutral species, 
calc. 27957 Da; found 27957 Da. 
 
Figure 55: Trypsin digest of 137, displaying found peptides in blue to map the sequence of the protein. The 
non-canonical amino acid is confirmed in the correct location, highlighted in red. 
3.4.3 sfGFP(N150-(L-threonyl)lysine)-His6 
The same protocol was used for the preparation of sfGFP(N150-105)-His6 138. The yield, 
ca. 18 mg per litre of culture, is strikingly lower than the yield of 137, suggesting poorer 
recognition of 105 compared to 86 by pylRSwt. Full-length, purified 138 was confirmed 










Figure 56: (left) 280 nm chromatogram of the purification of 138 by nickel affinity, eluting with an imidazole 
gradient; (right) SDS-PAGE of fractions containing 138: a clear band around the expected 28.0 kDa mass. 
ESI-FTICR-MS analysis similarly confirmed that the sample obtained contained 
exclusively full-length 138, corresponding to the expected mass to within ± 2 Da (Figure 
57). Trypsin digest confirmed that only position 150 corresponded to NCAA 105 (Figure 
58). This is the first documented incorporation of 105 in a protein. 
 
Figure 57: Raw (left) and deconvoluted (right) ESI-FTICR mass spectrum of 138. For the neutral species, 
calc. 27943 Da; found 27942 Da. 









Figure 58: Trypsin digest of 138, displaying found peptides in blue to map the sequence of the protein. The 
non-canonical amino acid is confirmed in the correct location, highlighted in brown. 
3.5 Conclusions 
All six synthesised lysine derivatives were assayed using EGFP as a reporter protein to 
ascertain their suitability in amber stop codon suppression with two different pylRS 
variants. The double mutant pylRSAF proved to be unsuitable for use with any of the six 
lysine derivatives studied, whilst the wild type pylRS was found to turn over 86 and 105. 
Both of these NCAAs were successfully incorporated into two variants of GFP containing 
amber stop codons, provisionally meeting the first of the three objectives of this project.  
97 
 
Chapter 4: Exploring Aldehyde Decaging 
A communication has been published based upon Chapter 4.2.274 




With two forms of caged aldehyde genetically encoded and incorporated into test 
proteins, attention turned to developing methodologies for exposing the protein 
aldehyde. 1,2-aminoalcohols and 1,1-aminothioethers do have a usable body of 
documented reactions within the organic chemistry domain,78, 275, 276 acting as a helpful 
starting point. The principle challenge is adapting this reactivity for the biological world, 
as chemistry offering minimal perturbation outside of the moiety of interest. Careful 
tuning of conditions is required to balance the rapidity and conversion of the desired 
reaction with that of any side reactions or other unwanted processes. 
4.2 Thiazolidine decaging 
One method has been published for decaging thiazolidines to unmask glyoxyl aldehydes 
on proteins,221 in which the protein thiazolidine is treated with 50 eq. silver acetate in 
10% (v/v) aqueous acetic acid. The proposed mechanism begins with coordination of 
the thiazolidine sulfur atom to a silver(I) ion, followed by departure of the silver-sulfur 
complex with imine formation stabilising C-2 (Figure 59). In aqueous solution, this 
species hydrolyses rapidly to form the glyoxyl aldehyde. The fatal flaw in this method is 
the use of 10% (v/v) acetic acid, presumably to accelerate imine hydrolysis and prevent 
reformation of the imine through protonation of the resulting silver-cysteamine complex. 
The working pH, below 3, is unsuitable for a large proportion of the proteome, 
demonstrating the need for a more biologically compatible method. Furthermore, this 
method is incompatible with buffers containing chloride, such as NaCl commonly used 
to stabilise proteins, due to the precipitation of AgCl. When this procedure was performed 
on thiazolidine 136, the EGFP precipitated instantly and no portion remained soluble, 
preventing any detection by mass spectrometry. The thiazolidine may have been 
decaged, but the inability to detect or use the subsequent protein aldehyde limits the 
utility of this method. 
 
Figure 59: Proposed mechanism for the silver- and acid-mediated ring opening of a thiazolidine to afford a 
glyoxyl aldehyde and silver-cysteamine complex. 
The combination of a Lewis acid, Ag+, and a Brønsted-Lowry acid, AcOH, initially seems 
intuitive: unmasking the electrophilic aldehyde by capturing the nucleophilic heteroatoms 
with which it has condensed to form the thiazolidine, pairing the soft sulfur atom with soft 
Ag+ and the hard nitrogen atom with H+. The use of a superior Lewis acid would putatively 
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make the Brønsted-Lowry acid redundant, preventing thiazolidine reformation through 
tight coordination of the cysteamine by-product to a Lewis acid whilst foregoing the use 
of protein-denaturing low pH conditions. Whilst mercury salts have seen use for synthetic 
applications of thiazolidine ring opening without the need for acids,277 their use was ruled 
out owing to toxicity and potential off-target reactions with other protein sulfur atoms. A 
similar strategy was trialled on thiazolidine peptides, where the glyoxyl aldehyde peptide 
was liberated using a palladium complex at neutral pH.278 Palladium has been used for 
other decaging strategies, such as with propargyl and allyl protecting groups as 
previously discussed (Figure 23),156 including use with live cells to demonstrate a low 
level of cytotoxicity. Hence palladium reagents stood out as candidates to be effective 
thiazolidine decaging reagents. 
4.2.1 Palladium reagent screen 
For the decaging reaction of thiazolidine 136 to afford protein glyoxyl 139, palladium 
reagents 140-144 were screened (Figure 60). These reagents were selected following 
previous documented use in aqueous conditions or bioconjugations, demonstrating 
biocompatibility and reactivity to an appreciable extent.156, 199, 279, 280  
 
Figure 60: Palladium complexes screened for the decaging of protein thiazolidine 136 to afford a protein 
glyoxyl as aldehyde 139-ald or hydrate 139-hyd. 
Each reagent was trialled with 136, varying only the equivalents of each complex and 
the reaction time, after which the reaction mixture was quenched with DTT and purified 
by desalting. The extent of decaging was quantified by ESI-FTICR-MS (Table 1), 
comparing the deconvoluted peaks corresponding to 136 and 139 (Figure 61). Where a 
palladium reagent has led to protein precipitation, quantification data are based on any 
100 
 
remaining soluble protein, as the protein precipitate is removed from solution during the 
desalting process so no protein signal can be observed. This has led to some missing 
values in the table, where insufficient protein remains in solution for detection by MS. 
Conversion is estimated through a comparison of the deconvoluted peak cluster areas 
corresponding to protein starting materials and products on the assumption that all 
protein species ionise to comparable extents. Owing to sources of random error in the 
measurement of the peak intensities, problems with peak resolution, and the algorithm 
used for peak deconvolution, estimated conversions are quoted to the nearest 10% to 
cautiously take account of the limit of precision of this estimation method. Conversions 
are based upon single data points rather than replicates, as the purpose of this screen 
is to qualitatively identify promising palladium reagents for thiazolidine decaging, with 
subsequent optimisation to increase the conversion where needed, rather than to 
precisely quantify the decaging ability of each palladium reagent screened. 
Table 1: Palladium reagents 140-144 at the indicated stoichiometric equivalents screened for the decaging 
of protein thiazolidine 136 (final protein concentration 310 μM in 1 × PBS) over the indicated time interval at 
37 °C, before quenching with DTT and isolating the protein by centrifugation and desalting. Decaging 






t / h % decaged No protein 
precipitation 
140 100   6   nd  
140 100 24   nd  
141 100   6     0 ✔ 
141 100 24     0 ✔ 
142 100   6   30  
142 100 24   nd  
142     1   1 100 ✔ 
143     1   1   10 ✔ 
143 100   1   nd  
144 100   1     0 ✔ 
144 100   6   40 ✔ 
144 200   6   40 ✔ 
144 100 24   80 ✔ 
144 100 36   90 ✔ 





Figure 61: From partial to full decaging using 142. Decaging with 100 eq. for 6 h (left) led to only ca. 30% 
decaging of 136 due, at least in part, to protein precipitation, whilst a single equivalent for one hour (right) 
led to complete decaging to form 139-ald (calc. 28573 Da, found 28573 Da) and 139-hyd (calc. 28591 Da, 
found 28592 Da), predominantly existing as the aldehyde rather than the hydrated diol. 
Incubation of 136 with 140 led to instant protein precipitation, whilst 141 appeared to 
have no effect upon either the thiazolidine or the protein. This is likely due to the size of 
the bulky amphos ligands, conferring some aqueous solubility but hindering the 
palladium centre from reaching the thiazolidine given the surrounding protein mass. 
Precipitation was initially observed with 142, although this must have only been partial 
precipitation as sufficient quantities remained in solution to quantify the partial decaging 
of the thiazolidine. Lowering the equivalents of 142 not only avoided protein precipitation 
but also led to 100% conversion within one hour. A similar strategy achieved a modicum 
of success with 143: lowering the equivalents from 100 to 1 led to no protein precipitation, 
but the decaging observed was only minor. For reagent 144, altering the time proved to 
be more effective than altering the equivalents used. Doubling the equivalents offered 
no improvement to decaging, whilst increasing the time to nearly two days afforded 
complete conversion (albeit at a very slow pace). Whilst 144 can be used to decage the 
thiazolidine to completion, use of 142 will lead to the same positive result on a much 
shorter timescale. For this reason, further thiazolidine decaging work makes use of 142. 
Reagent 144 stands alone in this table as the only Pd0 species, whilst reagents 140-143 
are sources of PdII. This is likely a factor in the unusual behaviour of this reagent for 
decaging compared to the other reagents screened. Whilst soluble in DMSO, 144 is 
known to be almost completely insoluble in water.281 When prepared as a stock in an 
organic solvent, e.g. THF, and diluted into water, microcrystals of 144 are known to form 










nanoparticles are also formed, but to a much lesser extent and this arises from impurities 
in 144 rather than the reagent itself.283 The decaging activity likely arises from exposed 
palladium centres on the surface of such microparticles, which is slowly lost as the 
exposed surface area decreases due to aggregation. This heterogeneous mechanism is 
profoundly less efficient than the homogeneous mode afforded by 142, a far more active 
reagent for the decaging of 136. 
4.2.2 Optimised procedure 
With the palladium reagent selected, further work sought to probe the optimal conditions 
required for this decaging: retaining complete conversion in the shortest time through a 
streamlined procedure. The DTT quench had been adapted from peptide chemistry and, 
whilst successful in removing palladium from the solution as judged by mass spectra, 
required a large excess of DTT and sometimes extensive centrifugation to clarify the 
reaction mixture.278 An alternative quench, reported for use with palladium decaging of 
protein propargyl carbamate groups,156 required only addition of 3-mercaptopropanoic 
acid as a stock solution followed by desalting, alleviating the need for centrifugation. This 
procedure is reported as a highly effective quench in combination with desalting, justified 
with ICP-MS quantification of the palladium retained in solution, and is practically more 
straightforward and reliable than the use of DTT. This quench was used in subsequent 
decaging trials. 
Initial reagent screens had been conducted at 37 °C to maximise the chance of 
discovering any reactivity from the decaging reagents trialled. Lower temperatures would 
broaden the scope of this method, with exposure to lower temperatures generally 
preferred when handling to inhibit denaturation. At 7 °C, the ca. 10% conversion 
observed was markedly poorer than at 37 °C, but at 19 °C, 100% conversion was still 
observed. As the higher temperature served no functional purpose, further decaging 
work was performed at carefully monitored room temperature. 
The palladium reagent 142 had initially been delivered as a 100 × stock in DMSO during 
reagent screening, where the solubility of all complexes in DMSO allowed for a 
consistent method of delivery. The role of this cosolvent was explored by comparison 
with DMF, 1,4-dioxane and MeCN (Figure 62,  
Table 2), with water being unsuitable due to the insolubility of 142 at the required 30 mM 
concentration. The use of DMF and 1,4-dioxane solutions led to slightly poorer decaging, 
whilst MeCN led to almost the same decaging activity exhibited using DMSO. 
Nevertheless, DMSO was still shown to be the most effective solvent for the aldehyde 




Figure 62: Decaging of 136, as observed by MS, using 142 prepared in either MeCN (blue), DMF (green) or 
1,4-dioxane (red). Spectra are normalised relative to the peak for 139-ald. 
 
Table 2: Solvent effect in the decaging of protein thiazolidine 136. 
Solvent % decaged 
DMSO 100 
MeCN   90 
DMF   80 
1,4-dioxane   60 
 
With the stock solution, temperature and quench improved, the optimised procedure was 
trialled using the second thiazolidine construct 137 to afford protein glyoxyl 145 (Figure 
63). Pleasingly, the same conditions led to complete decaging as expected following a 
straightforward protocol. One limitation of this method of monitoring decaging is the 
presence of MeCN adducts, where the mass of 145-hyd + MeCN is indistinguishable 
(within 1 Da) from that of starting material 137. This is problematic for protein substrates 
where the glyoxyl aldehyde exists mostly as the hydrate, as is the case with 145 but not 
with 139, perhaps fortuitously given the difficulties this would have posed when 
attempting to quantify decaging during reagent screens. In this instance, the putative 
MeCN adduct is so low in abundance relative to the main peaks of interest that decaging 
does appear to have reached completion. Further verification of this will take place 












Figure 63: Decaging of protein thiazolidine 137 to afford protein glyoxyl 145 (top). ESI-FTICR-MS data show 
the consumption of 137 (lower left; calc. 27957 Da, found 27956 Da) to afford 145-ald (lower right; calc. 
27898 Da, found 27900 Da) and 145-hyd (calc. 27916 Da, found 27918 Da). 
4.2.3 Aldehyde versus hydrate 
One notable difference is observed between the mass spectra of protein glyoxyl species 
139 and 145: the balance of the aldehyde versus the hydrate. In aqueous solution, 
glyoxyl aldehydes are so electrophilic that nucleophilic water attacks the glyoxyl to form 
a more stable hydrate species. This is observed with 145, where the glyoxyl exists 
predominantly as the hydrate, in line with expectations.231 However, the mass spectrum 
of 139 depicts the opposite scenario, where the aldehyde is predominantly not hydrated. 
Given the high degree of similarity between the EGFP and sfGFP scaffolds, the most 
likely explanation is the residue microenvironment.  
In both sfGFP and EGFP, residue N150 is retained and is positioned in the middle of a 
β-sheet. At this location, the principle interactions responsible for maintaining protein fold 
involve the main chain of this residue and not the side chain, which is exposed to solvent 
and has a reasonable degree of freedom. This is why position 150 is a suitable site for 














and can be altered with minimal structural perturbation whilst being available for chemical 
reactivity. Position 39 is markedly different, however. This residue was one of the key 
mutations leading to the sfGFP scaffold owing to the increased stability of the protein 
upon the Y39N mutation, as mentioned earlier. In EGFP, position 39 lies on a β-turn, but 
in sfGFP the effect of the single Y39N mutation is to tighten this β-turn into a more stable 
310-helix, leading to a substantial improvement in fold stability (Figure 64).284 Here, the 
side-chain carboxylate of D36, at the N-terminal end of the 310-helix, interacts with the 
N39 side chain amide. This has the effect of bringing these two residues closer together 
compared to the same site in EGFP, with the effect of forming a tighter turn at the end of 
the β-sheet. Residue 39 is indeed exposed to solvent, as seen in the crystal structure 
and through the documented reactivity of NCAAs installed at this site,169, 170 but the 
participation of its side chain in protein-stabilising interactions need also be considered. 
 
Figure 64: EGFP residue Y39 forms part of a β-turn (green) with little side-chain interaction (left, PDB: 2Y0G). 
This contrasts with sfGFP residue N39, where the residue has rotated to position the side chain amide to 
hydrogen bond with the side chain carboxylate of residue D36 (right, PDB: 2B3P). This tighter geometry 
takes the form of a 310 helix rather than a β-turn, bringing together two strands of the β-barrel and stabilising 
the protein fold. 
Whilst this difference in the mass spectra between 139 and 145 initially appears to be 
merely superficial, there is an important consideration to be made when attempting to 
modify 139. Is this difference a limitation of the analytical method or are the two glyoxyl 
aldehydes chemically different? Has the microenvironment around 139 residue 39 
stabilised the glyoxyl aldehyde to the point of diminished reactivity? From a broader 
perspective, this acts as a reminder of the considerations required for judicious 
placement of NCAAs using amber stop codon suppression. The primary concern is 
typically whether the NCAA may the protein, but clearly there is a need to consider how 
the rest of the protein may perturb the NCAA. This is not always obvious from crystal 
structures alone; had sfGFP not been developed, the full extent of the involvement of the 














Whilst the primary objective of the decaging procedure is liberation of a reactive glyoxyl 
aldehyde, some discussion of the mechanism is worthwhile for the purposes of method 
optimisation. Given that palladium reagent 142 can effect thiazolidine decaging without 
the need for a low pH, its superiority over the previous AgOAc strategy seems clear. This 
is likely due to the different geometries of complexation available to Ag+, typically forming 
linear complexes, versus Pd2+, capable of forming linear and square planar complexes. 
When cysteamine is released from the thiazolidine, the amino group can also coordinate 
to the Pd2+ centre to form a more stable chelated complex, tightly trapping the 
cysteamine. This is not possible with Ag+, requiring high H+ concentrations to protonate 
the cysteamine and prevent thiazolidine reformation. 
The use of palladium can be something of a double-edged sword, however. The reagent 
must possess a careful balance between affinity for the thiazolidine versus affinity for the 
rest of the protein, where the metal may facilitate pathways such as protein denaturation 
or aggregation through coordination to cysteine thiols or methionine thioethers. For the 
palladium reagents screened, this is reflected in the number of equivalents required. For 
reagent 142, an affinity for decaging is clear, but the protein precipitation seen at high 
equivalents clearly demonstrates the need to tailor the decaging method to the protein 
to achieve the correct balance, a common theme in biorthogonal chemistry.  
The ligands of the palladium complex are evidently a factor in the reactivity of each 
complex. 140 only led to protein precipitation and its effect on decaging is unknown, due 
to the inability to quantify the decaged protein by mass spectrometry. 141 appeared to 
be inert, putatively due to the bulky ligands as mentioned. At low equivalents, very little 
decaging was observed with 143, likely owing to the ligand: the 1,5-cyclooctadiene ligand 
chelates to the Pd2+ centre and serves to block off a face of the complex, providing steric 
bulk that inhibits nucleophilic attack by the thiazolidine sulfur atom.  
The success of 142 is likely due to the dinuclear complex dissociating in the stock 
solution, on account of the differences in decaging observed when altering the solvent 
used for this purpose. Mononuclear complexes of palladium with DMSO, MeCN and 
DMF are well known, where the coordinating solvent acts as a suitable ligand.285 The 
trend seen in  
Table 2 suggests some influence of the coordinating atom on this process, in the order 
S > N (free) > N (hindered) > O. Whilst 142 is prepared as a dinuclear species and 
delivered as one equivalent, in the reaction mixture two equivalents of mononuclear Pd2+ 
are available to react with the thiazolidine. The mononuclear complex formed from 142 
is likely composed of small ligands that do not chelate, such as a PdCl2L2-type complex 
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where L = coordinating solvent, minimising the bulk around the Pd2+ centre. This is one 
factor behind the enhanced reactivity of this PdCl2L2 complex towards protein 
thiazolidines compared to analogues 141 and 143, in addition to the extra equivalent of 
Pd2+ present.  
With this considered, a mechanism for this decaging reaction is proposed based upon 
Figure 59. A Pd2+ complex coordinates to the thiazolidine sulfur atom and causing ring 
opening,286 followed by imine hydrolysis and coordination of the cysteamine amino group 
to form a Pd(cysteamine)L2 chelate (Figure 65).  
 
Figure 65: Proposed mechanism for the palladium-mediated ring opening of a thiazolidine to afford a glyoxyl 
aldehyde and silver-cysteamine complex. L = coordinating solvent ligand, e.g. DMSO. 
4.3 Threonine oxidation 
With one aldehyde-decaging method in hand with the thiazolidine 86, attention turned 
towards the threonine derivative 105. The 1,2-aminoalcohol motif led to periodate 
oxidation as the most obvious route due to the general reliability and body of work behind 
this methodology. 
4.3.1 Condition screen 
A procedure for oxidising the mutated N-terminal serine residue of EGFP has been 
optimised and reported by Dr Richard Spears.244 These conditions were used as a 
starting point for the oxidation of 138 to form protein glyoxyl 145, using six eq. NaIO4 and 
18 eq. L-methionine as a sacrificial reducing agent to prevent off-target oxidation (Figure 
66). These conditions led to 60% conversion within four minutes of oxidation: a promising 
start, but apparently a more challenging substrate to oxidise than an N-terminal serine 




Figure 66: (top) Oxidation of protein 1,2-aminoalcohol 138 to afford protein glyoxyl 145. ESI-FTICR-MS data 
show some consumption of 137 (lower left; calc. 27943 Da, found 27942 Da) to afford 145-ald (lower right; 
calc. 27898 Da, found 27897 Da) and 145-hyd (calc. 27916 Da, found 27916 Da) to approximately 60% 
conversion. 
Attempts to increase this conversion were largely unsuccessful. Longer reaction times, 
from four to eight or twelve minutes, led to no improvement, with conversion stalling at 
40-60%. Increasing the quantity of NaIO4 to ten eq. (and correspondingly L-methionine 
to 20 eq.) led to overoxidation of the protein after eight minutes, with additional +16 peaks 
appearing in the mass spectra of the oxidised proteins. One consideration was whether 
a by-product of periodate oxidation, in this case acetaldehyde, was reacting with the 
exposed protein glyoxyl aldehyde 145 in a crossed-aldol reaction to afford product 146, 
differing in mass from 138 by only 1 Da (Figure 67). Indeed this “accidental aldol” led to 
the reported OPAL method for modifying protein aldehydes.287 This was investigated 
through trypsin digest, as the peptides produced can be characterised to within 0.1 Da, 
sufficient to discriminate between 145 and 146, as well as through the use of peptide 
fragmentation. Through this peptide mapping, the presence of 145-ald and 145-hyd was 
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evidence of the aldol by-product 146 was found. Oxidation was indeed proceeding but 
hampered by some unknown factor. 
 
Figure 67: Putative aldol interception of 145 by the acetaldehyde released from periodate oxidation, leading 
to unwanted side product 146, indistinguishable from 138 by intact protein mass spectrometry alone. 
4.3.2 Optimised conditions 
Reviewing literature protocols led to closer inspection of the buffer composition used. 
Sodium phosphate buffers are commonplace, as is the use of NaCl, but potassium ions 
are seldom encountered. This was the one component of PBS that stood out as 
suspicious. One hypothesis is that potassium cations interact with the periodate anion 
and can precipitate as potassium periodate, poorly soluble in water (ca. 8 mM) at the 
typical 0 °C of periodate oxidation, as was observed in early applications of periodate 
oxidation.288 Given that periodate was only used in 5 eq., even minor precipitation of 
periodate could noticeably affect the extent and rate of oxidation. 
A batch of 138 was prepared by Dr Tessa Keenan under potassium-free conditions, 
substituting PBS with 20 mM sodium phosphate buffer, 150 mM NaCl, pH 7.4. This 
composition approximates the buffering capacity and ionic strength of PBS but without 
any potassium. With conditions of 100 μM 138, 5 eq. NaIO4, and 10 eq. L-methionine, 
oxidation reached completion in four minutes (Figure 68). 145 exists almost completely 
as the hydrate and a minor extent of N-terminal methionine cleavage is also seen 
accompanying oxidative cleavage. The effect of removing potassium, seemingly an 





Figure 68: Optimised periodate oxidation of 138 affords 139, predominantly as the hydrated aldehyde (calc. 
27916 Da, found 27918 Da). 
4.4 Beyond the GFP scaffold 
Thus far GFPs have served as handy test proteins for trialling new methodologies for 
aldehyde decaging. To be truly of use however, these new strategies must be applicable 
to as substantial a proportion of the proteome as possible; not all proteins are as well 
behaved as GFP. A further substrate was sought to serve as a testbed and an enhanced 
challenge for aldehyde decaging. 
4.4.1 Introducing BiGalK 
Whilst this project was underway, in the same laboratory Dr Tessa Keenan was 
undertaking extensive work with enzymatic glycosylation. One particular protein enjoying 
particular usage was Bifidobacterium infantis galactokinase, BiGalK, which catalyses the 
phosphorylation of galactose to form galactose-1-phosphate and can be produced using 
recombinant methods in E. coli in appetisingly high yields.289 Furthermore, when a 
sample was submitted for ESI-FTICR-MS analysis, this protein was remarkably 
straightforward to observe using this technique. One previous protein substrate, Bacillus 
circulans xylanase (Bcx), had proven to be far less amenable to study by ESI-MS at 
concentrations below 1 mM and required MALDI-MS, which is unsuitable for detecting 
intact protein mass changes of 40-60 Da from decaging. Given these positive practical 






developed aldehyde decaging methods. Notably, the N-terminal residue of BiGalK is a 
threonine residue, presenting an opportunity for multiple modifications using orthogonal 
aldehyde strategies. 
Whilst the kinetics, sequence and expression conditions of BiGalK were reported, at that 
time no crystal structure of BiGalK had been obtained. Structural understanding of 
BiGalK, including active site composition, was largely restricted to sequence analysis 
and comparison with homologues. This was an impediment when considering where 
exactly the amber stop codon should be installed in BiGalK, with little information on 
which residues would be exposed on the protein surface or potentially involved in 
enzymatic activity. Residue K417, located almost at the C-terminus of this 423-residue 
protein, was selected as its position and hydrophilic properties suggested that this 
residue would be exposed on the surface of the protein. More recently, Dr Tessa Keenan 
has obtained crystal structures of BiGalK that substantiate this claim. The C-terminus of 
BiGalK is highly disordered: the final residue with defined electron density is K417, and 
even the side chain of this residue is too disordered to be defined (Figure 69). Despite 
this, the C-terminal tail appears to be exposed to the solvent rather than buried within 
the protein. Whilst the zeal for using an unexplored protein was a helpful motivator in 
driving this research, having access to this structure would have greatly informed the 
rational mutation design process and would perhaps have permitted a more ambitiously 
located residue to have been selected for mutation. Nevertheless, using site-directed 
mutagenesis residue K417 was mutated to the amber stop codon to afford the desired 
BiGalK(K417TAG)-His6 construct ready for production. 
 
Figure 69: Preliminary crystal structure of BiGalK, provided by Dr Tessa Keenan (unpublished), with residue 
K417 highlighted. 
As the N-terminal residue of BiGalK is threonine, the thiazolidine was first selected for 
installation by amber stop codon suppression, in order to unequivocally demonstrate 
single aldehyde decaging and obtain a homogeneous protein scaffold. The production 
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of thiazolidine-containing BiGalK(K417TAG)-His6 147 required little alteration from the 
protocol for the production of wild-type BiGalK, with only an additional induction for the 
pBAD vector and addition of NCAA 86 required. An expression trial found comparable 
high yields of BiGalK across several timings for these protocol additions, demonstrating 
little sensitivity to when the pEVOL plasmid was induced or when NCAA was added. A 
preparative scale protocol to produce 147 was thus designed from the reported 
GFP(TAG) and wild-type BiGalK protocols. Purification by Ni affinity afforded ca. 30 mg 
of 147 per litre of culture, lower than the 80 mg / L culture for wild-type BiGalK or 40 mg 
/ L culture of thiazolidine-containing EGFP 136 but still a high yield providing a usable 
quantity of protein. 
Characterisation by ESI-FTICR-MS confirmed the presence of full-length 147 containing 
86 in place of a lysine residue (Figure 70). This spectrum was complicated by the 
presence of multiple sodium, MeCN and phosphate adducts, but the masses found 
match those expected. Disappointingly, the N-terminal methionine residue was present 
in over 90% of the protein, complicating the MS data and precluding the possibility of a 
dual aldehyde decaging strategy as Thr1 was not available for oxidation. Nevertheless, 
a new protein thiazolidine was at hand ready to trial aldehyde decaging. 
 
Figure 70: Raw (left) and deconvoluted (right) ESI-FTICR mass spectrum of 147. For the dominant species, 
a sodiated MeCN adduct, calc. 45936 Da; found 45936 Da. For the methionine-cleaved species, calc. 45805 
Da; found 45804 Da. 
4.4.2 Decaging BiGalK 
The first trial of decaging protein thiazolidine 147 to afford protein glyoxyl 148 was a 
reproduction of the conditions established using GFPs, with 300 μM of both 147 and 












the concentration of 142 led to protein precipitation, so instead the protein concentration 
was decreased, effectively raising the equivalents of 142 without raising the working 
concentration to a point where protein denaturation occurred (Table 3, Figure 71). 
Table 3: Optimisation of concentrations of protein thiazolidine 147 and palladium reagent 142 required to 
achieve full decaging. 
[147] / μM [142] / μM Eq. 142 % conversion 
300 300 1.0     0 
200 300 1.5   50 
100 150 1.5     0 
  75 300 4.0 100 
 
Figure 71: Decaging of protein thiazolidine 147 to afford protein glyoxyl 148 (top, masses shown correspond 
to the predominant sodiated acetonitrile adduct). ESI-FTICR-MS data show ca. 50% decaging at 1.5 eq. 142 
at 300 μM (lower left), increasing to 100% conversion when 142 is added as 4 eq. at 300 μM (lower right), 
affording 148-hyd; with Met1, calc. 45895 Da, found 45894 Da; without Met1, calc. 45764 Da, found 45765 
Da. 
At 1.5 eq. 142 at 300 μM, conversion increased to 50%, whilst the same number of 
equivalents but halved concentration of 142 and 147 led to no conversion. Pleasingly, 
complete decaging was observed with 4 eq. 142 at 300 μM. These results suggest that 
147 + Pi 




















a delicate balance exists between protein precipitation and thiazolidine decaging, where 
maximising the extent of decaging must be carefully weighed against any protein 
precipitation. Just as with periodate oxidation, each protein construct requires careful 
optimisation of palladium decaging conditions. Residue microenvironment, surrounding 
protein bulk and palladium-induced precipitation affinity are all likely factors responsible 
for achieving this balance. In this situation, a balance of both equivalents and 
concentration of palladium is required to achieve full decaging without protein 
precipitation. This work does show, however, that thiazolidine decaging is suitable for 
proteins beyond GFPs, broadening the scope of applicable substrates. 
 
4.5 Conclusions 
A procedure for protein thiazolidine decaging to expose glyoxyl aldehydes has been 
developed using palladium reagent 142. For GFPs, this protocol requires only one 
equivalent of 142 and reaches full decaging within one hour at room temperature without 
protein precipitation. This procedure was then optimised for use on another protein 
scaffold, BiGalK, which again led to full decaging within one hour. 
A second route to protein glyoxyls was optimised through the use of protein 1,2-
aminoalcohols. Oxidation of this pseudo-N-terminal threonine residue with NaIO4 affords 
the same glyoxyl revealed through palladium decaging of thiazolidines. Possessing two 
separate routes to the same reactive aldehyde species increases the utility of the glyoxyl 
aldehyde, raising the likelihood of at least one suitable decaging method being found for 
the protein of interest. Both routes reach full conversion rapidly under mild, biocompatible 
conditions, meeting the second objective of this project.   
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The final objective of this project was to demonstrate the reactivity of the decaged protein 
aldehyde through the use of established aldehyde modification chemistry. The previous 
chapter focussed upon the aldehyde from an analytical perspective: can it be observed 
and quantified? This chapter considers the aldehyde from a more practical perspective: 
what does it do and how well? Herein lie the opportunities for showcasing the aldehyde 
not just as a peak in a mass spectrum, but as a handle for adding function to proteins in 
exciting and useful ways.  
5.2 Oxime ligation 
5.2.1 Overview 
Oxime ligation is arguably the staple ligation method of protein aldehydes,77 taking 
advantage of the aldehyde electrophilicity by using a strong nucleophile to form a more 
stable condensation product. This nucleophile typically benefits from the α-effect, 
wherein the nucleophilicity of a heteroatom can be enhanced by the presence of an 
adjacent heteroatom, such as hydrazine or aminooxy nucleophiles to form hydrazones 
and oximes respectively. Even with this enhanced nucleophilicity, some form of catalysis 
is required to activate the aldehyde towards electrophilic attack. This initially took the 
form of acid catalysis, where pH 4 was required to tag a glyoxyl-containing antibody with 
an aminooxy reagent containing an 125I radiolabel.290 Such a low pH is not suitable for all 
proteins- the EGFP and sfGFP scaffolds are denatured at pH 4- so nucleophilic catalysis 
was developed as an alternative. Aniline, and other substituted aniline derivatives, allow 
modification within 20 h at neutral pH, with more electron-rich anilines such as p-
anisidine affording the greatest rate enhancements.291 The protonated aniline Schiff base 
intermediate is even more electrophilic than a protonated glyoxyl aldehyde, leading to a 
much higher rate of ligation under compatible conditions with reliably high conversion 
(Figure 72). However, the resulting bioconjugate is not particularly stable, as every 
mechanistic step is a reversible equilibrium. At neutral pH in aqueous conditions, the 
half-life of a hydrazone is on the order of one hour, compared to a fortnight for an oxime 
linkage (the temperature for this is not reported),80 although this reversibility need not 
always be a disadvantage depending upon the application. Nevertheless, oxime ligation 





Figure 72: The rate of oxime ligation is greatly enhanced by aniline catalysis via the protonated aniline Schiff 
base intermediate. 
5.2.2 Protein modification using oxime ligation 
A variety of aniline-catalysed protocols have been reported;89, 221, 240 one of the selling 
points of this ligation strategy is the scope for altering the substrates and conditions as 
the situation demands. Aniline typically remains at a working concentration of 0.1 M in 
order to drive formation of the reactive Schiff base intermediate. Oxime ligation was 
trialled upon protein glyoxyl 139 using ca. 35 eq. of biotin- and dansyl-aminooxy probes 
123 and 124 to form protein oximes 149 and 150 (Figure 73). Full conversion was 
observed by ESI-FTICR-MS after 24 h, demonstrating that the decaged glyoxyls not only 
look like aldehydes, but also react like aldehydes. The mass spectra are complicated by 
the presence of unreacted probe, falling in the mass range of the protein charge ladder 
and not being sufficiently removed by the desalting process. Some efforts have been 
made to remove the signals from these mass spectra during data acquisition where the 
probe signals were masking the protein signals, simplifying the spectra for more reliable 
deconvolution. This process was then repeated using protein glyoxyl 145, where once 












Figure 73: Oxime ligation of protein aldehyde 139 with aminooxy biotin probe 123 or aminooxy dansyl probe 
124 (top). In both cases, ESI-FTICR-MS data show the complete consumption of 139-ald to afford 
biotinylated protein 149 (lower left; calc. 29347 Da, found 29348 Da) and dansylated protein 150 (lower right, 
calc. 29355 Da, found 29356 Da) with the protein-probe linkage schematically depicted as a bold bond. 
 
Figure 74: Oxime ligation of protein aldehyde 145 with aminooxy biotin probe 123 or aminooxy dansyl probe 
124 (top). In both cases, ESI-FTICR-MS data show the complete consumption of 145-hyd to afford 
biotinylated protein 151 (lower left; calc. 28672 Da, found 28673 Da) and dansylated protein 152 (lower right, 












As further verification and a demonstration of the bioconjugate utility, dansylated 
bioconjugate 153 was visualised by fluorescence following denaturing SDS-PAGE, 
ensuring that any fluorescent signals only arise from the dansyl group appended to a 
protein (Figure 75). The fluorescent gel confirms successful bioconjugation, with a band 
at ca. 29 kDa for 153 fluorescing as expected whilst negative control 145 could only be 
seen by Coomassie staining. Analogously, biotinylated protein 149 was visualised using 
colorimetric Western blotting. Following incubation with anti-biotin substrates, a band 
was detected for 149 at the expected mass of ca. 30 kDa, whilst no band was observed 
for negative control 139. These data conclusively demonstrate the reactivity and 
functional labelling of the decaged protein glyoxyl aldehydes using oxime ligation. 
 
Figure 75: (left) Coomassie staining (upper) and fluorescence (lower) of unmodified negative control 145 
and dansylated protein 153 following denaturing SDS-PAGE; (right) Coomassie staining (upper) and 
Western blotting with an anti-biotin substrate (lower) of unmodified negative control 139 and biotinylated 
protein 149 following denaturing SDS-PAGE. 
5.3 OPAL 
5.3.1 Overview 
The organocatalytic protein aldol ligation, OPAL, is a relatively new addition to the field 
of protein aldehyde modification, arising from a deep interest in the opportunities for 
protein modification presented by aldehyde handles within the Fascione laboratory. As 
mentioned, this reaction was first discovered when a protein glyoxyl reacted with 
acetaldehyde, released by the periodate oxidation exposing the protein glyoxyl. Diligent 
development of OPAL by Dr Richard Spears appropriated some of the most powerful 
developments in organocatalytic aldol reactions and crossed-aldol reactions to produce 
a remarkably simple yet effective protein modification strategy.244 
Only three reagents are required for OPAL: an acceptor aldehyde, a donor aldehyde and 
an organocatalyst. The acceptor aldehyde must be non-enolisable and highly 
electrophilic, with the protein glyoxyl aldehyde proving to be an ideal candidate for this 





















role. The most reactive donor aldehydes, the nucleophilic species, were found to be 
phenacetaldehyde derivatives. Proline tetrazole 154 acts as an organocatalyst, 
condensing with the donor aldehyde to form a highly nucleophilic enamine that attacks 
the acceptor aldehyde (Figure 76).244 The product links together both aldehydes through 
a stable carbon-carbon bond linkage and contains a β-hydroxy aldehyde group that can 
subsequently undergo oxime ligation, opening up routes for dual modification of proteins. 
OPAL has already enjoyed a creative array of applications, including folate labelling for 
potential use in cancer-targeting therapeutics and the mimicry of two post-translational 
modifications installed on a protein implicated in Leishmania virulence. 
 
Figure 76: Donor aldehydes slowly attack the acceptor aldehyde via the enol tautomer, but the use of 
organocatalyst 154 opens up a much faster pathway through the formation of a more nucleophilic enamine. 
5.3.2 Protein modifiation using OPAL  
As with oxime ligation, a helpful degree of flexibility surrounds OPAL, with the 
consequence that little optimisation is required to achieve full conversion. Protein and 
probe conditions are largely the same as those used in oxime ligation, but far fewer 
equivalents are required of the organocatalytic proline tetrazole 154 compared to the 
vast excess of catalytic aniline required for oxime ligation. Protein glyoxyls 139 and 145 
were reacted with dansyl probe 131 at neutral pH for just one hour, after which 100% 
conversion to dansylated proteins 155 and 156 was observed by ESI-FTICR-MS (Figure 
77). The β-hydroxyaldehyde does not appear to be hydrated to an appreciated extent, a 




Figure 77: OPAL using aminooxy biotin probe 123 with protein aldehydes 139 (upper left) and 145 (upper 
right). In both cases, ESI-FTICR-MS data show the complete consumption of the protein aldehyde to afford 
dansylated proteins protein 155 (lower left; calc. 29330 Da, found 29332 Da) and 156 (lower right, calc. 
28655 Da, found 28657 Da) with the protein-probe linkage schematically depicted as a bold bond. The β-
hydroxyaldehyde is observed only as the aldehyde form without hydration. 
Fluorescence imaging of 155 and 156 following denaturing SDS-PAGE further confirmed 
successful labelling (Figure 78). 
 
Figure 78: (left) Coomassie staining (upper) and fluorescence (lower) of unmodified negative control 139 
and dansylated protein 155 following denaturing SDS-PAGE; (left) Coomassie staining (upper) and 
fluorescence (lower) of unmodified negative control 145 and dansylated protein 156 following denaturing 
SDS-PAGE. 
Labelling of protein glyoxyls 139 and 145 with biotin probe 130 was performed by Dr 
Richard Spears and the same success was reported.244 As a further demonstration of 




























Richard Spears, cell lysate material from the preparation of thiazolidine-containing 136 
was treated with palladium reagent 142 and then biotin probe 130 under OPAL 
conditions, with biotin affinity chromatography using monomeric avidin successfully 
capturing and then eluting the biotinylated EGFP. This protein pull-down work is an 
elegant demonstration of the biocompatibility and utility of the palladium-OPAL pair, 
delivering even in the challenging milieu of cell lysate material with exquisite selectivity. 
5.4 SPANC 
5.4.1 Overview 
Strain-promoted alkyne-nitrone cycloaddition, SPANC, has seen use not only through in 
vitro protein modification, 245 but also live-cell labelling,292 nanoparticle loading,293 and 
functionalisation of polymers.294 The electrophilicity of the aldehyde partner is exploited 
as a means by which a nitrone can be formed: first through the formation of a Schiff base 
with organocatalytic p-anisidine, then through nucleophilic attack by an N-substituted 
hydroxylamine compound. The resulting nitrone acts as a 1,3-dipole ready to undergo a 
cycloaddition with a strained alkyne such as a BCN (Figure 79). Varying the substituent 
on the hydroxylamine has allowed the pairing of SPANC with CuAAC, where N-
propargylhydroxylamine was used to form the nitrone. The resulting isoxazoline linkage 
is generally stable, although some highly reactive cycloalkynes are documented to 
undergo rearrangements after SPANC.295 Strain-promoted cycloadditions are generally 
regarded as bioorthogonal on account of the paucity of suitable 1,3-dipoles such as 
azides, nitrones and nitrile oxides found in nature, as well as the limited reactivity of 
strained alkyne dipolarophiles towards functional groups commonly found in cellular 
milieu.
 
Figure 79: Promoted by p-anisidine catalysis, the protein glyoxyl condenses with N-methylhydroxylamine to 
form an oxime, becoming a nitrone upon deprotonation. This protein nitrone undergoes a [3+2] cycloaddition 
with a strained alkyne to furnish the isoxazoline bioconjugate. 
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5.4.2 Protein modification using SPANC 
As SPANC had seen previous use on protein glyoxyl aldehydes, the conditions reported 
served as a helpful starting point for trialling conditions. The p-anisidine organocatalyst 
is required in large excess, as is the case with oxime ligation, and 50 equivalents of N-
methylhydroxylamine serve to drive nitrone formation to completion, but only 20 
equivalents of strained alkyne are needed to completely consume the protein nitrone. 
Hence protein glyoxyls 139 (Figure 80) and 145 (Figure 81) were reacted with BCN 
probes 133 and 134 under SPANC conditions to form labelled proteins 157-160 at pH 
6.8 for 18 h. Once again complete conversion was observed by ESI-FTICR-MS for all 
four trial reactions.  
 
Figure 80: SPANC of protein aldehyde 139 with BCN biotin probe 133 or BCN dansyl probe 134 (top). In 
both cases, ESI-FTICR-MS data show the complete consumption of 139-ald to afford biotinylated protein 
157 (lower left; calc. 29497 Da, found 29499 Da) and dansylated protein 158 (lower right, calc. 29504 Da, 

























Figure 81: SPANC of protein aldehyde 145 with BCN biotin probe 133 or BCN dansyl probe 134 (top). In 
both cases, ESI-FTICR-MS data show the complete consumption of 139-ald to afford biotinylated protein 
159 (lower left; calc. 28822 Da, found 28824 Da) and dansylated protein 160 (lower right, calc. 28829 Da, 
found 28831 Da) with the protein-probe linkage schematically depicted as a bold bond. 
Labelled proteins 157-160 were then visualised by fluorescence and Western blotting 
following denaturing SDS-PAGE as a further confirmation of successful modification 
(Figure 82). 
 
Figure 82: (left) Coomassie staining (upper), fluorescence (middle) and Western blotting with an anti-biotin 
substrate (lower) of unmodified negative control 139, biotinylated protein 157 and dansylated protein 158 
following denaturing SDS-PAGE; (right) Coomassie staining (upper), fluorescence (middle) and Western 
blot with an anti-biotin substrate (lower) of unmodified negative control 145, biotinylated protein 159 and 































The decaged protein glyoxyl aldehydes have been shown to undergo three standard and 
useful bioconjugation reactions of oxime ligation, OPAL and SPANC. Using this 
chemistry, proteins have been tagged with biotin and dansyl groups, as demonstrated 
by Western blots and fluorescence. For in vitro protein modification, OPAL and SPANC 
had only seen usage on N-terminal glyoxyl aldehydes. This work has shown that these 
bioconjugations are not limited in scope to the N-terminus, removing a heavy restriction 
on the use of this chemistry. The “internal aldehyde” exhibits comparable reactivity to an 
N-terminal glyoxyl aldehyde and presents new opportunities for site-selective protein 
modification beyond the protein N-terminus.   
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Two non-canonical amino acids harbouring caged glyoxyl aldehydes, 86 and 105, have 
been found to be suitable for amber stop codon suppression using the M. mazei 
pyrrolysyl tRNA-synthetase (wild type) pair, producing full-length protein containing the 
caged aldehyde. Four other potential caged aldehyde NCAAs were not recognised to an 
appreciable extent by either wild-type tRNA synthetase or the Y306A-Y384F mutant. 
Proteins containing 86 were found to liberate the glyoxyl aldehyde upon treatment with 
palladium complex 142, the palladium complex most active in decaging without inducing 
protein precipitation. This procedure requires some optimisation for individual proteins, 
in order to balance the reactivity of the palladium complex to open the thiazolidine with 
potential side-reactions including protein precipitation. Alternatively, proteins containing 
105 underwent oxidative cleavage using NaIO4 to afford the same protein glyoxyl 
aldehyde. Together, 86 and 105 present two different routes for accessing the glyoxyl 
aldehyde, offering useful flexibility when a particular protein of interest may be intolerant 
of one decaging procedure but not another. 
Most crucially of all, the exposed protein glyoxyl serves as an excellent handle for site-
specific protein modification. Bioconjugations using oxime ligation, OPAL and SPANC 
proceeded to full conversion, conferring additional avidin affinity or fluorescent 
functionality through the use of reactive probes bearing biotin or dansyl groups. As 
judged by the methods used here, the “internal aldehyde” exposed from 86 or 105 
appears to exhibit the same reactivity as its N-terminal counterpart, functioning as a 
useful bioorthogonal handle for chemical protein modification.  
6.2 Future work 
6.2.1 Optimised amber stop codon suppression 
Whilst 86 and 105 are substrates for wild-type M. mazei pylRS, the recognition is not 
optimal. The assay used here to determine successful amber stop codon suppression is 
only qualitative, but clear differences in protein yields can be seen from both the SDS-
PAGE and fluorescence when comparing 86 and 105 to positive control 29. For proteins 
such as GFPs and BiGalK, where yields are typically high, this is not a major issue. 
However, the utility of 86 and 105 would be increased were a tRNA synthetase evolved 
specifically to recognise these NCAAs, as the increased protein yields would make this 
strategy more practical for use with proteins with challenging production protocols. 
Indeed, this strategy has become commonplace when developing new NCAAs for amber 
stop codon suppression: one synthetase out of many variants is selected to work with a 
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particular NCAA, whilst the approach outlined in this thesis is the converse. This work 
has not shown that NCAAs 96, 99, 101 and 110 are unsuitable for amber stop codon 
suppression, but that no suitable tRNA synthetase of those screened was found to 
recognise these NCAAs. A directed evolution approach, screening a library of 
synthetases with mutations in key locations, would not only conclusively rule in or rule 
out 96, 99, 101 or 110 from amber stop codon suppression, but also find the optimal 
mutants for the recognition of 86 and 105, leading to superior protein yields. 
6.2.2 Applications of this work: in vitro 
As previously discussed, the field of chemical protein modification operates with two 
distinct objectives. The first centres on chemistry: finding the widest array of strategies 
for chemical modification of proteins. The work in this thesis has focussed on this 
direction, seeking to add a new instrument to the toolbox of methods available. It is not 
the intention of this work to appear as superior or inferior to any other method; its utility 
lies in being an option, one of many, such that for even the most challenging protein or 
situation a suitable modification strategy exists. 
The second objective in this field of more broad than pure chemistry: developing 
applications for chemical protein modification, showcasing the powerful chemistry 
through situations with a greater impact than test beds. This has primarily focussed on 
therapeutics, although biophysical applications are also under consideration.296 The 
prominence of this objective is increasing over time, where impact is valued over novelty. 
One of the key tests of contemporary chemical protein modification strategies is its 
suitability for the generation of ADCs, pushing the chemistry well beyond the comfort of 
well-behaved test proteins tagged with fluorophores and often requiring multiple 
modifications. Palladium decaging, paired with suitable ligation such as OPAL, does 
seem to be a suitable platform for this purpose, given the site selectivity of both methods 
and the stability of the resulting bioconjugate. One common drawback of amber stop 
codon suppression, however, is the low yield of proteins produced this way. Ameliorating 
this issue requires extensive protein production optimisation and likely the mutation of a 
superior pylRS, with greater recognition of 86. Nevertheless, antibody modification is the 
next logical step for developing this work, adding impact to the novelty. 
A further application of the palladium decaging is post-translational mimicry. Prior to this 
work, glyoxyl aldehydes had been restricted to protein N-termini, but PTMs face no such 
restriction and can be found in a far greater range of locations on the protein. Given that 
this work has lifted the site restriction, glyoxyl aldehydes are now more suitable as 
handles for post-translational mimicry. The dual modification of hydrophilic surface 
protein A, HASPA, using OPAL on an N-terminal glyoxyl aldehyde followed by oxime 
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ligation on the ensuing β-hydroxyaldehyde, has demonstrated the suitability of protein 
aldehydes for this task.244 Using palladium decaging and subsequent bioconjugation, this 
post-translation mimicry can extend beyond the N-terminus into multiple locations, slowly 
advancing on nature’s own methods for post-translational modification. 
6.2.3 Applications of this work: live cell labelling 
Applications of chemical protein modification in vitro, such as ADCs, still have a central 
place in the field. Increasing in prominence is the need for demonstrations of chemical 
methods in living systems towards in vivo applications, where site specificity is truly 
tested by a more diverse milieu and side reactions with a greater range of substrates are 
possible- in addition to maintaining the health of the organism under investigation. 
Palladium complex 142 has seen use for live-cell protein deprotection, with negligible 
cytotoxic effects observed through careful control of the concentration of palladium.156 
Furthermore, palladium decaging and OPAL biotinylation has been shown to succeed in 
cell lysate material, owing to the selectivity of both methodologies.244 This suggests the 
suitability of palladium-mediated thiazolidine decaging for live cell labelling in tandem 
with a bioconjugation strategy. Cellular incorporation of a thiazolidine through 
promiscuous metabolic pathways, such as the GlcNAc pathway,297 would serve to 
smuggle the caged aldehyde into live cells ready for decaging and bioconjugation, such 








7.1 Chemical synthesis 
7.1.1 General methods 
Solvents and Starting Materials 
All solvents were dried prior to use according to standard methods, with the exception of 
solvents used for flash chromatography purposes, where GPR-grade solvents were 
used. All commercially-available reagents were used as received. Analytical grade 
reagents were supplied by Sigma-Aldrich, Fisher Scientific, VWR International, and TCI. 
29 and 34 were purchased from Sirius Fine Chemicals. 
General Procedures 
All solution-phase reactions were carried out under a dry nitrogen atmosphere using 
oven-dried glassware unless otherwise stated. All concentrations were performed in 
vacuo unless stated otherwise. Analytical TLC was performed on silica gel 60-F254 with 
detection by fluorescence and/or charring following immersion in a solution of ninhydrin 
(1.5 g in 100 mL n-butanol and 3 mL acetic acid). All compounds reported in this section 
have been synthesised for the first time unless explicitly stated otherwise. 
Instrumentation 
Small-molecule HRMS data were obtained at room temperature on a Bruker Daltonics 
micrOTOF. Analytical HPLC of peptides was performed on a Shimadzu Prominence 
HPLC equipped with a Shimadzu photodiode array using an Accucore C18 2.6 µm 
column, 2.1 × 150 mm. All samples were run using gradients of HPLC-grade H2O and 
MeCN, spiked with 0.1% (v/v) FA. Infra-red spectra were recorded on a PerkinElmer 
UATR2 spectrometer. Optical rotations were recorded at 20 °C using a Bellingham & 
Stanley ADP450 series polarimeter and values reported in units of 10-1 deg cm2 g-1. 
1H and 13C NMR spectra were recorded at 500 MHz and 126 MHz respectively on a 
Bruker AV500 instrument using an internal deuterium lock at room temperature. Signals 
were assigned using additional DEPT135, COSY, HSQC and HMBC experiments. 
Chemical shifts are reported in ppm according to the following references: DMSO-d6: δH 
2.50; δC 39.52 (centre of septet).  
The following abbreviations were used to describe signal multiplicities or appearances: 
s, singlet; d, doublet; t, triplet; dt, doublet of triplets; q, quartet; qd, quartet of doublets; 
quint, quintet; dq, doublet of quintets; m, multiplet.  
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Acyclic amino acid carbon atoms are labelled with Greek letters (in subscript) in 
accordance with IUPAC conventions, with hydrogen and nitrogen atoms labelled with the 
Greek letter of the carbon atom to which they are attached. Prime symbols (') are used 
to label atoms of the second residue in a dipeptide. Thiazolidine carbon and nitrogen 
atoms are labelled with numbers in accordance with IUPAC conventions, with hydrogen 





7.1.2 Solution-phase synthesis 
 
N-hydroxysuccinimidyl 2-(tert-butoxycarbonylamino)-acetate 98 
 
N-hydroxysuccinimide (0.73 g, 6.3 mmol, 1.05 eq.) was added to a solution of 2-(tert-
butoxycarbonylamino)-acetic acid 97 (1.05 g, 6.0 mmol, 1.0 eq.) in 1:1 (v/v) EtOAc:1,4-
dioxane (18 mL) at 0 °C. Dicyclohexylcarbodiimide (1.30 g, 6.3 mmol, 1.05 eq.) was 
added in one portion and the reaction left to warm to r.t. and stirred for 3 h. The reaction 
mixture was filtered through a Celite pad and concentrated. The crude product was 
redissolved in EtOAc (20 mL) and washed sequentially with 5% (w/w) NaHCO3 (10 mL), 
H2O (10 mL) and brine (10 mL). The organic layer was dried over MgSO4, filtered and 
concentrated to afford crude N-hydroxysuccinimidyl 2-(tert-butoxycarbonylamino)-
acetate 98 as a white powder of sufficient purity for further manipulation (0.82 g, 50%); 
δH (500 MHz, DMSO-d6): 7.47 (major rotamer) and 7.09 (minor) (t, 1H, 3J 6.2 Hz, NH), 
4.09 (major) and 4.02 (minor) (d, 2H, 3J 6.2 Hz, Hα), 2.81 (s, 4H, Su CH2), 1.39 (major) 
and 1.37 (minor) (s, 9H, Boc CH3); δC (126 MHz, DMSO-d6): 170.0 (Su CO), 167.1 
(major) and 166.9 (minor) (CO2Su, mixture of rotamers), 155.6 (major) and 154.4 (minor) 
(CO2NH), 79.2 (minor) and 78.8 (major) (C(CH3)3), 41.2 (minor) and 39.7 (major) (Cα), 
28.1 (major) and 27.6 (minor) (Boc CH3), 25.4 (Su CH2); IR (ATR): 3296, 2984, 2935, 
1733, 1704, 1678, 1531, 1368, 1290, 1210, 1167, 1083, 1047, 993, 948, 902, 866, 814, 
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764, 746, 644, 616; HRMS: found [M+Na]+ 295.0897; C11H16N2O6Na requires 295.0901 




acetamido)-hexanoic acid 100 
 
DIPEA (1.75 mL, 10 mmol, 4.0 eq.) and a solution of N-hydroxysuccinimidyl 2-(tert-
butoxycarbonylamino)-acetate 98 (0.68 g, 2.5 mmol, 1.0 eq.) in DCM (9 mL) were added 
sequentially at r.t. to a stirred suspension of (2S)-2-(tert-butoxycarbonylamino)-6-
aminohexanoic acid 99 (0.62 g, 2.5 mmol, 1.0 eq.) in DCM (12 mL). The reaction mixture 
was stirred at r.t. for 3 h, filtered and concentrated. The residue was redissolved in DCM 
(30 mL) and washed with sat. citric acid (10 mL) and brine (10 mL). The organic layer 
was dried over MgSO4, filtered and concentrated to afford crude (2S)-2-(tert-
butoxycarbonylamino)-6-(2-(tert-butoxycarbonylamino)-acetamido)-hexanoic acid 100 
as an off-white powder of sufficient purity for further manipulation (0.78 g, 77%); δH (500 
MHz, DMSO-d6) 7.72 (t, 1H, 3J 5.4 Hz, HNε), 7.01 (d, 1H, 3J 8.0 Hz, HNα), 6.85 (t, 1H, 3J 
6.1 Hz, HNα'), 3.78-3.84 (m, 1H, Hα), 3.48 (d, 2H, 3J 6.1 Hz, Hα'), 2.97-3.07 (m, 2H, Hε), 
1.22-1.65 (m, 24H, Boc CH3, Boc CH3, Hβ, Hγ, Hδ); δC (126 MHz, DMSO-d6) 174.2 
(CO2H), 169.0 (CONH), 155.7, 155.6 (Boc CO2N), 78.0, 77.9 (C(CH3)3), 53.4 (Cα), 43.2 
(Cα'), 38.2 (Cε), 30.4 (Cβ), 28.7 (Cγ), 28.2 (Boc CH3), 23.0 (Cδ); IR (ATR): 3321, 2978, 
2933, 1691, 1516, 1453, 1392, 1366, 1247, 1158, 1050, 1024, 946, 860, 780, 562; 




(2S)-2-amino-6-(2-aminoacetamido)-hexanoic acid 96 
 
Trifluoroacetic acid (4 mL) was added dropwise to a stirred solution of (2S)-2-(tert-
butoxycarbonylamino)-6-(2-(tert-butoxycarbonylamino)-acetamido)-hexanoic acid 100 
(0.63 g, 1.55 mmol) in DCM (8 mL) at 0 °C and left to reach rt. Once the reaction was 
determined complete by TLC, usually within 3 h, the reaction mixture was triturated with 
ice-cold Et2O (30 mL), filtered, and washed with ice-cold Et2O (4 × 20 mL). The resulting 
off-white powder was redissolved in 10% (v/v) aqueous acetic acid and lyophilised to 
afford the product (2S)-2-amino-6-(2-aminoacetamido)-hexanoic acid 96 as a fluffy off-
white powder (470 mg, diacetate salt, 94%); [α]D +7.2 (c 0.9, H2O); δH (500 MHz, DMSO-
d6): 8.40 (t, 1H, 3J 5.5 Hz, HNε), 3.78 (t, 1H, 3J 6.2 Hz, Hα), 3.52 (s, 2H, Hα'), 3.08-3.12 
(m, 2H, Hε), 1.70-1.82 (m, 2H, Hβ), 1.25-1.46 (m, 4H, Hγ, Hδ); δC (126 MHz, DMSO-d6): 
171.1 (CO2H), 165.7 (CONH), 52.1 (Cα), 40.1 (Cα'), 38.6 (Cε), 29.7 (Cβ), 28.4 (Cγ), 21.8 
(Cδ); IR (ATR): 2945, 1663, 1508, 1435, 1257, 1183, 1132, 1014, 914, 837, 798, 722, 








N-hydroxysuccinimide (0.73 g, 6.3 mmol, 1.05 eq.) was added to a solution of (2S)-3-
(tert-butoxy)-2-(tert-butoxycarbonylamino)-propanoic acid 102 (1.57 g, 6.0 mmol, 1.0 
eq.) in 1:1 (v/v) EtOAc:1,4-dioxane (18 mL) at 0 °C. Dicyclohexylcarbodiimide (1.30 g, 
6.3 mmol, 1.05 eq.) was added in one portion and the reaction left to warm to r.t. and 
stirred for 3 h. The reaction mixture was filtered through a Celite pad and concentrated. 
The crude product was redissolved in EtOAc (20 mL) and washed sequentially with 5% 
(w/w) NaHCO3 (10 mL), H2O (10 mL) and brine (10 mL). The organic layer was dried 
over MgSO4, filtered and concentrated to afford crude N-hydroxysuccinimidyl (2S)-3-
(tert-butoxy)-2-(tert-butoxycarbonylamino)-propanoate 103 as a white powder of 
sufficient purity for further manipulation (1.10 g, 51%); δH (500 MHz, DMSO-d6): 7.32 
(major rotamer) and 6.92 (minor) (d, 1H, 3J 8.3 Hz, NH), 4.45-4.52 (major) and 4.32-4.37 
(minor) (m, 1H, Hα), 3.62-3.68 (m, 2H, Hβ), 2.80 (s, 4H, Su CH2), 1.39 (major) and 1.37 
(minor) (s, 9H, Boc CH3), 1.14 (major) and 1.08 (minor) (s, 9H, ether CH3); δC (126 MHz, 
DMSO-d6): 170.2 (minor) and 169.8 (major) (Su CO, mixture of rotamers), 167.0 (major) 
and 166.3 (minor) (CO2Su), 155.1 (major) and 154.7 (minor) (CO2NH), 79.4 (minor) and 
78.8 (major) (Boc C(CH3)3), 73.2 (ether C(CH3)3), 61.0 (major) and 60.7 (minor) (Cβ) 54.3 
(minor) and 53.0 (major) (Cα), 28.1 (major) and 27.6 (minor) (Boc CH3), 27.1 (minor) and 
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27.0 (major) (ether CH3), 25.4 (Su CH2); IR (ATR): 3410, 2982, 2935, 1820, 1783, 1735, 
1714, 1475, 1444, 1427, 1364, 1196, 1170, 1102, 1083, 1064, 1046, 1036, 995, 912, 
867, 835, 810, 774, 749, 647, 576, 553; HRMS: found [M+Na]+ 381.1633; C16H26N2O7Na 






butoxycarbonylamino)-propanamido)-hexanoic acid 104 
 
DIPEA (1.75 mL, 10 mmol, 4.0 eq.) and a solution of N-hydroxysuccinimidyl (2S)-3-(tert-
butoxy)-2-(tert-butoxycarbonylamino)-propanoate 103 (0.90 g, 2.5 mmol, 1.0 eq.) in 
DCM (8 mL) were added sequentially at r.t. to a stirred suspension of (2S)-2-(tert-
butoxycarbonylamino)-6-aminohexanoic acid 99 (0.62 g, 2.5 mmol, 1.0 eq.) in DCM (12 
mL). The reaction mixture was stirred at r.t. for 3 h, filtered and concentrated. The residue 
was redissolved in DCM (30 mL) and washed with sat. citric acid (10 mL) and brine (10 
mL). The organic layer was dried over MgSO4, filtered and concentrated to afford crude 
(2S)-2-(tert-butoxycarbonylamino)-6-((2S)-3-(tert-butoxy)-2-(tert-butoxycarbonylamino)-
propanamido)-hexanoic acid 104 as an off-white powder of sufficient purity for further 
manipulation (1.20 g, 98%); δH (500 MHz, DMSO-d6) 7.80 (t, 1H, 3J 5.0 Hz, HNε), 6.98 
(d, 1H, 3J 8.0 Hz, HNα), 6.85 (d, 1H, 3J 8.3 Hz, HNα'), 3.95 (dt, 1H, 3J 8.4 Hz, 3Jα'-β' 5.6 
Hz, Hα'), 3.80 (dt, 1H, 3J 7.9 Hz, 3Jα-β 7.0 Hz, Hα), 3.38-3.43 (m, 2H, Hβ'), 2.94-3.12 (m, 
2H, Hε), 1.20-1.65 (m, 24H, Boc CH3, Boc CH3, Hβ, Hγ, Hδ), 1.09 (s, 9H, ether CH3); δC 
(126 MHz, DMSO-d6) 174.3 (CO2H), 169.9 (CONH), 155.6, 155.0 (Boc CO2N), 78.1, 77.9 
(Boc C(CH3)3), 72.6 (ether C(CH3)3), 62.0 (Cβ'), 54.9 (Cα'), 53.4 (Cα), 38.2 (Cε), 30.3 (Cβ), 
28.6 (Cγ), 28.2, 28.1 (Boc CH3), 27.2 (ether CH3), 22.9 (Cδ); IR (ATR): 3321, 2976, 2933, 
1705, 1661, 1501, 1392, 1365, 1247, 1161, 1088, 1019, 860, 779, 735; HRMS: found 




(2S)-2-amino-6-((2S)-2-amino-3-hydroxypropanamido)hexanoic acid 101 
 
Deprotection cocktail 95:2.5:2.5 (v/v) TFA:TIS:H2O  (4 mL) was added dropwise to a 
stirred solution of (2S)-2-(tert-butoxycarbonylamino)-6-((2S)-3-(tert-butoxy)-2-(tert-
butoxycarbonylamino)-propanamido)-hexanoic acid 104 (1.01 g, 2.06 mmol) in DCM (8 
mL) at 0 °C and left to reach rt. Once the reaction was determined complete by TLC, 
usually within 3 h, the reaction mixture was triturated with ice-cold Et2O (30 mL. The 
suspension was centrifuged at 4 000 × g for 5 min, supernatant decanted, and the 
peptide pellet resuspended in ice-cold Et2O (20 mL), with this process repeated 5 times 
in total, after which the pellet was left to air dry. The resulting off-white powder was 
redissolved in 10% (v/v) aqueous acetic acid and lyophilised to afford (2S)-2-amino-6-
((2S)-2-amino-3-hydroxypropanamido)-hexanoic acid 101 as an off-white foam (560 mg, 
diacetate salt, 77%); [α]D +21.1 (c 1.0, H2O); δH (500 MHz, DMSO-d6): 8.41 (t, 1H, 3J 5.5 
Hz, HNε), 3.55-3.63 (m, 4H, Hα, Hα', Hβ'), 3.08-3.12 (m, 2H, Hε), 1.69-1.79 (m, 2H, Hβ), 
1.28-1.47 (m, 4H, Hγ, Hδ); δC (126 MHz, DMSO-d6): 171.1 (CO2H), 166.6 (CONH), 60.3 
(Cβ'), 54.4 (Cα'), 52.1 (Cα), 38.5 (Cε), 29.7 (Cβ), 28.3 (Cγ), 21.7 (Cδ); IR (ATR): 3316, 2944, 
1661, 1572, 1521, 1432, 1273, 1251, 1184, 1127, 1037, 836, 799, 721, 600, 542; HRMS: 







N-hydroxysuccinimide (0.91 g, 7.9 mmol, 1.05 eq.) was added to a solution of (2S,3R)-
3-(tert-butoxy)-2-(tert-butoxycarbonylamino)-butanoic acid 106 (2.06 g, 7.5 mmol, 1.0 
eq.) in 1:1 (v/v) EtOAc:1,4-dioxane (22 mL) at 0 °C. Dicyclohexylcarbodiimide (1.62 g, 
7.9 mmol, 1.05 eq.) was added in one portion and the reaction left to warm to r.t. and 
stirred for 3 h. The reaction mixture was filtered through a Celite pad and concentrated. 
The crude product was redissolved in EtOAc (20 mL) and washed sequentially with 5% 
(w/w) NaHCO3 (10 mL), H2O (10 mL) and brine (10 mL). The organic layer was dried 
over MgSO4, filtered and concentrated to afford crude N-hydroxysuccinimidyl (2S,3R)-3-
(tert-butoxy)-2-(tert-butoxycarbonylamino)-butanoate 107 as a white powder of sufficient 
purity for further manipulation (1.25 g, 45%); δH (500 MHz, DMSO-d6): 6.97 (d, 1H, 3J 9.3 
Hz, NαH), 4.42 (dd, 1H, 3J 9.3 Hz, 3Jα-β 4.1 Hz, Hα), 4.02-4.07 (m, 1H, Hβ), 2.80 (s, 4H, 
Su H), 1.40 (s, 9H, Boc CH3), 1.19 (d, 3H, 3Jβ-γ 6.2 Hz, Hγ), 1.14 (s, 9H, ether CH3); δC 
(126 MHz, DMSO-d6): 169.9 (Su CO), 166.8 (CO2H), 155.2 (Boc CO2NH), 78.9 (Boc 
C(CH3)3), 73.9 (ether C(CH3)3), 67.2 (Cβ), 57.9 (Cα), 28.2 (Boc CH3), 28.1 (ether CH3), 
25.4 (Su CH2), 19.6 (Cγ); IR (ATR): 3351, 2978, 2935, 2119, 1819, 1781, 1732, 1711, 
1512, 1456, 1368, 1241, 1205, 1151, 1120, 1090, 1059, 957, 914, 868, 825, 792, 644, 
605, 546; HRMS: found [M+Na]+ 395.1793; C17H28N2O7Na requires 395.1789 (Δ = -1.0 






butoxycarbonylamino)-butanamido)-hexanoic acid 108 
 
DIPEA (2.1 mL, 12 mmol, 4.0 eq.) and a solution of N-hydroxysuccinimidyl (2S,3R)-3-
(tert-butoxy)-2-(tert-butoxycarbonylamino)-butanoate 107 (1.12 g, 3.0 mmol, 1.0 eq.) in 
DCM (9 mL) were added sequentially at r.t. to a stirred suspension of (2S)-2-(tert-
butoxycarbonylamino)-6-aminohexanoic acid 99 (738 mg g, 3.0 mmol, 1.0 eq.) in DCM 
(15 mL). The reaction mixture was stirred at r.t. for 3 h, filtered and concentrated. The 
residue was redissolved in DCM (30 mL) and washed with sat. citric acid (10 mL) and 
brine (10 mL). The organic layer was dried over MgSO4, filtered and concentrated to 
afford crude (2S)-2-(tert-butoxycarbonylamino)-6-((2S,3R)-3-(tert-butoxy)-2-(tert-
butoxycarbonylamino)-butanamido)-hexanoic acid 108 as a white fluffy powder of 
sufficient purity for further manipulation (1.25 g, 83%); δH (500 MHz, DMSO-d6) 7.71 (t, 
1H, 3J 5.6 Hz, HNε), 6.95 (d, 1H, 3J 8.0 Hz, HNα), 5.95 (t, 1H, 3J 9.1 Hz, HNα'), 3.79-3.90 
(m, 3H, Hα, Hα', Hβ'), 2.93-3.12 (m, 2H, Hε), 1.23-1.65 (m, 24H, Boc CH3, Boc CH3, Hβ, 
Hγ, Hδ), 1.08 (s, 9H, ether CH3), 1.00 (d, 3H, 3Jβ'-γ' 6.2 Hz, Hγ'); δC (126 MHz, DMSO-d6) 
174.2 (CO2H), 169.8 (CONH), 155.5, 155.1 (Boc CO2N), 78.3, 77.8 (Boc C(CH3)3), 73.3 
(ether C(CH3)3), 67.4 (Cβ'), 59.4 (Cα'), 53.4 (Cα), 38.4 (Cε), 30.4 (Cβ), 28.5 (Cγ), 28.2, 28.1 
(Boc CH3), 28.0 (ether CH3), 23.1 (Cδ), 19.9 (Cγ'); IR (ATR): 3436, 2980, 1722, 1706, 
1493, 1453, 1424, 1391, 1364, 1312, 1248, 1216, 1160, 1091, 1068, 1038, 946, 864, 
836, 793, 775, 754, 683; HRMS: found [M+Na]+ 526.3089; C24H45N3O8Na requires 




(2S)-2-amino-6-((2S,3R)-2-amino-3-hydroxybutanamido)-hexanoic acid 105 
 
Deprotection cocktail 95:2.5:2.5 (v/v) TFA:TIS:H2O (4 mL) was added dropwise to a 
stirred solution of (2S)-2-(tert-butoxycarbonylamino)-6-((2S,3R)-3-(tert-butoxy)-2-(tert-
butoxycarbonylamino)-butanamido)-hexanoic acid 108 (1.11 g, 2.2 mmol) in DCM (6 mL) 
at 0 °C and left to reach rt. Once the reaction was determined complete by TLC, ca. 3 h, 
the reaction mixture was split into two portions and each portion triturated with ice-cold 
Et2O (30 mL). The suspension was centrifuged at 4 000 × g for 5 min, supernatant 
decanted, and the peptide pellet resuspended in ice-cold Et2O (20 mL), with this process 
repeated 5 times in total, after which the pellet was left to air dry. The resulting off-white 
solid was redissolved in 10% (v/v) aqueous acetic acid and lyophilised to afford (2S)-2-
amino-6-((2S,3R)-2-amino-3-hydroxybutanamido)-hexanoic acid 105 as a fluffy white 
foam (706 mg, diacetate salt, 87%); [α]D +9.5 (c 1.1, H2O); δH (500 MHz, DMSO-d6): 8.53 
(t, 1H, 3J 5.6 Hz, HNε), 3.85 (app. quint., 1H, 3Jα'-β', β'-γ' 6.5 Hz, Hβ'), 3.79 (t, 1H, 3Jα-β 6.3 
Hz, Hα), 3.48 (d, 1H, 3Jα'-β' 6.8 Hz, Hα'), 3.14 (app. dq, 1H, 2J 12.7 Hz, 3J 6.6 Hz, Hε), 3.05 
(app. dq, 1H, 2J 12.9 Hz, 3J 6.5 Hz, H'ε), 1.70-1.82 (m, 2H, Hβ), 1.24-1.47 (m, 4H, Hγ, Hδ) 
1.12 (d, 3H, 3Jβ'-γ' 6.4 Hz, Hγ'); δC (126 MHz, DMSO-d6): 171.1 (CO2H), 166.8 (CONH), 
65.8 (Cβ'), 58.5 (Cα'), 52.1 (Cα), 38.5 (Cε), 29.7 (Cβ), 28.3 (Cγ), 21.8 (Cδ), 20.0 (Cγ'); IR 
(ATR): 2944, 1660, 1512, 1432, 1250, 1182, 1131, 918, 838, 798, 721, 599, 517; HRMS: 








N-hydroxysuccinimide (0.44 g, 3.9 mmol, 1.1 eq.) was added to a solution of (2R)-3-(tert-
butoxy)-2-(tert-butoxycarbonylamino)-propanoic acid 111 (0.91 g, 3.5 mmol, 1.0 eq.) in 
1:1 (v/v) EtOAc:1,4-dioxane (10 mL) at 0 °C. Dicyclohexylcarbodiimide (0.79 g, 3.9 mmol, 
1.1 eq.) was added in one portion and the reaction left to warm to r.t. and stirred for 3 h. 
The reaction mixture was filtered through a Celite pad and concentrated. The crude 
product was redissolved in EtOAc (20 mL) and washed sequentially with 5% (w/w) 
NaHCO3 (10 mL), H2O (10 mL) and brine (10 mL). The organic layer was dried over 
MgSO4, filtered and concentrated to afford crude N-hydroxysuccinimidyl (2R)-3-(tert-
butoxy)-2-(tert-butoxycarbonylamino)-propanoate 112 as a white powder of sufficient 
purity for further manipulation (0.96 g, 76%); δH (500 MHz, DMSO-d6): 7.32 (major 
rotamer) and 6.92 (minor) (d, 1H, 3J 8.3 Hz, NH), 4.48-4.52 (major) and 4.33-4.37 (minor) 
(m, 1H, Hα), 3.62-3.68 (m, 2H, Hβ), 2.80 (s, 4H, Su CH2), 1.40 (major) and 1.37 (minor) 
(s, 9H, Boc CH3), 1.14 (major) and 1.08 (minor) (s, 9H, ether CH3); δC (126 MHz, DMSO-
d6): 169.8 (Su CO), 167.0 (major) and 166.3 (minor) (CO2Su, mixture of rotamers), 155.1 
(major) and 154.7 (minor) (CO2NH), 79.4 (minor) and 78.8 (major) (Boc C(CH3)3), 73.2 
(ether C(CH3)3), 61.0 (major) and 60.7 (minor) (Cβ) 54.3 (minor) and 53.0 (major) (Cα), 
28.1 (major) and 27.6 (minor) (Boc CH3), 27.0 (ether CH3), 25.4 (Su CH2); IR (ATR): 
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3410, 2980, 2934, 1819, 1783, 1735, 1713, 1475, 1445, 1426, 1365, 1195, 1165, 1102, 
1082, 1065, 1046, 1035, 995, 912, 866, 810, 775, 749, 647, 577, 553; HRMS: found 





butoxycarbonylamino)-propanamido)-hexanoic acid 113 
 
DIPEA (1.75 mL, 10 mmol, 4.0 eq.) and a solution of N-hydroxysuccinimidyl (2R)-3-(tert-
butoxy)-2-(tert-butoxycarbonylamino)-propanoate 112 (0.90 g, 2.5 mmol, 1.0 eq.) in 
DCM (8 mL) were added sequentially at r.t. to a stirred suspension of (2S)-2-(tert-
butoxycarbonylamino)-6-aminohexanoic acid 99 (0.62 g, 2.5 mmol, 1.0 eq.) in DCM (12 
mL). The reaction mixture was stirred at r.t. for 3 h, filtered and concentrated. The residue 
was redissolved in DCM (30 mL) and washed with sat. citric acid (10 mL) and brine (10 
mL). The organic layer was dried over MgSO4, filtered and concentrated to afford crude 
(2S)-2-(tert-butoxycarbonylamino)-6-((2R)-3-(tert-butoxy)-2-(tert-butoxycarbonylamino)-
propanamido)-hexanoic acid 113 as a white foam of sufficient purity for further 
manipulation (1.04 g, 85%); δH (500 MHz, DMSO-d6) 7.77 (t, 1H, 3J 5.7 Hz, HNε), 6.97 
(d, 1H, 3J 8.0 Hz, HNα), 6.42 (d, 1H, 3J 8.2 Hz, HNα'), 3.78-3.97 (m, 2H, Hα', Hα), 3.38-
3.44 (m, 2H, Hβ'), 2.96-3.09 (m, 2H, Hε), 1.20-1.65 (m, 24H, Boc CH3, Boc CH3, Hβ, Hγ, 
Hδ), 1.09 (s, 9H, ether CH3); δC (126 MHz, DMSO-d6) 174.3 (CO2H), 169.8 (CONH), 
155.6, 155.0 (Boc CO2N), 78.1, 77.9 (Boc C(CH3)3), 72.6 (ether C(CH3)3), 62.0 (Cβ'), 54.9 
(Cα'), 53.4 (Cα), 38.2 (Cε), 30.3 (Cβ), 28.6 (Cγ), 28.2, 28.1 (Boc CH3), 27.2 (ether CH3), 
22.9 (Cδ); IR (ATR): 3331, 2976, 1705, 1501, 1392, 1365, 1247, 1161, 1088, 1019, 860, 





(2S)-2-amino-6-((2R)-2-amino-3-hydroxypropanamido)-hexanoic acid 109 
 
Deprotection cocktail 95:2.5:2.5 (v/v) TFA:TIS:H2O  (4 mL) was added dropwise to a 
stirred solution of (2S)-2-(tert-butoxycarbonylamino)-6-((2R)-3-(tert-butoxy)-2-(tert-
butoxycarbonylamino)-propanamido)-hexanoic acid 113 (1.01 g, 2.06 mmol) in DCM (6 
mL) at 0 °C and left to reach rt. Once the reaction was determined complete by TLC, 
usually within 3 h, the reaction mixture was triturated with ice-cold Et2O (30 mL). The 
suspension was centrifuged at 4 000 × g for 5 min, supernatant decanted, and the 
peptide pellet resuspended in ice-cold Et2O (20 mL), with this process repeated 5 times 
in total, after which the pellet was left to air dry. The resulting off-white powder was 
redissolved in 10% (v/v) aqueous acetic acid and lyophilised to afford (2S)-2-amino-6-
((2R)-2-amino-3-hydroxypropanamido)-hexanoic acid 109 as a fluffy off-white foam (657 
mg, diacetate salt, 93%); [α]D +31.8 (c 1.0, H2O); δH (500 MHz, DMSO-d6): 8.45 (t, 1H, 
3J 5.6 Hz, HNε), 3.66-3.82 (m, 4H, Hα, Hα', Hβ'), 3.07-3.11 (m, 2H, Hε), 1.71-1.82 (m, 2H, 
Hβ), 1.28-1.46 (m, 4H, Hγ, Hδ); δC (126 MHz, DMSO-d6): 171.2 (CO2H), 166.8 (CONH), 
60.5 (Cβ'), 54.6 (Cα'), 52.2 (Cα), 38.6 (Cε), 29.8, (Cβ), 28.4 (Cγ), 21.8 (Cδ); IR (ATR): 3317, 
2946, 1661, 1581, 1519, 1428, 1278, 1255, 1184, 1129, 1039, 840, 802, 720, 600, 518; 








N-hydroxysuccinimide (257 mg, 2.2 mmol, 1.1 eq.) was added to a solution of (2R,3S)-
3-(tert-butoxy)-2-(tert-butoxycarbonylamino)-butanoic acid 114 (561 mg, 2.0 mmol, 1.0 
eq.) in 1:1 (v/v) EtOAc:1,4-dioxane (6 mL) at 0 °C. Dicyclohexylcarbodiimide (460 mg, 
2.2 mmol, 1.1 eq.) was added in one portion and the reaction left to warm to r.t. and 
stirred for 3 h. The reaction mixture was filtered through a Celite pad and concentrated. 
The crude product was redissolved in EtOAc (10 mL) and washed sequentially with 5% 
(w/w) NaHCO3 (10 mL), H2O (5 mL) and brine (5 mL). The organic layer was dried over 
MgSO4, filtered and concentrated to afford crude N-hydroxysuccinimidyl (2R,3S)-3-(tert-
butoxy)-2-(tert-butoxycarbonylamino)-butanoate 115 as a white foam of sufficient purity 
for further manipulation (483 mg, 64%); δH (500 MHz, DMSO-d6): 6.97 (d, 1H, 3J 9.3 Hz, 
NαH), 4.42 (dd, 1H, 3J 9.3 Hz, 3Jα-β 4.1 Hz, Hα), 4.02-4.07 (m, 1H, Hβ), 2.80 (s, 4H, Su H), 
1.40 (s, 9H, Boc CH3), 1.19 (d, 3H, 3Jβ-γ 6.2 Hz, Hγ), 1.14 (s, 9H, ether CH3); δC (126 
MHz, DMSO-d6): 169.9 (Su CO), 166.8 (CO2H), 155.2 (Boc CO2NH), 78.9 (Boc C(CH3)3), 
73.9 (ether C(CH3)3), 67.2 (Cβ), 57.9 (Cα), 28.2 (Boc CH3), 28.1 (ether CH3), 25.4 (Su 
CH2), 19.6 (Cγ); IR (ATR): 3350, 2978, 2933, 1819, 1781, 1731, 1710, 1512, 1456, 1367, 
1242, 1205, 1152, 1120, 1090, 1059, 957, 914, 868, 825, 791, 644, 605, 546; HRMS: 





butoxycarbonylamino)-butanamido)-hexanoic acid 116 
 
DIPEA (0.6 mL, 5.2 mmol, 4.0 eq.) and a solution of N-hydroxysuccinimidyl (2R,3S)-3-
(tert-butoxy)-2-(tert-butoxycarbonylamino)-butanoate 115 (483 mg, 1.3 mmol, 1.0 eq.) in 
DCM (6 mL) were added sequentially at r.t. to a stirred suspension of (2S)-2-(tert-
butoxycarbonylamino)-6-aminohexanoic acid 99 (320 mg g, 1.3 mmol, 1.0 eq.) in DCM 
(9 mL). The reaction mixture was stirred at r.t. for 3 h, filtered and concentrated. The 
residue was redissolved in DCM (15 mL) and washed with sat. citric acid (5 mL) and 
brine (5 mL). The organic layer was dried over MgSO4, filtered and concentrated to afford 
crude (2S)-2-(tert-butoxycarbonylamino)-6-((2R,3S)-3-(tert-butoxy)-2-(tert-
butoxycarbonylamino)-butanamido)hexanoic acid 116 as a white foam of sufficient purity 
for further manipulation (635 mg, 97%); δH (500 MHz, DMSO-d6) 7.71 (t, 1H, 3J 5.6 Hz, 
HNε), 6.98 (d, 1H, 3J 8.0 Hz, HNα), 5.95 (t, 1H, 3J 9.2 Hz, HNα'), 3.70-3.90 (m, 3H, Hα, Hα', 
Hβ'), 2.97-3.08 (m, 2H, Hε), 1.21-1.73 (m, 24H, Boc CH3, Boc CH3, Hβ, Hγ, Hδ), 1.08 (s, 
9H, ether CH3), 1.00 (d, 3H, 3Jβ'-γ' 6.2 Hz, Hγ'); δC (126 MHz, DMSO-d6) 174.2 (CO2H), 
169.9 (CONH), 155.6, 155.1 (Boc CO2N), 78.3, 77.9 (Boc C(CH3)3), 73.3 (ether C(CH3)3), 
67.3 (Cβ'), 59.4 (Cα'), 53.4 (Cα), 38.5 (Cε), 30.4 (Cβ), 28.5 (Cγ), 28.2, 28.1 (Boc CH3), 28.0 
(ether CH3), 23.1 (Cδ), 20.0 (Cγ'); IR (ATR): 3320, 2979, 1708, 1663, 1496, 1392, 1366, 
1249, 1161, 1065, 1022, 959, 857, 779; HRMS: found [M+Na]+ 526.3108; C24H45N3O8Na 




(2S)-2-amino-6-((2S,3R)-2-amino-3-hydroxybutanamido)-hexanoic acid 110 
 
Deprotection cocktail 95:2.5:2.5 (v/v) TFA:TIS:H2O (2 mL) was added dropwise to a 
stirred solution of (2S)-2-(tert-butoxycarbonylamino)-6-((2R,3S)-3-(tert-butoxy)-2-(tert-
butoxycarbonylamino)-butanamido)-hexanoic acid 116 (588 mg, 1.2 mmol) in DCM (3 
mL) at 0 °C and left to reach rt. Once the reaction was determined complete by TLC, ca. 
3 h, the reaction mixture was triturated with ice-cold Et2O (30 mL). The suspension was 
centrifuged at 4 000 × g for 5 min, supernatant decanted, and the peptide pellet 
resuspended in ice-cold Et2O (20 mL), with this process repeated 5 times in total, after 
which the pellet was left to air dry. The resulting off-white solid was redissolved in 10% 
(v/v) aqueous acetic acid and lyophilised to afford (2S)-2-amino-6-((2R,3S)-2-amino-3-
hydroxybutanamido)hexanoic acid 110 as a fluffy off-white foam (539 mg, 
di(trifluoroacetate) salt, 97%); [α]D -52.2 (c 1.0, H2O); δH (500 MHz, DMSO-d6): 8.50 (t, 
1H, 3J 5.6 Hz, HNε), 3.85 (app. quint., 1H, 3Jα'-β', β'-γ' 6.4 Hz, Hβ'), 3.77 (t, 1H, 3Jα-β 6.3 Hz, 
Hα), 3.46 (d, 1H, 3Jα'-β' 6.8 Hz, Hα'), 3.15 (app. dq, 1H, 2J 12.6 Hz, 3J 6.5 Hz, Hε), 3.05 
(app. dq, 1H, 2J 13.0 Hz, 3J 6.5 Hz, H'ε), 1.70-1.82 (m, 2H, Hβ), 1.24-1.47 (m, 4H, Hγ, Hδ) 
1.12 (d, 3H, 3Jβ'-γ' 6.3 Hz, Hγ'); δC (126 MHz, DMSO-d6): 171.0 (CO2H), 166.7 (CONH), 
65.8 (Cβ'), 58.5 (Cα'), 52.1 (Cα), 38.4 (Cε), 29.7 (Cβ), 28.2 (Cγ), 21.8 (Cδ), 20.0 (Cγ'); IR 
(ATR): 2980, 1662, 1581, 1519, 1429, 1250, 1184, 1130, 1038, 932, 838, 799, 721, 599, 






Thiazolidine 2-carboxylic acid 119 
 
A solution of 2-mercaptoethylamine hydrochloride 118 (15.2 g, 134 mmol, 1.0 eq) in 5:2 
(v/v) ethanol:pyridine (70 mL) was added to a stirred solution of glyoxylic acid 117 (50% 
solution in water, 21.8 g, 147 mmol, 1.1 eq.) in ethanol (25 mL). The reaction was left to 
stir for 2 h at r.t., after which the off-white precipitate was isolated by filtration and washed 
with ethanol, yielding racemic thiazolidine-2-carboxylic acid 119 as a white powder (15.4  
g, 86%), used without further purification; δH (500 MHz, DMSO-d6): 4.83 (s, 1H, H-2), 
3.33-3.38 (m, 1H H-5), 2.97-3.02 (m, 1H, H-5'), 2.75-2.83 (m, 2H, H-4, H-4'); δC (126 
MHz, DMSO-d6): 172.0 (CO2H), 66.3 (C-2), 52.8 (C-5), 34.5 (C-4); IR (ATR): 3110, 1622, 
1590, 1376, 1354, 1323, 1300, 1277, 998, 881, 866, 721, 643; HRMS: Found [M+H]+ 
134.0270; C4H8NO2S requires 134.0270 (Δ = 0.2 ppm). Characterisation data in 




3-(tert-butoxycarbonyl)thiazolidine-2-carboxylic acid 120 
 
A stirred suspension of thiazolidine-2-carboxylic acid 119 (5.2 g, 39 mmol, 1.0 eq.) in 2:1 
(v/v) H2O:THF (120 mL) was cooled to 0 °C with stirring and NaHCO3 (9.9 g, 118 mmol, 
3.0 eq.) added in portions. Di-tert-butyl dicarbonate (9.0 g, 41 mmol, 1.05 eq.) was added 
in one portion and the mixture was left stirring for 18 h at r.t.. The reaction mixture was 
cooled to 0 °C, diluted with EtOAc (80 mL), and acidified to pH 3 using 12 M HCl. The 
organic layer was extracted, washed with brine (80 mL), dried over MgSO4 and 
concentrated to yield racemic 3-(tert-butoxycarbonyl)thiazolidine-2-carboxylic acid 120 
as a white solid (8.6 g, 94%); δH (500 MHz, DMSO-d6): 5.10 and 5.03 (s, 1H, H-2, mixture 
of rotamers), 3.70 (br app. s, 2 H, H-5, H-5'), 3.06 (br app. s, 2H, H-4, H-4'), 1.40 and 
1.36 (s, 9H, Boc CH3, mixture of rotamers); δC (126 MHz, DMSO-d6): 172.0 and 171.6 
(CO2H, mixture of rotamers), 152.9 and 152.1 (Boc CO2NH, mixture of rotamers), 80.0 
(C(CH3)3), 59.5 and 59.0 (C-2, mixture of rotamers), 49.7 and 49.3 (C-5, mixture of 
rotamers), 30.3 and 29.1 (C-4, mixture of rotamers), 28.0 and 27.8 (Boc CH3, mixture of 
rotamers); IR (ATR):  2982, 1804, 1756, 1371, 1211, 1113, 1062, 843, 774; HRMS: found 
[M+Na]+ 256.0610; C9H15NO4SNa requires 256.0614 (Δ = 1.9 ppm). Characterisation 







N-hydroxysuccinimide (0.61 g, 5.3 mmol, 1.05 eq.) was added to a solution of 3-(tert-
butoxycarbonyl)thiazolidine-2-carboxylic acid 120 (1.17 g, 5.0 mmol, 1.0 eq.) in 1:1 (v/v) 
EtOAc:1,4-dioxane (16 mL) at 0 °C. Dicyclohexylcarbodiimide (1.09 g, 5.3 mmol, 1.05 
eq.) was added in one portion and the reaction left to warm to r.t. and stir for 3 h. The 
reaction mixture was filtered through a Celite pad and concentrated. The crude product 
was redissolved in EtOAc (20 mL) and washed sequentially with 5% (w/v) NaHCO3 (10 
mL), H2O (10 mL) and brine (10 mL). The organic layer was dried over MgSO4, filtered 
and concentrated to afford racemic N-hydroxysuccinimidyl 3-(tert-
butoxycarbonyl)thiazolidine-2-carboxylate 121 as an off-white powder (1.56 g, 94%); δH 
(500 MHz, DMSO-d6): 5.72 and 5.66 (s, 1H, H-2, mixture of rotamers), 3.81 (br app. s, 
1H, H-5), 3.69 (br app. s, 1H, H-5'), 3.20 (br app. s, 2H, H-4, H-4'), 2.81 (s, 4H, OSu 
CH2), 1.42 (s, 9H, Boc CH3); δC (126 MHz, DMSO-d6): 169.7 (Su CO), 167.0 (CO2Su), 
151.5 (CO2NH), 81.1 (C(CH3)3), 58.1 and 57.4 (C-2, mixture of rotamers), 49.7 and 49.5 
(C-5, mixture of rotamers), 29.4 (C-4), 27.8 and 27.5 (Boc CH3), 25.5 and 25.0 (Su CH2); 
IR (ATR): 2980, 1810, 1774, 1732, 1699, 1455, 1386, 1367, 1205, 1162, 1140, 1114, 
1062, 1046, 991, 793, 648; HRMS: found [M+Na]+ 353.0781; C13H18N2O6SNa requires 







butoxycarbonyl))-hexanoic acid 122 
 
DIPEA (2.8 mL, 16 mmol, 4.0 eq.) and a solution of N-hydroxysuccinimidyl 3-(tert-
butoxycarbonyl)thiazolidine-2-carboxylate 121 (1.32 g, 4.0 mmol, 1.0 eq.) in DCM (12 
mL) were added sequentially at r.t. to a stirred suspension of (2S)-2-(tert-
butoxycarbonylamino)-6-aminohexanoic acid 99 (0.98 g, 4.0 mmol, 1.0 eq.) in DCM (20 
mL). The reaction mixture was stirred at r.t. for 3 h, filtered and concentrated. The residue 
was redissolved in DCM (30 mL) and washed with sat. citric acid (10 mL) and brine (10 
mL). The organic layer was dried over MgSO4, filtered and concentrated to afford a 
diastereomeric mixture of (2S)-2-(tert-butoxycarbonylamino)-6-(thiazolidine-2-
carboxamido-3-(tert-butoxycarbonyl))-hexanoic acid 122 as an off-white foam (1.68 g, 
91%); δH (500 MHz, DMSO-d6) 7.96 (s, 1H, HNε), 6.97 (d, 1H, 3J 7.9 Hz, HNα), 5.14 and 
5.02 (s, 1H, H-2, mixture of rotamers), 3.67-3.81 (m, 3H, Hα, H-5, H-5'), 2.99-3.14 (m, 
4H, Hε, H-4, H-4'), 1.22-1.64 (m, 24H, Boc CH3, Boc CH3, Hβ, Hγ, Hδ); δC (126 MHz, 
DMSO-d6) 174.2 (CO2H), 170.1 (CONH), 155.6 and 152.23 (Boc CO2N, mixture of 
rotamers), 79.6 and 77.9 (C(CH3)3, mixture of rotamers), 60.2 (C-2), 53.4 (Cα), 50.0 (C-
5), 38.3 (Cε), 30.4 (Cβ), 29.0 and 28.6 (Cγ, mixture of rotamers), 28.2 and 27.9 (Boc CH3), 
22.9 (Cδ); ); IR (ATR): 2930, 1668, 1528, 1390, 1365, 1255, 1157, 1047, 891, 857, 778, 








(2S)-2-amino-6-(thiazolidine-2-carboxamido)-hexanoic acid 86 
 
Trifluoroacetic acid (60 mL) was added dropwise to a stirred solution of (2S)-2-(tert-
butoxycarbonylamino)-6-(thiazolidine-2-carboxamido-3-(tert-butoxycarbonyl))-hexanoic 
acid 122 (26.3 g, 57.0 mmol) in DCM (120 mL) at 0 °C and left to reach r.t.. Once the 
reaction was determined complete by TLC, usually within 3 h, the reaction mixture was 
triturated with ice-cold Et2O (240 mL), filtered, and washed with ice-cold Et2O (4 × 50 
mL). The resulting off-white powder was redissolved in 10% (v/v) aqueous acetic acid 
and lyophilised to afford a diastereomeric mixture of (2S)-2-amino-6-(thiazolidine-2-
carboxamido)-hexanoic acid 86 as a fluffy off-white powder (19.6 g, 
acetate/trifluoroacetate salt, 90%); δH (500 MHz, DMSO-d6): 8.46 (t, 1H, 3J 5.4 Hz, HNε), 
8.29 (br s, 3H, H2Nα, HN-2), 5.10 (s, 1H, H-2), 3.86 (t, 1H, 3J 5.8 Hz, Hα), 3.53 (dt, 1H, 2J 
11.7 Hz, 3J 6.0 Hz, 3J 6.0 Hz, H-5), 3.38 (dt, 1H, 2J 11.7 Hz, 3J 6.5 Hz, 3J 6.5 Hz, H-5'), 
3.01-3.10 (m, 4H, H-4, H-4', Hε), 1.73-1.80 (m, 2H, Hβ), 1.29-1.45 (m, 4H, Hγ, Hδ); δC (126 
MHz, DMSO-d6): 171.0 (CO2H), 167.5 (CONH), 62.2 (C-2), 51.9 (Cα), 50.4 (C-5), 38.6 
(Cε), 31.5 (C-4), 29.6 (Cβ), 28.3 (Cγ), 21.7 (Cδ); IR (ATR): 2944, 1660, 1430, 1180, 1128, 






7.1.3 Solid-phase synthesis 
General Methods 
Preloaded resin preparation 
The preloaded 2-chlorotrityl resin was weighed out into a 2 mL SPPS cartridge fitted with 
a PTFE stopcock, swollen in DCM for 30 min and then filtered. 
Fmoc deprotection 
A solution of 20% piperidine in DMF was added to the resin and gently agitated by 
rotation for 2 minutes. The resin was filtered off and repeated four more times, followed 
by washes with DMF (5 × 2 min with rotation). 
Amino acid coupling 
DIPEA (11 eq.) was added to a solution of amino acid (5 eq.) and HCTU (5 eq.) dissolved 
in the minimum volume of DMF and the solution added to the resin. The reaction mixture 
was gently agitated by rotation for 1 h, and the resin filtered off and washed with DMF (3 
× 2 min with rotation). 
Cleavage Cocktails 
Deprotection and resin cleavage: 95:2.5:2.5 (v/v) TFA:H2O:triisopropylsilane. Cleavage 
only: 4:1 (v/v) DCM: 1,1,1,3,3,3-hexafluoroisopropanol. 
Cleavage and Isolation 
The resin was washed with DCM (3 × 2 min with rotation) and MeOH (3 × 2 min with 
rotation). The resin was dried on a vacuum manifold and further dried on a high vacuum 
line overnight. A solution of cleavage cocktail was added to the resin and gently agitated 
by rotation for 60 min.  
For peptides cleaved and deprotected: the reaction mixture was drained into ice-cold 
Et2O and centrifuged at 5000 × g at 4 °C until pelleted (5-10 min). The supernatant was 
carefully decanted and subsequently resuspended, centrifuged and supernatant 
decanted three more times. The peptide pellet was dissolved in 10% (v/v) aq. AcOH and 
lyophilised. 
For proteins undergoing further couplings: the reaction mixture was drained and 





The names and structures of all standard and non-standard residues and N-terminal 
capping moieties featuring in the peptides synthesised are listed below.  
Residues: bioK, Nε-(+)-biotinyl L-lysine; dansK, Nε-dansyl L-lysine; G, glycine; PEG2, 8-
amino-2,6-dioxaoctanoic acid.  








This peptide was synthesised by Dr Martin Fascione. 
Peptide 123 was synthesised according to the general SPPS protocol using preloaded 
H-Gly-2ClTrt resin (168 mg, loading 0.53 mmol g-1, 0.089 mmol), Fmoc-bioK-OH and 
Fmoc-PEG2-OH and capped with 3 eq. Boc-NHOAc-OSu, no HCTU. Resin cleavage 
and deprotection, purification and lyophilisation afforded the peptide as a fluffy white 
powder (10.7 mg, 16%). 
HRMS: found [M+H]+ 793.3784; C32H57N8O13S requires 793.3760 (Δ = -2.4 ppm); HPLC: 







This peptide was synthesised by Dr Martin Fascione. 
Peptide 124 was synthesised according to the general SPPS protocol using preloaded 
H-Gly-2ClTrt resin (100 mg, loading 0.53 mmol g-1, 0.053 mmol), Fmoc-dansK-OH and 
Fmoc-PEG2-OH and capped with 3 eq. Boc-NHOAc-OSu, no HCTU. Resin cleavage 
and deprotection, purification and lyophilisation afforded the peptide as a fluffy yellow 
powder (6.8 mg, 15%). 
HRMS: found [M+H]+ 800.3504; C34H54N7O13S requires 800.3495 (Δ = -1.4 ppm); HPLC: 






Precursor peptide 128 was synthesised according to the general SPPS protocol using 
preloaded H-Gly-2ClTrt resin (100 mg, loading 0.54 mmol g-1, 0.054 mmol), Fmoc-bioK-
OH and Fmoc-PEG2-OH and capped with 125. Resin cleavage and deprotection, 
purification and lyophilisation afforded the peptide as a fluffy white powder (41 mg, 98%). 
HRMS: found [M+H]+ 782.3781; C35H56N7O11S requires 782.3753; HPLC: tR = 9.99 min. 
 
This peptide was oxidised and purified by Dr Richard Spears. 
Solutions of L-methionine (stock 200 mM in 0.1 M phosphate buffer, 0.1 M NaCl, pH 7.0, 
250 μL, final concentration 55 mM) and NaIO4 (stock 112 mM in 0.1 M phosphate buffer, 
0.1 M NaCl, pH 7.0, 210 μL, final concentration 26 mM) were added to peptide 128 (stock 
26 mM in 0.1 M phosphate buffer, 0.1 M NaCl, pH 7.0, 500 μL, final concentration 14 
mM). The reaction was mixed thoroughly and left in the dark at 0 °C for 2 min. The 
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peptide was then purified by reversed-phase chromatography (Grace Davison Extract 
Clean, equilibrated in 1:1 H2O:MeCN, eluted with 0-100% MeCN in H2O gradient), diluted 






Precursor peptide 129 was synthesised according to the general SPPS protocol using 
preloaded H-Gly-2ClTrt resin (85 mg, loading 0.54 mmol g-1, 0.046 mmol), Fmoc-dansK-
OH and Fmoc-PEG2-OH and capped with 125. Resin cleavage and deprotection, 
purification and lyophilisation afforded the peptide as a fluffy yellow powder (33 mg, 
92%). 
HRMS: found [M+H]+ 789.3511; C37H53N6O11S requires 789.3488 ; HPLC: tR = 11.28 min. 
 
This peptide was oxidised and purified by Dr Richard Spears. 
Solutions of L-methionine (stock 200 mM in 0.1 M phosphate buffer, 0.1 M NaCl, pH 7.0, 
250 μL, final concentration 55 mM) and NaIO4 (stock 112 mM in 0.1 M phosphate buffer, 
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0.1 M NaCl, pH 7.0, 210 μL, final concentration 26 mM) were added to peptide 129 (stock 
26 mM in 0.1 M phosphate buffer, 0.1 M NaCl, pH 7.0, 500 μL, final concentration 14 
mM). The reaction was mixed thoroughly and left in the dark at 0 °C for 2 min. The 
peptide was then purified by reversed-phase chromatography (Grace Davison Extract 
Clean, equilibrated in 1:1 H2O:MeCN, eluted with 0-100% MeCN in H2O gradient), diluted 






Precursor peptide 126-OH was synthesised according to the general SPPS protocol 
using preloaded H-Gly-2ClTrt resin (75 mg, loading 0.52 mmol g-1, 0.039 mmol), Fmoc-
bioK-OH and Fmoc-PEG2-OH and isolated following resin cleavage (no deprotection), 
purification and concentration. The residue was dissolved in DMF (1 mL) and BCNmoc-
OSu 132 (13 mg, 0.044 mmol, 1.1 eq.) and DIPEA (9 μL, 0.049 mmol, 1.2 eq.) added. 
The reaction was left stirring at r.t. for 16 h, then concentrated, redissolved in MeOH and 
purified by size-exclusion chromatography (Sephadex LH-20, equilibrated in MeOH, 
eluted with isocratic MeOH) to afford 133 as a fluffy white powder (24 mg, 68%). 
HRMS: found [M+Na]+ 918.4283; C41H65N7O13S requires 918.4253 (Δ = -2.5 ppm); 







Precursor peptide 127-OH was synthesised according to the general SPPS protocol 
using preloaded H-Gly-2ClTrt resin (127 mg, loading 0.52 mmol g-1, 0.066 mmol), Fmoc-
bioK-OH and Fmoc-PEG2-OH and isolated following resin cleavage (no deprotection), 
purification and concentration. The residue was dissolved in DMF (2 mL) and BCNmoc-
OSu 132 (21 mg, 0.072 mmol, 1.1 eq.) and DIPEA (14 μL, 0.079 mmol, 1.2 eq.) added. 
The reaction was left stirring at r.t. for 16 h, then concentrated, redissolved in MeOH and 
purified by size-exclusion chromatography (Sephadex LH-20, equilibrated in MeOH, 
eluted with isocratic MeOH) to afford 134 as a fluffy yellow powder (33 mg, 55%). 
HRMS: found [M+Na]+ 925.4010; C43H62N6O13SNa requires 925.3988 (Δ = -1.1 ppm); 




7.1.4 NMR spectra 
N-hydroxysuccinimidyl 2-(tert-butoxycarbonylamino)-acetate 98 
1H (500 MHz, DMSO-d6):  




acetamido)hexanoic acid 100 
1H (500 MHz, DMSO-d6):  
13C (126 MHz, DMSO-d6):   
168 
 
(2S)-2-amino-6-(2-aminoacetamido)hexanoic acid 96 
1H (500 MHz, DMSO-d6):  





1H (500 MHz, DMSO-d6):  





butoxycarbonylamino)-propanamido)-hexanoic acid 104 
1H (500 MHz, DMSO-d6):  




(2S)-2-amino-6-((2S)-2-amino-3-hydroxypropanamido)-hexanoic acid 101 
1H (500 MHz, DMSO-d6):  






1H (500 MHz, DMSO-d6):  




butoxycarbonylamino)-butanamido)-hexanoic acid 108 
1H (500 MHz, DMSO-d6):  
13C (126 MHz, DMSO-d6):   
174 
 
(2S)-2-amino-6-((2S,3R)-2-amino-3-hydroxybutanamido)-hexanoic acid 105 
1H (500 MHz, DMSO-d6):  






1H (500 MHz, DMSO-d6):  
 





butoxycarbonylamino)-propanamido)-hexanoic acid 113 
1H (500 MHz, DMSO-d6):  
 




(2S)-2-amino-6-((2R)-2-amino-3-hydroxypropanamido)-hexanoic acid 109 
1H (500 MHz, DMSO-d6):  
 






1H (500 MHz, DMSO-d6):  
 





butoxycarbonylamino)-butanamido)-hexanoic acid 116 
1H (500 MHz, DMSO-d6):  
 




(2S)-2-amino-6-((2S,3R)-2-amino-3-hydroxybutanamido)-hexanoic acid 110 
1H (500 MHz, DMSO-d6):  
 




Thiazolidine 2-carboxylic acid (racemate) 119 
1H NMR (500 MHz, DMSO-d6): 
 





3-(tert-butoxycarbonyl)thiazolidine-2-carboxylic acid (racemate) 120 
1H (500 MHz, DMSO-d6): 
 






1H (500 MHz, DMSO-d6):  




butoxycarbonyl))-hexanoic acid 122 
1H (500 MHz, DMSO-d6): 




(2S)-2-amino-6-(thiazolidine-2-carboxamido) hexanoic acid 86 
1H (500 MHz, DMSO-d6):  
13C (126 MHz, DMSO-d6):  
186 
 
7.2 Molecular biology and protein expression 
7.2.1 Plasmid information 
The vectors pEVOL, harbouring pylT and pylRS (M. mazei, wild type or Y306A Y384F 
double mutant) genes, and pBAD, harbouring the EGFP(Y39TAG) gene, were provided 
by Edward Lemke following an MTA and have been previously described. The pBAD 
vector harbouring the sfGFP(N150TAG) gene was a gift from Ryan Mehl (Addgene 
plasmid #85483). The pET22b plasmid harbouring the BiGalK gene was supplied by Dr 
Tessa Keenan. 
7.2.2 Site-directed mutagenesis 
Mutation of the N-terminal residue of GFP(Y39TAG) to serine (from aspartate as part of 
a FLAG tag originally encoded in pBAD-GFP(Y39TAG)) was performed using an Agilent 
Quikchange Multi Site-Directed Mutagenesis Kit according to the provided protocol using 
the following primers (Sigma): 
5' -  CACTTTATCATCATCATCTTTGTAAGACATGGTTAATTCCTCCTGTTAGCCC  - 3' 
5' -  GGGCTAACAGGAGGAATTAACCATGTCTTACAAAGATGATGATGATAAAGTG  - 3' 
 
Mutation of BiGalK-His6 K417 to the amber stop codon was performed using an Agilent 
Quikchange Multi Site-Directed Mutagenesis Kit according to the provided protocol using 
the following primers (Sigma): 
5' - GCCGCGAGGCCTAGCTTGCGGCC - 3' 
5' - GGCCGCAAGCTAGGCCTCGCGGC - 3' 
 
7.2.3 tRNA synthetase substrate recognition assay 
The pBAD vector containing ampicillin resistance and Ser-EGFP(Y39TAG) genes, 
together with the pEVOL vector containing tRNAPyl, pylRS (M. mazei, either wild type or 
Y306A Y384F double mutant) and chloramphenicol resistance genes, were co-
transformed into electrocompetent E. coli Top10 cells and selected on LB agar plates 
containing ampicillin (100 µg/ml) and chloramphenicol (35 µg/ml). Two starter cultures 
were prepared by picking a single colony from one of the two transformants (pBAD-
EGFP(Y39TAG)-His6 and either pEVOL-pylT-pylRSwt or pEVOL-pylT-pylRSAF, 
subsequently referred to as pylRSwt and pylRSAF cultures). 
100 mL Terrific Broth Medium containing ampicillin (100 µg/ml) and chloramphenicol (35 
µg/ml) in a 250 mL baffled conical flask was inoculated with 1.0 mL of either the pylRSwt 
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or pylRSAF overnight culture. The preparative cultures were grown at 37 °C with shaking 
(220 rpm). Typically within 3 h, the cultures reached an OD600 of 0.2-0.3. At this point, 10 
mL from each preparative culture was aliquoted into a 50 mL Falcon tube, to which a 
solution of test NCAA (86, 96, 101, 105, 109 or 110) or positive control (29 for pylRSwt 
and 34 for pylRSAF) was added (stock concentration 50 mM in 0.1 M NaOH, 400 μL, final 
concentration 2 mM). For negative controls, a solution of 0.1 M NaOH (400 μL) was 
added. Each aliquot was left at 37 °C with shaking (220 rpm) for 30 min, at which point 
L-arabinose (stock 20% (w/v), 10 μL, final concentration 0.02% (w/v)) was added to 
induce gene expression and cultures left to grow for 16-18 h at 37 °C with shaking (220 
rpm). 
1.5 mL of each aliquot culture was taken and clarified by centrifugation (7000 × g, 10 
min). The supernatant was decanted and each pellet resuspended in 75 μL Bugbuster 
with 0.75 u benzonase and protease inhibitors. The resuspended cell pellets were left to 
lyse chemically at r.t. with gentle rocking (1 h) and then clarified by centrifugation (17 
000 × g, 30 min). The supernatant was collected and either visualised by fluorescence 
or analysed by Coomassie-stained SDS-PAGE. 
7.2.4 Expression and purification of green fluorescent proteins 
The pBAD vector containing ampicillin resistance and either Ser-GFP(Y39TAG) or 
sfGFP(N10TAG) genes, together with the pEVOL vector containing tRNAPyl, pylRS (M. 
mazei, wild type) and chloramphenicol resistance genes, were co-transformed into 
electrocompetent E. coli Top10 cells and selected on LB agar plates containing ampicillin 
(100 µg/ml) and chloramphenicol (35 µg/ml).  
For small-scale expression, 0.5 mL of an overnight culture grown from a single colony 
was inoculated into 50 mL Terrific Broth Medium containing ampicillin (100 µg/ml) and 
chloramphenicol (35 µg/ml) in a 250 mL baffled conical flask. At 37 °C with shaking (220 
rpm), cells typically grew within 3 h to an OD600 of 0.2-0.3, at which point NCAA (stock 
solution 80 mM in 0.1 M NaOH (aq.)) was added to a final concentration of 1.5 mM. The 
cultures were allowed to grow until an OD600 of 0.4-0.6, at which point protein expression 
was induced by addition of L-arabinose (stock solution 20% (w/w)) at a final concentration 
of 0.02% (w/w) and left to grow for 16-18 h at 37 °C with shaking (220 rpm). 
The cultures were harvested by centrifugation (6 000 × g, 4 °C, 20 min). Pellets were 
resuspended in 4 × PBS, 10 mM imidazole, pH 8.0 with a Pierce Protease Inhibitor 
(EDTA-free) tablet and then lysed by sonication on ice for 6 × 30 s with 30 s intervals. 
The lysate was clarified by centrifugation (20 000 × g, 4 °C, 20 min) and loaded onto a 
Ni HiTrap Chelating HP column (1 ml, GE Healthcare) pre-equilibrated in 4 × PBS, 10 
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mM imidazole, pH 8.0. The column was washed with 10 column volumes of this buffer 
and then eluted using a gradient of 0-100% 4 × PBS, 500 mM imidazole, pH 8.0 over 7.5 
column volumes, taking 0.5 mL fractions, and the column washed with 7.5 column 
volumes of 4 × PBS, 500 mM imidazole, pH 8.0, taking 0.5 mL fractions. Fractions 
containing full-length protein (as determined by SDS-PAGE) were pooled, dialysed into 
1 × PBS, pH 7.4 and concentrated (Vivaspin centrifugal concentrator, 10000 MWCO) to 
a final concentration of 330 µM (as determined by UV-visible spectroscopy, ε280 = 2.0 × 
104 dm³ mol-1 cm-1) and stored at -80 °C. 
For large-scale expressions, the procedure was followed largely as above with 1 L 
cultures inoculated with 10 mL of an overnight culture, to which NCAA and L-arabinose 
were added to the same final concentrations. For purification, a larger Ni HiTrap 
Chelating HP column (5 mL, GE Healthcare) was used, taking 2.5 mL fractions. This 
procedure is identical whether using NCAAs 86 or 105. 
7.2.5 Expression and purification of BiGalK 
The pET22b vector containing ampicillin resistance and BiGalK(K417TAG) genes, 
together with the pEVOL vector containing tRNAPyl, pylRS (M. mazei, wild type) and 
chloramphenicol resistance genes, were co-transformed into electrocompetent E. coli 
BL21-DE3 cells and selected on LB agar plates containing ampicillin (100 µg/ml) and 
chloramphenicol (35 µg/ml).  
For small-scale expression, 0.5 mL of an overnight culture grown from a single colony 
was inoculated into 50 mL LB medium containing ampicillin (100 µg/ml) and 
chloramphenicol (35 µg/ml) in a 250 mL baffled conical flask. At 37 °C with shaking (220 
rpm), cells typically grew within 3 h to an OD600 of 0.2-0.3, at which point NCAA (stock 
solution 80 mM in 0.1 M NaOH (aq.), final concentration 1.5 mM) and L-ara (stock 
solution 20% (w/v) final concentration 0.02% (w/v)), were added. The cultures were 
allowed to grow until an OD600 of 0.8, at which point protein expression was induced by 
addition of IPTG (stock solution 1 M in H2O, final concentration 0.2 mM) and left to grow 
for 16-18 h at 16 °C with shaking (220 rpm). 
The cultures were harvested by centrifugation (8 000 × g, 4 °C, 20 min). Pellets were 
resuspended in 50 mM Tris buffer, 20 mM imidazole, pH 8.0 with a Pierce Protease 
Inhibitor (EDTA-free) tablet and then lysed by sonication on ice for 6 × 30 s with 30 s 
intervals. The lysate was clarified by centrifugation (20 000 × g, 4 °C, 20 min) and loaded 
onto a Ni HiTrap Chelating HP column (1 mL, GE Healthcare) pre-equilibrated in 50 mM 
Tris buffer, 20 mM imidazole, pH 8.0. The column was washed with 10 column volumes 
of this buffer and then eluted using a gradient of 0-100% 50 mM Tris, 250 mM imidazole, 
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pH 8.0 over 7.5 column volumes, taking 0.5 mL fractions, and the column washed with 
7.5 column volumes of 50 mM Tris, 250 mM imidazole, pH 8.0, taking 0.5 mL fractions. 
Fractions containing full-length protein (as determined by SDS-PAGE) were pooled, 
dialysed into 1 × PBS, pH 7.4 and concentrated (Vivaspin centrifugal concentrator, 
10000 MWCO) to a final concentration of 330 µM (as determined by UV-visible 
spectroscopy, ε280 = 3.0 × 104 dm³ mol-1 cm-1) and stored at -80 °C. 
 
7.2.6 Protein characterisation 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis and staining 
All SDS-PAGE analysis was performed using handcast 12% polyacrylamide gels. 
Samples were reduced by boiling for 10 min (2% SDS, 2 mM 2-mercaptoethanol, 4% 
glycerol, 40 mM Tris-HCl pH 6.8, 0.01% bromophenol blue).  Molecular weight markers 
used were PageRuler Plus Prestained Protein Ladder (Thermo Scientific). Each gel was 
run at 200 volts for 45-80 min. For Coomassie stain experiments, the gel was washed 
with fixing solution (40% (v/v) MeOH, 10% AcOH), stained with 0.1% (w/v) Coomassie 
Brilliant Blue R-250 (50% (v/v) MeOH, 10% AcOH), and finally repeatedly washed with 
destain solution (50% (v/v) MeOH, 10% AcOH). Images of the resulting gels were 
captured and analysed using a Syngene G:BOX Chemi XRQ equipped with a Synoptics 
4.0 MP camera, with GeneSys software (Version 1.5.7.0). 
Determination of protein concentration 
Protein concentration was estimated using UV-visible absorption spectroscopy and the 
predicted molar absorption coefficient at 280 nm (ExPASy ProtParam). This predicted 
ε280 value is based on empirical data relating to the molar absorption coefficients of 
tyrosine, tryptophan and cystine, respectively 1490, 5500 and 125 dm3 mol-1 cm-1,301 with 
other canonical residues demonstrating negligible absorbance at 280 nm. The predicted 
molar absorption coefficient is therefore only based upon the primary sequence of the 
protein and is an estimate, as secondary and tertiary protein structure may influence 
individual residue microenvironments and perturb the value of the molar absorption 
coefficient. This method also encounters difficulties with post-translational modifications, 
such as the chromophore of GFP and derivatives. However, the ε280 of the GFP 
chromophore is known to be low253 and can be ignored in an estimate of GFP 




For fluorescent imaging of fluorescently modified proteins, the SDS PAGE gel was 
washed with fixing solution (40% MeOH, 10% AcOH). Visualisation of protein 
fluorescence, and images of the resulting gels, were captured by excitation at 302 nm 
and analysed using a Syngene G:BOX Chemi XRQ equipped with a Synoptics 4.0 MP 
camera in line with GeneSys software (Version 1.5.7.0). 
Western blot analysis 
For Western blot analysis, 2.5 µg of biotinylated protein samples or negative controls 
were run on 12% SDS–PAGE and transferred onto a nitrocellulose membrane filter (0.45 
µm, Amersham Protran Sandwich, GE Healthcare) using an electroblot apparatus (Bio-
Rad, Hercules, CA) at 100 V, 350 mA for 1 h in cooled transfer buffer (25 mM Tris–HCl 
pH 8.3, 192 mM glycine, 0.1% SDS, 20% (v/v) methanol). The membrane was incubated 
in blocking solution (Phosphate-buffered saline (PBS) tablets, Sigma)) containing 5% 
(w/v) non-fat dry milk powder for 16 h at 4 °C. The membrane was processed through 
sequential incubations with primary antibody, alkaline phosphatase anti-biotin (goat, 
Vector Labs, CA) 1:1000 dilution in PBS for 1 hour at room temperature, followed by 
washing in PBS, 0.01% Tween-20, and then incubation with visualising substrate 
BCIP/NBT Alkaline Phosphatase Substrate Kit (Vector Labs, CA) until immunoreactive 
proteins on the membrane were visible (ca. 20 min). The reaction was stopped by 
washing the membrane in distilled water. The membranes were imaged using a Syngene 
G:BOX Chemi XRQ equipped with a Synoptics 4.0 MP camera, with GeneSys software 
(Version 1.5.7.0). 
Protein mass spectrometry 
Protein ESI mass spectra were obtained on a Bruker Solarix XR 9.4 T FTICR instrument. 
Samples were desalted and analysed at a final concentration of 0.3-10 μM in 50:50:1 
(v/v) H2O:MeCN:FA. Mass spectra were analysed and deconvoluted using Bruker 
DataAnalysis 4.4. 
Trypsin digest 
All trypsin digests were performed by Dr Adam Dowle. 
A solution of protein (5 μg in 100 μL 100 mM ammonium bicarbonate) was reduced with 
5 mM DTT for 30 min at 50 °C and alkylated with 15 mM iodoacetamide for 30 min in the 
dark at r.t., followed by digestion by the addition of 0.2 μg trypsin (sequencing grade, 
Promega) and incubated overnight at 37 °C. Protease activity was stopped with aqueous 
trifluoroacetic acid (1% (v/v)). 
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The resulting mixture of peptides was loaded onto a Pepmap (50 cm × 2 μm, 100 Å) and 
a Thermo C18 EasyNano nanocapillary column (15 cm × 75 μm) and eluted over a 
gradient of aqueous 3-35% (v/v) MeCN over 35 min into a Thermo Orbitrap Fusion hybrid 
mass spectrometer. MS1 and MS2 spectra were acquired in the Orbitrap mass analyser 
with Easy-IC internal calibration. Data-dependent acquisition was performed in top 
speed mode using a fixed 1 s cycle, selecting the most intense precursors with charge 
states 2-5. HCD was used for peptide fragmentation with 32% activation energy. 
Resulting spectral data were searched against the expected protein sequences using 
the PEAKS-DB search program. Search criteria specified: enzyme, trypsin; peptide 
tolerance, 3 ppm; MS/MS tolerance, 0.01 Da. Carbamidomethylation (C) was set as a 
fixed modification. Peptide matches were filtered to achieve a global false discovery 




7.3 Protein modification protocols 
7.3.1 Palladium reagent screen 
 
For a typical 100 μL scale reaction, palladium reagent 140-144 (stock 0.55 M in DMSO 
for 100 eq., 6 μL, final concentration 31 mM) was added to 136 (stock 330 μM in 1 × 
PBS, pH 7.4, 100 μL, final concentration 310 μM) in a 0.5 mL Eppendorf tube. The 
reaction mixture was vortex mixed (1 s) and incubated in a water bath at 37 °C. The 
reaction was quenched by the addition of DTT (a spatula tip, ca. 5 mg) and clarified by 
centrifuged (5 000 × g, 2 min or longer as needed). The supernatant was decanted and 
desalted using a PD SpinTrap G25 column (GE Healthcare Life Sciences) into H2O for 




7.3.2 Optimised palladium decaging procedure 
 
For a typical 100 μL scale reaction, palladium complex 142 (stock 30 mM in DMSO, 1 
μL, final concentration 0.3 mM, 1 eq.) was added to protein thiazolidine 136 or 137 (stock 
0.3 mM in 1 × PBS, pH 7.4, 100 μL, final concentration 0.3 mM, 1 eq.) in a 0.5 mL 
Eppendorf tube, mixed by pipette tip swirling, and left at rt for 1 h. The reaction was 
quenched by the addition of 3-mercaptopropanoic acid (stock 1% (v/v) in 10 × PBS, pH 
7.4, 1 μL, final concentration 0.01% (v/v)) and left at rt for 15 min. The reaction mixture 
was diluted up to 500 μL with H2O and desalted using a PD Minitrap G-25 (GE 
Healthcare), gravity method, into H2O for analysis and further manipulation, affording 




7.3.3 Optimised periodate oxidation procedure 
 
 
For a typical 100 μL scale reaction, solutions of L-methionine (stock 102 mM in 20 mM 
phosphate buffer, 150 mM NaCl, pH 7.4, 1 μL, final concentration 1 mM, 10 eq.) and 
NaIO4 (stock 51 mM in 20 mM phosphate buffer, 150 mM NaCl, pH 7.4, 1 μL, final 
concentration 0.5 mM, 5 eq.) were added to protein 1,2-aminoalcohol 138 (stock 100 μM 
in 20 mM phosphate buffer, 150 mM NaCl, pH 7.4, 100 μL, final concentration 100 μM, 
1 eq.). After mixing by gentle pipetting, the reaction mixture was incubated at 0 °C in the 
dark for 4 min, after which the oxidised protein was purified by desalting using a PD 





7.3.4 Oxime ligation 
 
For a typical 100 μL scale reaction, aniline (neat, 1 μL, final concentration 0.1 M) and 
aminooxy probe 123 or 124 (stock 0.1 M in H2O, 2 μL, final concentration 2.0 mM) were 
added to protein glyoxyl 139 or 145 (stock 60 μM in 100 mM sodium phosphate buffer, 
pH 7.0, 97 μL, final concentration 58 μM) and mixed by pipette tip swirling. After 
incubation at 37 °C in a water bath for 24 h, the reaction was diluted up to 500 μL with 
H2O and desalted using a PD Minitrap G-25 (GE Healthcare), gravity method, into H2O 




7.3.5 Organocatalytic protein aldol ligation 
 
For a typical 100 μL scale reaction, solutions of phenacetaldehyde probe 131 (stock 50 
mM in H2O, 4 μL, final concentration 2 mM, 33 eq.) and proline tetrazole 154 (stock 400 
mM in 25 mM phosphate buffer, pH 7.5, 6 μL, final concentration 2.5 mM, 26 eq.) were 
added to protein glyoxyl 139 or 145 (stock 300 μM in H2O, 25 μL, final concentration 75 
μM, 1 eq.) and the solution made up to 100 μL with buffer (65 μL, 25 mM phosphate 
buffer, pH 7.5). After mixing by gentle pipetting, the reaction mixture was incubated at 37 
°C for 1 h, after which the modified protein was purified by desalting using a PD Minitrap 




7.3.6 SPANC ligation 
 
 
For a typical 100 μL scale reaction, solutions of p-anisidine (stock 1 M in 50% aq. MeCN, 
10 μL, final concentration 100 mM), N-methylhydroxylamine hydrochloride (stock 75 mM 
in 0.1 M NH4OAc, pH 6.8, 2 μL, final concentration 1.5 mM, 50 eq.) and BCN probe 133 
or 134 (stock 3 mM in 50% aq. MeCN, 20 μL, final concentration 600 μM, 20 eq.) were 
added to protein aldehyde 139 or 145 (stock 100 μM in H2O, 30 μL, final concentration 
30 μM, 1 eq.) and the solution made up to 100 μL with buffer (38 μL, 0.1 M NH4OAc, pH 
6.8). After mixing by gentle pipetting, the reaction mixture was incubated at 37 °C for 16 
h, after which the modified protein was purified by desalting using a PD Minitrap G-25 




Chapter 8: Appendix 
8.1 Protein sequences 
The locations of amber stop codons are denoted by X. The initial methionine residue has 
been assigned the residue number one for all protein constructs found to contain this 
residue after production, i.e. sfGFP and BiGalK. For the EGFP construct, literature 
examples have excluded the eight-residue FLAG tag from numbering and only the native 
sequence has been numbered.169 Following this example, the mutated FLAG tag has not 
been included in residue numbering and has been highlighted in gray to indicate this. 
Owing to the mutated FLAG tag, the EGFP proteins produced do not contain the initial 
methionine residue and this has been omitted. 
Ser-EGFP(Y39TAG)-His6 
         1         11         21         31         41         51 
 SYKDDDDKV SKGEELFTGV VPILVELDGD VNGHKFSVSG EGEGDATXGK LTLKFICTTG 
        61         71         81         91        101        111 
KLPVPWPTLV TTLTYGVQCF SRYPDHMKQH DFFKSAMPEG YVQERTIFFK DDGNYKTRAE 
       121        131        141        151        161        171 
VKFEGDTLVN RIELKGIDFK EDGNILGHKL EYNYNSHNVY IMADKQKNGI KANFKIRHNI 
       181        191        201        211        221        231 
EDGSVQLADH YQQNTPIGDG PVLLPDNHYL STQSALSKDP NEKRDHMVLL EFVTAAGITL  







1       10         20         30         40         50         60  
MVSKGEELFT GVVPILVELD GDVNGHKFSV RGEGEGDATN GKLTLKFICT TGKLPVPWPT  
        70         80         90        100        110        120  
LVTTLTYGVQ CFSRYPDHMK RHDFFKSAMP EGYVQERTIS FKDDGTYKTR AEVKFEGDTL  
       130        140        150        160        170        180  
VNRIELKGID FKEDGNILGH KLEYNFNSHX VYITADKQKN GIKANFKIRH NVEDGSVQLA  
       190        200        210        220        230        240  








1       10         20         30         40         50         60  
MTAVEFIEPL THEEGVSQAT KLFVDTYGAA PEGVWAAPGR VNLIGEHTDY NAGLCLPIAL  
        70         80         90        100        110        120  
PHRTFIALKP REDTKVRVVS GVAPDKVAEA DLDGLKARGV DGWSAYPTGV AWALRQAGFD  
       130        140        150        160        170        180  
KVKGFDAAFV SCVPLGSGLS SSAAMTCSTA LALDDVYGLG YGDSDAGRVT LINAAIKSEN  
       190        200        210        220        230        240  
EMAGASTGGL DQNASMRCTE GHALLLDCRP ELTPLENVSQ QEFDLDKYNL ELLVVDTQAP  
       250        260        270        280        290        300  
HQLNDGQYAQ RRATCEEAAK ILGVANLRVT ADGISKADDQ FQALKETLDA LPDETMKKRV  
       310        320        330        340        350        360  
RHVVTEIERV RSFVRAFAQG DIKAAGRLFN ASHDSLAADY EVTVPELDIA VDVARKNGAY  
       370        380        390        400        410        420  










ADC Antibody-drug conjugate 
ADP Adenosine diphosphate 
Alloc Allyloxycarbonyl 
ATP Adenosine triphosphate 
ATR Attenuated total reflectance 
BCN Bicyclo[6.1.0]non-4-yne 
Bcx Bacillus circulans xylanase 
BiGalK Bifidobacterium infantis galactokinase 
Bn Benzyl 
Boc Tert-butoxycarbonyl 
















DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
e.e. Enantiomeric excess 
EGFP Enhanced green fluorescent protein 
eq. Equivalents 
ESI Electrospray ionisation 
202 
 
FA Formic acid 
FGE Formylglycine-generating enzyme 
Fmoc 9H-fluoren-9-ylmethoxycarbonyl 
FRET Förster resonance energy transfer 
FTICR Fourier-transform ion cyclotron resonance 
GFP Green fluorescent protein 
GlcNAc N-acetylglucosamine 
GST Glutathione S-transferase 
HASPA Hydrophilic acylated surface protein A 
HCTU 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HPLC High-performance liquid chromatography 
HRMS High-resolution mass spectrometry 
ICP Inductively coupled plasma 
IR Infrared 
LB Lysogeny broth 
LC Liquid chromatography 
MALDI Matrix-assisted laser desorption/ionisation 
MeCN Acetonitrile 
MS Mass spectrometry 
NAD Nicotinamide adenine dinucleotide 
NADH Reduced nicotinamide adenine dinucleotide 
NCAA Non-canonical amino acid 
NCL Native chemical ligation 
NHS N-hydroxysuccinimide 
NMR Nuclear magnetic resonance 
OPAL Organocatalytic protein aldol ligation 
PB Phosphate buffer 
PBS Phosphate-buffered saline 
PDB Protein Data Bank 









pylRS Pyrrolysyl RNA synthetase 
pylT Pyrrolysyl tRNA 
RNA Ribonucleic acid 
RS tRNA synthetase 
r.t. Room temperature 
SAM S-adenosyl methionine 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sfGFP Superfolder green fluorescent protein 
SPAAC Strain-promoted alkyne-azide cycloaddition 
SPANC Strain-promoted alkyne-nitrone cycloaddition 
SPIEDAC Strain-promoted inverse electron-demand Diels-Alder cycloaddition 
SPPS Solid-phase peptide synthesis 
Su N-hydroxysuccinimidyl 




TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIS Triisopropylsilane 
TLC Thin-layer chromatography 
TMSCl Trimethylsilyl chloride 
Tris Tris(hydroxymethyl)aminomethane 
tRNA Transfer ribonucleic acid 
UV Ultraviolet 
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